DDI-MedLine.d95.s4	Resveratrol NNP B-noun.person	( ( 0	5 CD 0	- : 0	35 CD 0	micromol NN B-noun.quantity	/ : 0	l LS 0	) ) 0	induced VBN B-verb.creation	concentration NN B-noun.feeling	- : 0	dependent JJ B-adj.all	relaxation NN B-noun.cognition	of IN 0	mesenteric JJ B-adj.all	arteries NNS B-noun.shape	preconstricted VBN B-verb.creation	with IN 0	noradrenaline NN B-noun.person	( ( 0	8 CD B-adj.all	micromol NN B-noun.quantity	/ : 0	l LS 0	) ) 0	or CC 0	KCl NNP B-noun.person	( ( 0	125 CD 0	mmol NN B-noun.quantity	/ : 0	l LS 0	) ) 0	from IN 0	both DT 0	lean JJ B-adj.all	and CC 0	dietary JJ B-noun.person	- : 0	obese NN B-noun.animal	rats NNS I-noun.animal	. . 0	. . 0
DDI-DrugBank.d437.s9	Methadone NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	amprenavir NN B-noun.person	and CC 0	methadone NN B-noun.person	can MD 0	decrease VB B-verb.change	plasma NN B-noun.state	levels NNS B-noun.state	of IN 0	methadone NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d340.s27	A DT 0	dose NN B-noun.communication	adjustment NN B-noun.communication	is VBZ B-verb.stative	not RB B-adv.all	needed VBN B-verb.consumption	when WRB 0	zidovudine NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	with IN 0	VIRACEPT NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d196.s4	Nucleoside NNP B-noun.other	Analogues NNP I-noun.other	Didanosine NNP I-noun.other	Co NNP I-noun.other	- : 0	administration NN B-noun.time	of IN 0	COPEGUS NNP B-noun.group	and CC 0	didanosine NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d165.s5	In IN 0	vitro NN B-noun.animal	data NNS B-noun.cognition	suggest VBP B-verb.communication	that IN 0	itraconazole NN B-noun.person	, , 0	when WRB 0	compared VBN B-verb.cognition	to TO 0	ketoconazole VB B-verb.social	, , 0	has VBZ B-verb.possession	a DT 0	less RBR B-adv.all	pronounced JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	biotransformation NN B-noun.cognition	system NN 0	responsible JJ B-adj.all	for IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	astemizole NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d97.s37	Indinavir NNP B-noun.person	and CC 0	didanosine NN B-noun.act	formulations NNS B-noun.artifact	containing VBG B-verb.stative	buffer NN B-noun.substance	should MD 0	be VB 0	administered VBN B-verb.possession	at IN 0	least JJS 0	one CD 0	hour NN 0	apart RB 0	on IN 0	an DT 0	empty JJ B-adj.all	stomach NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d236.s20	Meperidine NNP B-noun.person	, , 0	Amphetamines NNS B-noun.person	potentiate VBP B-verb.communication	the DT 0	analgesic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	meperidine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d89.s3	Based VBN B-verb.cognition	on IN 0	adult NN B-noun.act	data NNS B-noun.cognition	, , 0	lower JJR B-adj.all	doses NNS B-noun.person	of IN 0	caffeine NN B-noun.act	may MD 0	be VB 0	needed VBN B-verb.consumption	following VBG 0	coadministration NN B-noun.person	of IN 0	drugs NNS B-noun.artifact	which WDT 0	are VBP 0	reported VBN B-verb.communication	to TO 0	decrease VB B-verb.cognition	caffeine NN 0	elimination NN 0	( ( 0	e.g. UH 0	, , 0	cimetidine NN B-noun.person	and CC 0	ketoconazole NN B-noun.artifact	) ) 0	and CC 0	higher JJR B-adj.all	caffeine NN B-noun.artifact	doses NNS B-noun.artifact	may MD 0	be VB 0	needed VBN B-verb.consumption	following VBG 0	coadministration NN B-noun.person	of IN 0	drugs NNS B-noun.artifact	that WDT 0	increase VBP B-verb.stative	caffeine NN 0	elimination NN 0	( ( 0	e.g. UH 0	, , 0	phenobarbital JJ B-adj.all	and CC 0	phenytoin NN B-noun.body	) ) 0	. . 0	. . 0
DDI-DrugBank.d5.s17	Therefore RB 0	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	bupropion NN B-noun.act	with IN 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	CYP2D6 JJ B-adj.all	isoenzyme NN B-noun.substance	including VBG B-verb.change	certain JJ B-adj.all	antidepressants NNS B-noun.attribute	( ( 0	e.g. UH 0	, , 0	nortriptyline NN B-noun.person	, , 0	imipramine NN B-noun.person	, , 0	desipramine NN B-noun.person	, , 0	paroxetine NN B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	sertraline NN B-noun.body	) ) 0	, , 0	antipsychotics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	haloperidol NN B-noun.person	, , 0	risperidone NN 0	, , 0	thioridazine NN 0	) ) 0	, , 0	beta JJ 0	- : 0	blockers NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	metoprolol NN B-noun.attribute	) ) 0	, , 0	and CC 0	Type_1C_antiarrhythmics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	propafenone NN B-noun.person	, , 0	flecainide NN 0	) ) 0	, , 0	should MD 0	be VB 0	approached VBN B-verb.communication	with IN 0	caution NN B-noun.cognition	and CC 0	should MD 0	be VB 0	initiated VBN B-verb.possession	at IN 0	the DT 0	lower JJR B-adj.all	end NN B-noun.person	of IN 0	the DT 0	dose JJ B-adj.all	range NN B-noun.location	of IN 0	the DT 0	concomitant JJ B-adj.all	medication NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d48.s3	Drugs NNS B-noun.artifact	that WDT 0	may MD 0	decrease VB B-verb.cognition	dasatinib NN B-noun.person	plasma NN B-noun.person	concentrations NNS I-noun.person	CYP3A4 NNP I-noun.person	Inducers NNPS I-noun.person	, , 0	Drugs NNP B-noun.person	that WDT 0	induce VBP B-verb.cognition	CYP3A4 JJ B-noun.phenomenon	activity NN B-noun.process	may MD 0	decrease VB B-verb.cognition	dasatinib NN B-noun.person	plasma NN B-noun.person	concentrations NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d269.s17	As IN 0	with IN 0	other JJ B-adj.all	agents_with_b JJ B-noun.person	- : 0	blocking_properties NNS B-noun.time	, , 0	if IN 0	COREG NNP B-noun.group	is VBZ B-verb.stative	to TO 0	be VB 0	administered VBN B-verb.possession	orally RB B-adv.all	with IN 0	calcium_channel_blockers NNS B-noun.person	of IN 0	the DT 0	verapamil NN B-noun.artifact	or CC 0	diltiazem VB B-verb.change	type NN B-noun.person	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	ECG NNP 0	and CC 0	blood NN B-noun.act	pressure NN B-noun.person	be VB 0	monitored VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d338.s4	While IN 0	no DT 0	in IN 0	vivo JJ B-adj.all	drug NN B-noun.person	- : 0	drug NN B-noun.group	interaction NN B-noun.act	studies NNS B-noun.artifact	were VBD 0	conducted VBN B-verb.stative	between IN 0	estazolam NN B-noun.act	and CC 0	inducers NNS B-noun.person	of IN 0	CYP3A NNP B-noun.person	, , 0	compounds NNS B-noun.person	that WDT 0	are VBP B-verb.stative	potent JJ B-noun.person	CYP3A NNP I-noun.person	inducers NNS I-noun.person	( ( 0	such JJ 0	as IN 0	carbamazepine NN 0	, , 0	phenytoin NN B-noun.person	, , 0	rifampin NN B-noun.person	, , 0	and CC 0	barbiturates NNS B-noun.artifact	) ) 0	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	decrease VB B-verb.cognition	estazolam NN B-noun.act	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d99.s10	Nevertheless RB B-adv.all	, , 0	caution NN B-noun.cognition	is VBZ 0	indicated VBN B-verb.communication	in IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	TCAs NNP B-noun.other	with IN 0	any DT 0	of IN 0	the DT 0	SSRIs NNP B-noun.location	and CC 0	also RB B-adv.all	in IN 0	switching VBG B-verb.motion	from IN 0	one CD 0	class NN 0	to TO 0	the DT 0	other JJ 0	. . 0	. . 0
DDI-DrugBank.d568.s20	Warfarin NNP B-noun.person	; : 0	Administration NNP B-noun.person	of IN 0	40 CD 0	mg RB 0	/ JJ 0	day NN 0	racemic JJ B-adj.all	citalopram NN B-noun.person	for IN 0	21 CD B-adj.all	days NNS B-noun.person	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	warfarin NN B-noun.location	, , 0	a DT 0	CYP3A4 JJ B-adj.all	substrate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d454.s0	- : 0	Lofexidine NN B-noun.location	may MD 0	enhance VB B-verb.change	the DT 0	CNS NNP B-noun.group	depressive JJ B-verb.creation	effects NNS B-noun.phenomenon	of IN 0	alcohol NN B-noun.food	, , 0	barbiturates NNS B-noun.artifact	and CC 0	other JJ 0	sedatives NNS B-noun.person	. . 0
DDI-DrugBank.d169.s3	Expected VBN B-verb.cognition	changes NNS B-noun.phenomenon	in IN 0	laboratory NN B-noun.artifact	assessments NNS B-noun.person	of IN 0	PT NNP 0	and CC 0	INR NNP 0	were VBD 0	observed VBN B-verb.perception	after IN 0	warfarin JJ B-adj.all	administration NN B-noun.person	, , 0	but CC 0	these DT 0	changes NNS B-noun.phenomenon	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	concomitant JJ B-adj.all	lenalidomide NN B-noun.person	administration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d331.s9	- : 0	Antihypertensives NNPS B-noun.person	, , 0	Bumetanide NNP B-noun.location	may MD 0	potentiate VB B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	various JJ B-adj.all	antihypertensive_drugs NNS B-noun.location	, , 0	necessitating VBG B-verb.consumption	a DT 0	reduction NN B-noun.act	in IN 0	the DT 0	dosage NN B-noun.quantity	of IN 0	these DT 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d110.s3	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	vasopressor_drugs NNS B-noun.artifact	( ( 0	for IN 0	the DT 0	treatment NN B-noun.communication	of IN 0	hypotension NN 0	related VBN B-verb.cognition	to TO 0	obstetric JJ B-adj.all	blocks NNS B-noun.event	) ) 0	and CC 0	ergot NN B-noun.person	- : 0	type_oxytocic_drugs NNS B-noun.object	may MD 0	cause VB B-verb.cognition	severe JJ 0	, , 0	persistent JJ B-adj.all	hypertension NN B-noun.feeling	or CC 0	cerebrovascular JJ B-adj.all	accidents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d217.s9	Diminished VBN B-verb.change	urinary JJ B-adj.all	excretion NN B-noun.act	of IN 0	norfloxacin NN B-noun.person	has VBZ 0	been VBN 0	reported VBN B-verb.communication	during IN 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	probenecid NN B-noun.person	and CC 0	norfloxacin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d89.s0	Therapeutic JJ B-adj.all	drug NN B-noun.phenomenon	monitoring NN B-verb.perception	can MD 0	avoid VB B-verb.social	iatrogenic JJ B-adj.pert	alterations NNS B-noun.act	caused VBN B-verb.creation	by IN 0	99mTc SYM 0	- : 0	methylene_diphosphonate NN B-noun.attribute	( ( 0	MDP)-gentamicin JJ B-adj.all	interaction NN B-noun.act	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d246.s5	When WRB 0	the DT 0	STADOL_NS NNS B-noun.artifact	was VBD 0	administered VBN B-verb.possession	30 CD B-adj.all	minutes NNS B-noun.time	after IN 0	the DT 0	sumatriptan NN B-noun.artifact	nasal NN I-noun.artifact	spray NN B-noun.artifact	, , 0	the DT 0	AUC NNP B-noun.group	of IN 0	butorphanol NN 0	increased VBD B-verb.change	11 CD B-adj.all	% NN 0	and CC 0	Cmax NNP B-noun.person	decreased VBD B-verb.change	18 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d250.s0	Certain JJ B-adj.all	other JJ B-adj.all	antibiotics NNS B-noun.person	( ( 0	aminoglycosides NNS B-noun.person	and CC 0	polymyxin NN B-noun.cognition	) ) 0	have VBP 0	also RB B-adv.all	been VBN 0	reported VBN B-verb.communication	to TO 0	interfere VB B-verb.stative	with IN 0	the DT 0	nerve NN B-noun.attribute	transmission NN B-noun.process	at IN 0	the DT 0	neuromuscular JJ B-adj.all	junction NN B-noun.location	. . 0	. . 0
DDI-MedLine.d86.s9	Because IN 0	of IN 0	the DT 0	pronounced JJ B-adj.all	intersubject JJ B-adj.all	variability NN B-noun.attribute	in IN 0	the DT 0	extent NN B-noun.attribute	of IN 0	the DT 0	sirolimus NN B-noun.attribute	- : 0	diltiazem NN 0	interaction NN 0	, , 0	whole JJ B-adj.all	blood NN B-noun.body	sirolimus NN I-noun.body	concentrations NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.change	closely RB B-adj.all	in IN 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	the DT 0	two CD 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d223.s9	The DT 0	extent NN B-noun.attribute	to TO 0	which WDT 0	SSRI NNP B-noun.group	- : 0	TCA NNP B-noun.group	interactions NNS B-noun.possession	may MD 0	pose VB B-verb.possession	clinical JJ B-adj.all	problems NNS B-noun.communication	will MD 0	depend VB B-verb.cognition	on IN 0	the DT 0	degree NN B-noun.communication	of IN 0	inhibition NN B-noun.attribute	and CC 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	the DT 0	SSRI NNP B-noun.group	involved VBD B-verb.stative	. . 0	. . 0
DDI-DrugBank.d531.s91	Specific JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.artifact	have VBP 0	not RB 0	been VBN 0	performed VBN B-verb.social	with IN 0	SUSTIVA NNP B-noun.group	and CC 0	NRTIs NNP B-noun.other	other JJ 0	than IN 0	lamivudine NN B-noun.location	and CC 0	zidovudine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s30	Therefore RB 0	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	clozapine NN B-noun.person	with IN 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	this DT 0	isozyme NN B-noun.attribute	, , 0	including VBG B-verb.stative	antidepressants NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	carbamazepine NN 0	, , 0	and CC 0	Type_1C_antiarrhythmics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	propafenone NN B-noun.person	, , 0	flecainide NN B-noun.person	and CC 0	encainide VB B-verb.social	) ) 0	, , 0	or CC 0	that WDT 0	inhibit VBP B-verb.stative	this DT 0	enzyme NN B-noun.cognition	( ( 0	e.g. UH 0	, , 0	quinidine NN B-noun.location	) ) 0	, , 0	should MD 0	be VB 0	approached VBN B-verb.communication	with IN 0	caution NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d212.s2	In IN 0	addition NN 0	, , 0	levetiracetam NN B-noun.person	does VBZ 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	in FW 0	vitro FW 0	glucuronidation NN 0	of IN 0	valproic_acid NNP B-noun.location	. . 0	. . 0
DDI-DrugBank.d551.s1	WelChol UH 0	_ PRP 0	was VBD 0	found VBN B-verb.cognition	to TO 0	have VB B-verb.social	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	bioavailability NN B-noun.cognition	of IN 0	digoxin NN B-noun.person	, , 0	lovastatin NN B-noun.person	, , 0	metoprolol NN B-noun.person	, , 0	quinidine NN B-noun.location	, , 0	valproic_acid NNP B-noun.person	, , 0	and CC 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d324.s37	There EX 0	was VBD B-verb.stative	no DT 0	apparent JJ B-adj.all	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	between IN 0	zaleplon NN B-noun.person	and CC 0	ibuprofen NN B-noun.person	following VBG B-verb.stative	single JJ B-adj.all	dose NN B-noun.event	administration NN B-noun.person	( ( 0	10 CD B-adj.all	mg NN B-noun.quantity	and CC 0	600 CD 0	mg NN B-noun.quantity	, , 0	respectively RB B-adv.all	) ) 0	of IN 0	each DT 0	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d307.s38	Strong JJ B-noun.person	inducers NNS I-noun.person	of IN 0	cytochrome NN B-noun.person	P450 NN I-noun.person	enzymes NNS B-noun.person	( ( 0	i.e. FW B-adv.all	carbamazepine NN I-adv.all	, , 0	phenytoin NN B-noun.person	and CC 0	phenobarbital NN B-noun.body	) ) 0	have VBP 0	been VBN 0	shown VBN B-verb.perception	to TO 0	decrease VB B-verb.communication	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	MHD NNP 0	( ( 0	29 CD B-noun.quantity	- : 0	40 CD B-adj.all	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d493.s3	The DT 0	safety NN B-noun.artifact	and CC 0	efficacy NN B-noun.person	of IN 0	anakinra NN B-noun.animal	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	HUMIRA NNP B-noun.group	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d313.s8	If IN 0	NovoLog NNP B-noun.person	is VBZ 0	mixed VBN B-verb.change	with IN 0	NPH_human_insulin NNP B-noun.person	, , 0	NovoLog NNP B-noun.person	should MD 0	be VB 0	drawn VBN B-verb.cognition	into IN 0	the DT 0	syringe NN B-noun.body	first RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d158.s2	Adrenergic_blockers NNS B-noun.person	Adrenergic_blockers NNS I-noun.person	are VBP 0	inhibited VBN B-verb.change	by IN 0	amphetamines NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d340.s12	Because IN 0	a DT 0	similar JJ B-adj.all	interaction NN B-noun.act	is VBZ B-verb.stative	likely JJ B-adj.all	, , 0	VIRACEPT NNP B-noun.group	should MD 0	also RB 0	not RB 0	be VB 0	administered VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	astemizole NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d434.s12	In IN 0	10 CD B-adj.all	otherwise RB B-adv.all	healthy JJ B-adj.all	subjects NNS B-noun.person	with IN 0	epilepsy NN B-noun.food	ingesting VBG B-verb.consumption	phenytoin NN I-verb.consumption	, , 0	the DT 0	steadystate NN B-noun.artifact	trough NN B-noun.person	( ( 0	Cmin NNP 0	) ) 0	phenytoin NN B-noun.substance	plasma NN B-noun.substance	concentration NN B-noun.event	was VBD B-verb.stative	17 CD B-adj.all	5 CD B-adj.all	micrograms NNS B-noun.quantity	/ . 0	mL. NNP B-noun.person	. . 0
DDI-DrugBank.d336.s0	Although IN 0	clinical JJ B-adj.all	studies NNS B-noun.group	have VBP 0	not RB B-adv.all	established VBN B-verb.creation	a DT 0	cause NN B-noun.act	and CC 0	effect NN B-noun.cognition	relationship NN I-noun.cognition	, , 0	physicians NNS B-noun.person	should MD 0	be VB B-verb.stative	aware JJ B-adj.all	that IN 0	variable JJ B-adj.all	effects NNS B-noun.phenomenon	an DT 0	blood NN B-noun.act	coagulation NN B-noun.artifact	have VBP 0	been VBN 0	reported VBN B-verb.communication	very RB B-adv.all	rarely RB B-adv.all	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	oral JJ B-adj.all	anticoagulants NNS B-noun.person	and CC 0	chlordiazepoxide NN 0	. . 0	. . 0
DDI-DrugBank.d48.s14	Drugs NNS B-noun.artifact	that WDT 0	may MD 0	have VB 0	their PRP$ 0	plasma NN B-noun.substance	concentration NN 0	altered VBN B-verb.change	by IN 0	dasatinib NN B-noun.person	CYP3A4 NNP I-noun.person	Substrates NNPS I-noun.person	, , 0	Dasatinib NNP B-noun.person	is VBZ B-verb.stative	a DT 0	time NN B-noun.time	- : 0	dependent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d83.s13	In IN 0	comparison NN 0	with IN 0	haloperidol NN B-noun.person	, , 0	the DT 0	adverse JJ B-adj.all	events NNS B-noun.person	reported VBD B-verb.communication	significantly RB B-adv.all	more RBR B-adv.all	frequently RB B-adv.all	with IN 0	olanzapine NN B-noun.person	in IN 0	> CD 0	or CC 0	= $ 0	3.5 CD 0	% NN 0	of IN 0	patients NNS B-noun.person	were VBD B-verb.stative	dry JJ B-adj.all	mouth NN B-noun.object	, , 0	bodyweight VBD B-verb.contact	gain NN B-noun.artifact	and CC 0	increased VBD B-verb.change	appetite NN B-noun.artifact	and CC 0	compared VBN B-verb.possession	with IN 0	risperidone NN 0	, , 0	only RB B-adv.all	bodyweight JJ B-adj.all	gain NN B-noun.person	occurred VBD B-verb.contact	significantly RB B-adv.all	more RBR B-adv.all	frequently RB B-adv.all	with IN 0	olanzapine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d39.s6	Exogenous JJ B-adj.all	estradiol NN 0	also RB B-adv.all	appeared VBD B-verb.communication	to TO 0	influence VB B-verb.communication	the DT 0	percentage NN B-noun.possession	of IN 0	endotoxin NN B-noun.cognition	- : 0	induced JJ B-verb.creation	deaths NNS B-noun.person	in IN 0	a DT 0	dose NN B-noun.person	- : 0	dependent JJ B-adj.all	manner NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d265.s0	Chlorthalidone NN 0	may MD 0	add VB B-verb.communication	to TO 0	or CC 0	potentiate VB B-verb.communication	the DT 0	action NN B-noun.process	of IN 0	other JJ B-adj.all	antihypertensive_drugs NNS B-noun.object	. . 0	. . 0
DDI-DrugBank.d355.s2	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	oxyphenbutazone NN B-noun.substance	and CC 0	androgens NNS B-noun.animal	may MD 0	result VB B-verb.stative	in IN 0	elevated JJ B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	oxyphenbutazone NN 0	. . 0	. . 0
DDI-DrugBank.d509.s2	1- CC 0	adrenergic JJ B-adj.all	receptor NN B-noun.cognition	antagonism NN B-noun.attribute	, , 0	aripiprazole NN B-noun.group	has VBZ B-verb.possession	the DT 0	potential NN B-noun.person	to TO 0	enhance VB B-verb.change	the DT 0	effect NN B-noun.cognition	of IN 0	certain JJ B-adj.all	antihypertensive_agents NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d531.s29	In IN 0	uninfected JJ B-adj.all	volunteers NNS B-noun.person	, , 0	46 CD 0	% NN 0	developed JJ B-adj.all	rash NN B-noun.person	while IN 0	receiving VBG B-verb.change	SUSTIVA NNP B-noun.group	and CC 0	clarithromycin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d531.s50	Plasma NNP B-noun.person	concentrations NNS I-noun.person	increased VBN B-verb.change	by IN 0	SUSTIVA NNP 0	( ( 0	efavirenz NN 0	) ) 0	, , 0	. . 0
DDI-DrugBank.d489.s2	Catecholamine SYM 0	- : 0	depleting VBG B-verb.communication	drugs NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	reserpine NN B-noun.location	) ) 0	may MD 0	have VB B-verb.possession	an DT 0	additive JJ B-adj.all	effect NN B-noun.cognition	when WRB 0	given VBN B-verb.possession	with IN 0	beta JJ B-noun.body	- : 0	blocking VBG B-verb.communication	agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d556.s0	Increased VBN B-verb.change	nephrotoxicity NN B-noun.attribute	has VBZ 0	been VBN 0	reported VBN B-verb.communication	following VBG B-verb.stative	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	cephalosporins NNS B-noun.artifact	and CC 0	aminoglycoside_antibiotics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d272.s1	Bromocriptine_mesylate NN B-noun.group	may MD 0	interact VB B-verb.change	with IN 0	dopamine_antagonists NNS B-noun.person	, , 0	butyrophenones NNS 0	, , 0	and CC 0	certain JJ B-adj.all	other JJ 0	agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d43.s13	The DT 0	optimal JJ B-adj.all	dosing NN B-noun.possession	interval NN I-noun.possession	for IN 0	coadministration NN B-noun.person	with IN 0	VIDEX NNP B-noun.group	should MD 0	be VB 0	determined VBN B-verb.communication	by IN 0	consulting VBG B-verb.communication	the DT 0	appropriate JJ B-adj.all	quinolone NN B-noun.artifact	package NN B-noun.artifact	insert NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d427.s10	multivitamins NNS B-noun.animal	containing VBG B-verb.consumption	zinc NN I-verb.consumption	, , 0	. . 0
DDI-DrugBank.d7.s2	Cyclophosphamide NNP B-noun.person	treatment NN I-noun.person	, , 0	which WDT 0	causes VBZ B-verb.stative	a DT B-adj.all	marked VBN I-adj.all	and CC 0	persistent JJ B-adj.all	inhibition NN B-noun.attribute	of IN 0	cholinesterase NN B-noun.phenomenon	activity NN B-noun.process	, , 0	potentiates VBZ B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	succinylcholine_chloride JJ 0	. . 0	. . 0
DDI-DrugBank.d500.s1	Since IN 0	bacteriostatic JJ B-adj.all	drugs NNS B-noun.artifact	may MD 0	interfere VB B-verb.stative	with IN 0	the DT 0	bactericidal JJ B-adj.all	action NN B-noun.process	of IN 0	penicillin NN B-noun.food	, , 0	it PRP 0	is VBZ B-verb.stative	advisable JJ B-adj.all	to TO 0	avoid VB B-verb.social	giving VBG B-verb.possession	tetracyclines NNS B-noun.communication	in IN 0	conjunction NN 0	with IN 0	penicillin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d38.s2	However RB 0	, , 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	stress NN B-noun.state	and CC 0	glucocorticoids NNS B-noun.person	on IN 0	the DT 0	subjective JJ B-adj.all	and CC 0	behavioral JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	psychostimulants NNS B-noun.person	have VBP 0	not RB 0	been VBN 0	well RB 0	studied VBN B-verb.cognition	in IN 0	humans NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d434.s11	Specific NNP B-noun.other	Effects NNPS I-noun.other	of IN I-noun.other	Felbatol NNP I-noun.other	_ ( I-noun.other	on IN I-noun.other	Other JJ I-noun.other	Antiepileptic_Drugs NNPS I-noun.other	Phenytoin NNP I-noun.other	, , 0	Felbatol NNP B-noun.person	_ , 0	causes VBZ B-verb.communication	an DT 0	increase NN B-noun.act	in IN 0	steady JJ B-adj.all	- : 0	state NN B-adj.all	phenytoin NN B-noun.substance	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d347.s8	Sucralfate NNP B-noun.person	should MD 0	not RB 0	be VB 0	taken VBN B-verb.social	within IN 0	2 CD B-adj.all	hours NNS B-noun.person	of IN 0	FACTIVE NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d217.s2	Therefore RB 0	, , 0	monitoring NN B-verb.perception	of IN 0	theophylline JJ 0	plasma NN B-noun.substance	levels NNS B-noun.attribute	should MD 0	be VB 0	considered VBN B-verb.cognition	and CC 0	dosage NN B-noun.act	of IN 0	theophylline NN 0	adjusted VBN B-verb.change	as IN 0	required VBN B-verb.stative	. . 0	. . 0
DDI-DrugBank.d163.s7	It PRP 0	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	if IN 0	hormonal_contraceptives NNS B-noun.artifact	differ VBP B-verb.stative	in IN 0	their PRP$ 0	effectiveness NN B-noun.cognition	when WRB 0	used VBN B-verb.consumption	with IN 0	Accutane NNP B-noun.person	. . 0	. . 0
DDI-MedLine.d58.s3	In IN 0	this DT 0	study NN B-noun.communication	we PRP 0	investigated VBD B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	ginsenosides NNS B-noun.person	on IN 0	high JJ B-adj.all	threshold JJ B-noun.artifact	voltage NN B-noun.act	- : 0	dependent JJ B-noun.person	Ca(2 NN I-noun.person	+ '' 0	) ) 0	channel NN 0	subtypes NNS B-noun.food	using VBG B-verb.consumption	their PRP$ 0	selective_Ca(2+)_channel_blockers NNS B-noun.other	nimodipine VBP B-verb.social	( ( 0	L SYM 0	- : 0	type NN B-noun.person	) ) 0	, , 0	omega JJ B-noun.person	- : 0	conotoxin_GVIA NN B-noun.group	( ( 0	N SYM 0	- : 0	type NN B-noun.person	) ) 0	, , 0	or CC 0	omega JJ B-adj.pert	- : 0	agatoxin_IVA RB 0	( ( 0	P SYM 0	- : 0	type NN B-noun.person	) ) 0	in IN 0	bovine NN 0	chromaffin NN B-noun.body	cells NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d76.s4	Therefore RB 0	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	Fluvoxamine NNP B-noun.person	Tablets NNPS I-noun.person	not RB B-adv.all	be VB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	MAOIs NNP B-noun.person	, , 0	or CC 0	within IN 0	14 CD B-adj.all	days NNS B-noun.time	of IN 0	discontinuing VBG B-verb.communication	treatment NN I-verb.communication	with IN 0	a DT 0	MAOI NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d86.s1	Interactions NNS B-noun.possession	may MD 0	also RB 0	occur VBP B-verb.stative	with IN 0	the DT 0	following NN 0	, , 0	anti NNS B-noun.person	- : 0	depressants NNS B-noun.group	/ POS 0	anti NNS B-noun.attribute	- : 0	anxiety_drugs NNS B-noun.time	, , 0	drugs NNS B-noun.person	used VBN B-verb.consumption	to TO 0	treat VB B-verb.social	an DT 0	overactive JJ B-adj.all	thyroid NN B-noun.body	, , 0	beta JJ 0	- : 0	blockers NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	propranolol NN 0	) ) 0	, , 0	sparfloxacin NN B-noun.person	, , 0	grepafloxacin NN B-noun.person	, , 0	guanethidine NN B-noun.person	, , 0	guanadrel NN B-noun.location	, , 0	metrizamide NN B-noun.attribute	, , 0	cabergoline NN B-noun.person	, , 0	lithium NN B-noun.person	, , 0	narcotic JJ B-adj.all	pain NN B-noun.cognition	medication NN B-noun.attribute	( ( 0	e.g. UH 0	, , 0	codeine NN 0	) ) 0	, , 0	drugs NNS B-noun.person	used VBN B-verb.consumption	to TO 0	aid VB B-verb.consumption	sleep NN I-verb.consumption	, , 0	drowsiness NN B-noun.person	- : 0	causing VBG B-verb.communication	antihistamines NNS B-noun.attribute	( ( 0	e.g. UH 0	, , 0	diphenhydramine NN 0	) ) 0	, , 0	any DT 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	may MD 0	make VB B-verb.cognition	you PRP 0	drowsy VBP B-verb.motion	. . 0	. . 0
DDI-MedLine.d137.s0	Glucose NNP B-noun.person	and CC 0	insulin VB B-verb.contact	exert JJ B-adj.all	additive JJ B-adj.all	ocular NN B-noun.state	and CC 0	renal JJ B-adj.all	vasodilator NN B-noun.phenomenon	effects NNS B-noun.phenomenon	on IN 0	healthy JJ B-adj.all	humans NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d113.s2	Aspirin NNP B-noun.person	, , 0	Concurrent NNP B-noun.person	administration NN I-noun.person	of IN 0	aspirin NN B-noun.animal	may MD 0	lower VB B-verb.change	meclofenamate_sodium JJ B-adj.all	plasma NN B-noun.substance	levels NNS B-noun.state	, , 0	possibly RB B-adv.all	by IN 0	competing VBG B-verb.competition	for IN 0	protein NN B-noun.person	- : 0	binding JJ B-verb.contact	sites NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d263.s17	If IN 0	intravenous JJ B-adj.all	pentamidine NN B-noun.person	is VBZ 0	required VBN B-verb.stative	to TO 0	treat VB B-verb.communication	Pneumocystis NNP B-noun.person	carinii NN I-noun.person	pneumonia NN B-noun.person	, , 0	treatment NN B-noun.plant	with IN 0	HIVID NNP B-noun.group	should MD 0	be VB 0	interrupted VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d249.s2	Because IN 0	prostaglandins NNS B-noun.person	play VBP B-verb.social	an DT 0	important JJ B-adj.all	role NN B-noun.attribute	in IN 0	hemostasis NN B-noun.location	, , 0	and CC 0	NSAIDs NNP B-noun.person	affect VBP B-verb.change	platelet NN B-verb.creation	function NN B-noun.act	as RB 0	well RB 0	, , 0	concurrent JJ B-adj.all	therapy NN B-noun.person	with IN 0	all DT 0	NSAIDs NNP B-noun.location	, , 0	including VBG B-verb.change	diclofenac NN B-noun.food	, , 0	and CC 0	warfarin NN B-noun.act	requires VBZ B-verb.stative	close JJ B-adj.all	monitoring NN B-noun.person	of IN 0	patients NNS B-noun.person	to TO 0	be VB B-verb.stative	certain JJ B-adj.all	that IN 0	no DT 0	change NN B-noun.act	in IN 0	their PRP$ 0	anticoagulant JJ B-adj.all	dosage NN B-noun.communication	is VBZ 0	required VBN B-verb.stative	. . 0	. . 0
DDI-DrugBank.d3.s16	The DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	TORADOL NNP B-noun.person	with IN 0	muscle_relaxants NNS B-noun.group	has VBZ 0	not RB 0	been VBN 0	formally RB B-adv.all	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d210.s31	Warfarin NNP B-noun.person	, , 0	Anticoagulant JJ B-adj.all	activity NN B-noun.state	should MD 0	be VB 0	monitored VBN B-verb.perception	, , 0	particularly RB B-adv.all	in IN 0	the DT 0	first JJ B-adj.all	few JJ B-noun.animal	days NNS B-noun.phenomenon	after IN 0	initiating VBG B-verb.motion	or CC 0	changing VBG B-verb.change	VIOXX NNP B-noun.group	therapy NN 0	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	warfarin NN B-noun.act	or CC 0	similar JJ B-adj.all	agents NNS B-noun.person	, , 0	since IN 0	these DT 0	patients NNS B-noun.person	are VBP B-verb.stative	at IN 0	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	bleeding VBG B-verb.body	complications NNS I-verb.body	. . 0	. . 0
DDI-DrugBank.d314.s23	In IN 0	addition NN 0	, , 0	ketoconazole NN B-noun.person	alone RB 0	can MD 0	inhibit VB B-verb.change	adrenal JJ B-adj.all	corticosteroid JJ B-adj.all	synthesis NN B-noun.body	and CC 0	may MD 0	cause VB B-verb.communication	adrenal JJ B-adj.all	insufficiency NN B-noun.attribute	during IN 0	corticosteroid JJ B-adj.all	withdrawal NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d109.s0	Ketoconazole NNP B-noun.group	/ NNP I-noun.group	Itraconazole NNP I-noun.group	, , 0	Macrolides NNP B-noun.person	, , 0	Including NNP B-noun.person	Erythromycin NNP I-noun.person	. . 0
DDI-DrugBank.d116.s0	Careful JJ B-adj.all	observation NN B-noun.act	is VBZ 0	required VBN B-verb.stative	when WRB 0	amantadine NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	central_nervous_system_stimulants NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d289.s23	Ketoconazole NNP B-noun.person	, , 0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	bosentan JJ 0	125 CD 0	mg IN 0	b.i.d NNP B-noun.person	. . 0	and CC 0	ketoconazole NN B-noun.person	, , 0	a DT 0	potent JJ B-noun.person	CYP3A4 NNP I-noun.person	inhibitor NN I-noun.person	, , 0	increased VBD B-verb.change	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	bosentan NN B-noun.act	by IN 0	approximately RB B-adj.all	2-fold JJ I-adj.all	. . 0	. . 0
DDI-DrugBank.d469.s7	Drugs NNS B-noun.artifact	which WDT 0	may MD 0	enhance VB B-verb.change	the DT 0	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	action NN B-noun.process	of IN 0	TRACRIUM NNP B-noun.group	include VBP B-verb.stative	, , 0	enflurane NN B-noun.person	, , 0	isoflurane NN B-noun.person	, , 0	halothane NN B-noun.person	, , 0	certain JJ B-adj.all	antibiotics NNS B-noun.person	, , 0	especially RB B-adv.all	the DT 0	aminoglycosides NNS B-noun.artifact	and CC 0	polymyxins NNS B-noun.person	, , 0	lithium NN B-noun.person	, , 0	magnesium NN B-noun.person	salts NNS B-noun.substance	, , 0	procainamide NN B-noun.person	, , 0	and CC 0	quinidine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d59.s1	The DT 0	pressor NN B-noun.substance	effects NNS B-noun.phenomenon	of IN 0	ERGOMAR NNP B-noun.group	and CC 0	other JJ B-adj.all	vasoconstrictor_drugs NNS B-noun.plant	can MD 0	combine VB B-verb.cognition	to TO 0	cause VB B-verb.communication	dangerous JJ B-adj.all	hypertension NN B-noun.event	. . 0	. . 0
DDI-DrugBank.d353.s2	Repeating VBG B-verb.communication	the DT 0	study NN B-noun.artifact	with IN 0	6 CD B-adj.all	healthy JJ B-adj.all	male NN B-noun.person	volunteers NNS B-noun.person	in IN 0	the DT 0	absence NN B-noun.act	of IN 0	glibenclamide NN B-noun.attribute	did VBD 0	not RB B-adv.all	detect VB B-verb.cognition	an DT 0	effect NN B-noun.cognition	of IN 0	acitretin NN B-noun.person	on IN 0	glucose NN 0	tolerance NN 0	. . 0	. . 0
DDI-DrugBank.d295.s2	The DT 0	effects NNS B-noun.phenomenon	of IN 0	coadministration NN B-noun.person	of IN 0	BARACLUDE NNP 0	with IN 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	renally RB B-adv.all	eliminated VBN B-verb.emotion	or CC 0	are VBP 0	known VBN B-verb.cognition	to TO 0	affect VB B-verb.change	renal JJ B-adj.all	function NN B-noun.act	have VBP 0	not RB 0	been VBN 0	evaluated VBN B-verb.communication	, , 0	and CC 0	patients NNS B-noun.person	should MD 0	be VB 0	monitored VBN B-verb.change	closely RB B-adj.all	for IN 0	adverse JJ B-adj.all	events NNS B-noun.event	when WRB 0	BARACLUDE NNP 0	is VBZ 0	coadministered VBN B-verb.contact	with IN 0	such JJ B-adj.all	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d15.s1	After IN 0	prolonged VBN B-verb.social	administration NN B-noun.person	of IN 0	neuroleptics NNS B-noun.person	the DT 0	displacing JJ B-adj.all	effect NN B-noun.cognition	of IN 0	cerulein NN B-noun.communication	, , 0	an DT 0	analog NN B-noun.group	of IN 0	cholecystokinin NN B-adj.all	octapeptide NN B-noun.event	, , 0	was VBD 0	replaced VBN B-verb.social	by IN 0	the DT 0	stimulant JJ B-adj.all	action NN B-noun.person	on IN 0	3H SYM 0	- : 0	spiroperidol NN B-noun.substance	binding NN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d237.s16	certain JJ B-adj.all	tetracyclic_antidepressants NNS B-noun.artifact	( ( 0	such JJ 0	as IN 0	maprotiline NN 0	) ) 0	, , 0	. . 0
DDI-MedLine.d103.s4	Physiological JJ B-adj.pert	oral JJ B-adj.all	magnesium NN B-noun.person	load NN B-noun.phenomenon	constitutes VBZ B-verb.communication	the DT 0	best JJS B-adj.all	tool NN B-noun.act	for IN 0	diagnosis NN B-noun.act	of IN 0	magnesium NN B-noun.person	deficiency NN B-noun.person	and CC 0	the DT 0	first JJ B-adj.all	step NN B-noun.quantity	of IN 0	its PRP$ 0	treatment NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d531.s37	The DT 0	optimal JJ B-adj.all	dose NN B-noun.quantity	of IN 0	indinavir NN B-noun.person	, , 0	when WRB 0	given VBN B-verb.possession	in IN 0	combination NN 0	with IN 0	SUSTIVA NNP B-noun.group	, , 0	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	. . 0	. . 0
DDI-MedLine.d131.s5	It PRP 0	is VBZ 0	concluded VBN B-verb.cognition	that IN 0	neurotensin NN B-noun.person	modulates NNS B-noun.person	in IN 0	an DT 0	opposite JJ B-adj.all	way NN 0	the DT 0	function NN B-noun.act	of IN 0	the DT 0	enkephalinergic JJ B-adj.all	neurons NNS B-noun.motive	and CC 0	the DT 0	central JJ B-noun.body	action NN I-noun.body	of IN 0	tuftsin NN B-noun.food	. . 0	. . 0
DDI-MedLine.d66.s2	The DT 0	results NNS B-noun.communication	indicate VBP B-verb.communication	that IN 0	a DT 0	statistically RB B-adv.all	significant JJ B-adj.all	difference NN B-noun.state	exists VBZ B-verb.stative	between IN 0	the DT 0	excreted JJ B-adj.all	levels NNS B-noun.state	of IN 0	homocysteine NN B-noun.location	in IN 0	the DT 0	urine NN B-noun.location	of IN 0	both DT 0	control NN B-noun.state	and CC 0	levonorgestrel NN B-noun.attribute	- : 0	treated VBN B-verb.communication	rats NNS B-noun.person	and CC 0	the DT 0	levels NNS B-noun.artifact	shown VBN B-verb.perception	by IN 0	rats NNS B-noun.person	treated VBN B-verb.social	with IN 0	ethynyl_estradiol NN 0	. . 0	. . 0
DDI-DrugBank.d464.s0	Codeine NN B-noun.person	in IN 0	combination NN 0	with IN 0	other JJ B-adj.all	narcotic_analgesics NNS B-noun.person	, , 0	general JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	tranquilizers NNS B-noun.person	, , 0	sedative JJ B-adj.all	- : 0	hypnotics NNS B-noun.person	, , 0	or CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	( ( 0	including VBG B-verb.emotion	alcohol NN I-verb.emotion	) ) 0	has VBZ 0	additive JJ B-verb.change	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d297.s5	There EX 0	is VBZ B-verb.stative	insufficient JJ B-adj.all	experience NN B-noun.cognition	to TO 0	assess VB B-verb.cognition	the DT 0	safety NN B-noun.artifact	and CC 0	efficacy NN B-noun.person	of IN 0	ORENCIA NNP B-noun.group	administered VBD B-verb.possession	concurrently RB B-adv.all	with IN 0	anakinra NN B-noun.body	, , 0	and CC 0	therefore RB B-adv.all	such JJ B-adj.all	use NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d551.s2	WelChol NNP B-noun.person	_ CC 0	decreased VBD B-verb.change	the DT 0	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	of IN 0	sustained VBN B-verb.body	- : 0	release NN B-verb.body	verapamil NN 0	( ( 0	Calan_SR JJ 0	) ) 0	by IN 0	approximately RB B-noun.time	31 CD 0	% NN 0	and CC 0	11 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-MedLine.d109.s9	The DT 0	harmonic JJ B-adj.all	mean JJ B-adj.all	elimination NN B-noun.person	half NN B-noun.person	- : 0	life NN B-noun.person	was VBD B-verb.stative	45.7 CD 0	and CC 0	43.4 CD 0	hours NNS B-noun.quantity	for IN 0	rofecoxib NN B-noun.act	+ : 0	digoxin NN B-noun.person	and CC 0	placebo NN B-noun.person	+ : 0	digoxin NN B-noun.person	treatments NNS B-noun.plant	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d172.s7	Experience NN B-noun.person	with IN 0	nonsteroidal_anti JJ B-noun.person	- : 0	inflammatory_drugs NNS B-noun.cognition	( ( 0	NSAIDs NNP B-noun.person	) ) 0	suggests VBZ B-verb.communication	the DT 0	potential NN B-noun.person	for IN 0	interactions NNS B-noun.person	with IN 0	furosemide NN B-noun.artifact	and CC 0	ACE_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d448.s5	Increased VBN B-verb.change	ectopic JJ B-adj.pert	pacemaker NN B-noun.person	activity NN B-noun.person	can MD 0	occur VB B-verb.cognition	when WRB 0	pseudoephedrine NN B-noun.person	is VBZ 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	digitalis NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d252.s4	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	beta JJ B-adj.pert	- : 0	adrenergic_blocking_agents NNS B-noun.person	with IN 0	digitalis NNS B-noun.food	and CC 0	calcium_antagonists NNS B-noun.person	may MD 0	have VB B-verb.change	additive JJ B-adj.all	effects NNS B-noun.phenomenon	on IN 0	prolonging VBG B-verb.creation	atrioventricular JJ B-adj.all	conduction NN B-noun.shape	time NN B-noun.time	. . 0	. . 0
DDI-MedLine.d36.s2	We PRP 0	report VBP B-verb.communication	the DT 0	case NN B-noun.state	of IN 0	an DT 0	adolescent NN B-noun.person	with IN 0	altered JJ B-adj.all	consciousness NN B-noun.person	caused VBN B-verb.communication	by IN 0	carbamazepine NN 0	overdose NN 0	with IN 0	a DT 0	positive JJ B-adj.all	tricyclic_antidepressant JJ B-adj.all	level NN B-noun.attribute	to TO 0	alert VB B-verb.social	clinicians NNS B-noun.person	to TO 0	the DT 0	cross NN B-noun.person	- : 0	reactivity NN B-noun.process	of IN 0	carbamazepine NN 0	with IN 0	a DT 0	toxicology NN B-noun.person	screen NN B-noun.person	for IN 0	tricyclic_antidepressants NNS B-noun.act	. . 0	. . 0
DDI-MedLine.d63.s4	Intrathecal JJ B-adj.all	injection NN B-noun.act	of IN 0	naloxone NN 0	at IN 0	doses NNS B-noun.act	of IN 0	0.4 CD 0	to TO 0	40 CD B-adj.all	micrograms NNS B-noun.person	caused VBD B-verb.communication	a DT 0	dose NN B-noun.person	- : 0	related JJ B-adj.all	blockade NN B-noun.attribute	of IN 0	the DT 0	inhibition NN B-noun.attribute	of IN 0	the DT 0	tail NN B-noun.body	- : 0	flick NN B-noun.artifact	response NN I-noun.artifact	induced VBN B-verb.creation	by IN 0	intraventricular JJ B-adj.all	injection NN B-noun.act	of IN 0	beta JJ B-adj.pert	- : 0	endorphin NN B-noun.person	, , 0	and CC 0	a DT 0	high JJ B-adj.all	dose NN B-noun.quantity	of IN 0	naloxone NN B-noun.substance	( ( 0	40 CD B-adj.all	micrograms NNS B-noun.quantity	) ) 0	completely RB B-adv.all	blocked VBD B-verb.contact	the DT 0	tail NN B-noun.body	- : 0	flick NN 0	inhibition NN 0	induced VBN B-verb.creation	by IN 0	intraventricular JJ B-adj.all	beta NN B-noun.food	- : 0	endorphin NN B-noun.cognition	( ( 0	16 CD B-adj.all	micrograms NNS B-noun.quantity	) ) 0	. . 0	. . 0
DDI-DrugBank.d522.s24	Other JJ 0	drugs NNS B-noun.artifact	Drug NN B-noun.person	interactions NNS I-noun.person	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	erythromycin NN B-noun.food	and CC 0	other JJ 0	medications NNS B-noun.person	, , 0	including VBG B-verb.social	cyclosporine NN B-noun.act	, , 0	hexobarbital JJ B-adj.all	, , 0	carbamazepine NN 0	, , 0	alfentanil RB 0	, , 0	disopyramide NN 0	, , 0	phenytoin NN B-noun.person	, , 0	bromocriptine NN B-noun.person	, , 0	valproate NN B-noun.attribute	, , 0	astemizole NN B-noun.location	, , 0	and CC 0	lovastatin NN B-noun.feeling	. . 0	. . 0
DDI-DrugBank.d485.s27	Non SYM 0	- : 0	nucleoside_reverse_transcriptase_inhibitors NNS B-noun.person	( ( 0	NNRTIs NNP 0	) ) 0	, , 0	Nevirapine NNP B-noun.location	may MD 0	decrease VB B-verb.change	plasma NN B-noun.state	levels NNS B-noun.state	of IN 0	combination_hormonal_contraceptives NNS B-noun.person	, , 0	. . 0
DDI-DrugBank.d314.s1	Amphotericin_B JJ B-adj.all	injection NN B-noun.act	and CC 0	potassium NN B-noun.person	- : 0	depleting VBG B-verb.communication	agents NNS B-noun.person	, , 0	When WRB 0	corticosteroids NNS B-noun.animal	are VBP 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	potassium NN B-noun.person	- : 0	depleting VBG B-verb.communication	agents NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	amphotericin_B JJ 0	, , 0	diuretics NNS B-noun.person	) ) 0	, , 0	patients NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adj.all	for IN 0	development NN B-noun.process	of IN 0	hypokalemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d313.s3	Beta SYM 0	- : 0	blockers NNS B-noun.person	, , 0	clonidine NN B-noun.person	, , 0	lithium NN B-noun.substance	salts NNS B-noun.substance	, , 0	and CC 0	alcohol NN B-noun.act	may MD 0	either RB 0	potentiate JJ B-adj.all	or CC 0	weaken VB B-verb.body	the DT 0	blood NN B-noun.act	- : 0	glucose NN B-noun.person	- : 0	lowering VBG B-verb.motion	effect NN 0	of IN 0	insulin NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d467.s5	Under IN 0	similar JJ B-adj.all	conditions NNS B-noun.artifact	, , 0	bexarotene NN B-noun.person	concentrations NNS B-noun.person	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	concomitant JJ B-adj.all	atorvastatin NN B-adj.all	administration NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d558.s25	Inhibitors NNS B-noun.person	of IN 0	this DT 0	isoenzyme NN B-noun.cognition	( ( 0	e.g. UH 0	, , 0	macrolide_antibiotics NNS B-noun.person	, , 0	azole_antifungal_agents NNS B-noun.person	, , 0	protease_inhibitors NNS B-noun.person	, , 0	serotonin_reuptake_inhibitors NNS B-noun.person	, , 0	amiodarone NN 0	, , 0	cannabinoids NNS B-noun.communication	, , 0	diltiazem NN B-noun.person	, , 0	grapefruit NN B-adj.all	juice NN B-noun.person	, , 0	nefazadone NN 0	, , 0	norfloxacin NN B-noun.person	, , 0	quinine NN B-noun.location	, , 0	zafirlukast NN 0	) ) 0	should MD 0	be VB B-verb.stative	cautiously RB B-adv.all	coadministered VBN B-verb.contact	with IN 0	TIKOSYN NNP B-noun.group	as IN 0	they PRP 0	can MD 0	potentially RB B-adv.all	increase JJ B-adj.all	dofetilide NN 0	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d512.s6	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	ketoconazole NN B-noun.shape	, , 0	a DT 0	strong JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	, , 0	increased VBD B-verb.change	cinacalcet JJ B-adj.all	exposure NN B-noun.state	following VBG B-verb.stative	a DT 0	single JJ B-adj.all	90 CD B-adj.all	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	Sensipar NNP B-noun.person	by IN 0	2.3 CD 0	fold NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d439.s0	Corticotropin NNP B-noun.person	may MD 0	accentuate VB B-verb.cognition	the DT 0	electrolyte NN B-noun.location	loss NN B-noun.person	associated VBN B-verb.cognition	with IN 0	diuretic JJ B-adj.all	therapy NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d40.s10	The DT 0	most RBS 0	commonly RB B-adv.all	occurring VBG B-verb.stative	drug NN B-noun.person	interactions NNS I-noun.person	are VBP 0	listed VBN B-verb.social	below RB 0	, , 0	; : 0	Drugs NNS B-noun.person	that WDT 0	may MD 0	increase VB B-verb.change	plasma NN 0	phenytoin NN B-noun.body	concentrations NNS B-noun.attribute	include VBP B-verb.change	, , 0	acute JJ B-adj.all	alcohol NN B-noun.person	intake NN I-noun.person	, , 0	amiodarone NN 0	, , 0	chboramphenicol NN B-noun.person	, , 0	chlordiazepoxide NN 0	, , 0	cimetidine NN B-noun.person	, , 0	diazepam NN B-noun.person	, , 0	dicumarol NN B-noun.person	, , 0	disulfiram NN B-noun.person	, , 0	estrogens VBZ B-verb.cognition	, , 0	ethosuximide NN 0	, , 0	fluoxetine NN B-noun.person	, , 0	H2-antagonists NNS B-noun.person	, , 0	halothane NN B-noun.person	, , 0	isoniazid NN B-noun.person	, , 0	methylphenidate NN B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	phenylbutazone NN B-noun.person	, , 0	salicylates NNS B-noun.person	, , 0	succinimides VBZ B-verb.motion	, , 0	sulfonamides VBZ B-verb.motion	, , 0	tolbutamide NN 0	, , 0	trazodone NN 0	. . 0
DDI-DrugBank.d437.s4	HIV_Protease_Inhibitors NNS B-noun.person	, , 0	The DT 0	effect NN B-noun.cognition	of IN 0	amprenavir NN B-noun.person	on IN 0	total JJ B-adj.all	drug NN B-noun.act	concentrations NNS B-noun.attribute	of IN 0	other JJ B-adj.all	HIV_protease_inhibitors NNS B-noun.person	in IN 0	subjects NNS B-noun.artifact	receiving VBG B-verb.communication	both DT 0	agents NNS B-noun.person	was VBD 0	evaluated VBN B-verb.change	using VBG B-verb.consumption	comparisons NNS B-noun.person	to TO 0	historical JJ B-adj.all	data NNS B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d462.s6	Anticoagulants NNS B-noun.person	, , 0	Coagulation NNP B-noun.person	parameters NNS I-noun.person	should MD 0	be VB 0	tested VBN B-verb.social	more RBR B-adv.all	frequently RB B-adv.all	and CC 0	monitored VBD B-verb.perception	regularly RB B-adv.all	during IN 0	simultaneous JJ B-adj.all	administration NN B-noun.act	of IN 0	high JJ B-adj.all	doses NNS B-noun.attribute	of IN 0	heparin NN B-noun.person	, , 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	, , 0	or CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	that WDT 0	may MD 0	affect VB B-verb.change	the DT 0	blood NN B-noun.location	coagulation NN B-noun.act	system NN B-noun.cognition	or CC 0	the DT 0	thrombocyte NN B-noun.artifact	function NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d438.s30	Thus RB 0	cimetidine NN 0	appeared VBD 0	to TO 0	alter VB B-verb.change	the DT 0	renal JJ B-adj.all	excretion NN B-noun.act	of IN 0	both DT 0	gabapentin NN B-noun.communication	and CC 0	creatinine NN B-noun.person	, , 0	an DT 0	endogenous JJ B-adj.all	marker NN B-noun.person	of IN 0	renal JJ B-adj.all	function NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d225.s6	These DT 0	drugs NNS B-noun.artifact	include VBP B-verb.change	the DT 0	thiazides NNS B-noun.artifact	and CC 0	other JJ 0	diuretics NNS B-noun.person	, , 0	corticosteroids NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	thyroid_products NNS B-noun.body	, , 0	estrogens VBZ B-verb.cognition	, , 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	nicotinic_acid JJ 0	, , 0	sympathomimetics NNS B-noun.person	, , 0	calcium_channel_blocking_drugs NNS B-noun.communication	, , 0	and CC 0	isoniazid NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d236.s19	Lithium_carbonate JJ B-adj.all	, , 0	The DT 0	stimulatory JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	amphetamines NNS B-noun.animal	may MD 0	be VB 0	inhibited VBN B-verb.change	by IN 0	lithium_carbonate JJ B-noun.time	. . 0	. . 0
DDI-DrugBank.d172.s13	Aspirin NNP B-noun.person	, , 0	CELEBREX NNP B-noun.group	can MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	low JJ B-adj.all	dose NN 0	aspirin NN 0	. . 0	. . 0
DDI-DrugBank.d529.s3	The DT 0	physician NN B-noun.communication	should MD 0	be VB B-verb.stative	cautious JJ B-adj.all	when WRB 0	administering VBG B-verb.communication	flurbiprofen NN B-noun.person	to TO 0	patients NNS B-noun.person	taking VBG B-verb.social	anticoagulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d95.s3	Sildenafil_citrate JJ B-noun.attribute	; : 0	Theoretically RB B-adv.all	, , 0	L NNP 0	- : 0	arginine NN B-noun.act	supplements NNS B-noun.artifact	taken VBN 0	concomitantly RB B-adv.all	with IN 0	sildenafil_citrate JJ B-noun.attribute	, , 0	may MD 0	potentiate VB B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	the DT 0	drug NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d78.s16	include VBP B-verb.change	terfenadine NN B-noun.artifact	, , 0	astemizole NN B-noun.location	, , 0	cisapride NN 0	, , 0	midazolam NN B-noun.person	, , 0	and CC 0	triazolam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d428.s1	Concomitant JJ B-adj.all	use NN 0	of IN 0	ELLENCE NNP B-noun.group	with IN 0	other JJ 0	cardioactive JJ B-adj.all	compounds NNS B-noun.person	that WDT 0	could MD 0	cause VB B-verb.creation	heart NN 0	failure NN B-noun.person	( ( 0	e.g. UH 0	, , 0	calcium_channel_blockers NNS B-noun.location	) ) 0	, , 0	requires VBZ B-verb.stative	close JJ B-adj.all	monitoring NN B-noun.person	of IN 0	cardiac JJ B-adj.all	function NN B-noun.act	throughout IN 0	treatment NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d158.s19	Phenobarbital JJ B-adj.all	, , 0	Amphetamines NNPS B-noun.person	may MD 0	delay VB B-verb.stative	intestinal JJ B-adj.all	absorption NN B-noun.act	of IN 0	phenobarbital NN B-noun.artifact	, , 0	. . 0
DDI-DrugBank.d420.s3	If IN 0	antacids NNS B-noun.person	are VBP 0	required VBN B-verb.stative	during IN 0	OMNICEF NNP B-noun.person	therapy NN I-noun.person	, , 0	OMNICEF NNP B-noun.group	should MD 0	be VB 0	taken VBN B-verb.possession	at IN 0	least JJS 0	2 CD B-adj.all	hours NNS B-noun.artifact	before IN 0	or CC 0	after IN 0	the DT 0	antacid NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d347.s7	Magnesium- NNS B-noun.person	and/or CC 0	aluminum NN B-noun.person	- : 0	containing VBG B-verb.stative	antacids NNS B-noun.substance	, , 0	products NNS B-noun.artifact	containing VBG B-verb.stative	ferrous_sulfate NNP I-verb.stative	( ( 0	iron NN B-noun.person	) ) 0	, , 0	multivitamin_preparations NNS B-noun.person	containing VBG B-verb.stative	zinc NN B-noun.substance	or CC 0	other JJ B-adj.all	metal NN B-noun.object	cations NNS B-noun.artifact	, , 0	or CC 0	Videx NNP B-noun.person	( ( 0	didanosine NN 0	) ) 0	chewable NN B-noun.communication	/ : 0	buffered VBN B-verb.creation	tablets NNS B-noun.artifact	or CC 0	the DT 0	pediatric JJ B-adj.pert	powder NN B-noun.state	for IN 0	oral JJ B-adj.all	solution NN B-noun.cognition	should MD 0	not RB 0	be VB 0	taken VBN B-verb.social	within IN 0	3 CD B-adj.all	hours NNS B-noun.artifact	before IN 0	or CC 0	2 CD B-adj.all	hours NNS B-noun.person	after IN 0	FACTIVE NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d31.s1	When WRB 0	other JJ 0	potent JJ B-adj.all	parental JJ B-adj.all	antihypertensive_drugs NNS B-noun.object	, , 0	such JJ 0	as IN 0	diazoxide NN B-noun.person	, , 0	are VBP 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	hydralazine NN B-noun.person	, , 0	patients NNS B-noun.person	should MD 0	be VB B-verb.stative	continuously RB B-adv.all	observed VBN B-verb.perception	for IN 0	several JJ B-adj.all	hours NNS B-noun.person	for IN 0	any DT 0	excessive JJ B-adj.all	fall NN B-noun.act	in IN 0	blood NN B-adj.all	pressure NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d18.s1	Injection NN B-noun.person	, , 0	Lorazepam NNP B-noun.person	injection NN I-noun.person	, , 0	like IN 0	other JJ 0	injectable JJ B-adj.all	benzodiazepines NNS B-noun.person	, , 0	produces VBZ B-verb.cognition	depression NN B-noun.act	of IN 0	the DT 0	central JJ B-noun.body	nervous JJ I-noun.body	system NN B-noun.cognition	when WRB 0	administered VBN B-verb.possession	with IN 0	ethyl_alcohol NN B-noun.food	, , 0	phenothiazines NNS B-noun.body	, , 0	barbiturates NNS B-noun.person	, , 0	MAO_inhibitors NNS B-noun.person	, , 0	and CC 0	other JJ 0	antidepressants NNS B-noun.person	. . 0	When WRB 0	scopolamine NN B-noun.person	is VBZ 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	injectable JJ B-adj.all	lorazepam NN B-noun.person	, , 0	an DT 0	increased VBN B-adj.all	incidence NN B-noun.attribute	of IN 0	sedation NN B-noun.act	, , 0	hallucinations NNS B-noun.person	, , 0	and CC 0	irrational JJ B-adj.all	behavior NN B-noun.attribute	has VBZ 0	been VBN 0	observed VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d181.s0	Oxytocin NNP B-noun.person	or CC 0	other JJ B-adj.all	oxytocics NNS B-noun.person	( ( 0	concurrent JJ B-adj.all	use NN 0	with IN 0	dinoprost NN B-noun.group	may MD 0	result VB B-verb.stative	in IN 0	uterine JJ 0	hypertonus NN 0	, , 0	possibly RB 0	causing VBG B-verb.creation	uterine NN B-noun.phenomenon	rupture NN B-noun.attribute	or CC 0	cervical JJ B-adj.all	laceration NN B-noun.act	, , 0	especially RB B-adv.all	in IN 0	the DT 0	absence NN B-noun.act	of IN 0	adequate JJ B-adj.all	cervical JJ B-adj.all	dilatation NN B-noun.act	, , 0	. . 0
DDI-DrugBank.d422.s8	The DT 0	effect NN B-noun.cognition	of IN 0	BREVIBLOC NNP B-noun.person	on IN 0	the DT 0	duration NN 0	of IN 0	succinylcholine NN B-noun.person	- : 0	induced VBN B-verb.creation	neuromuscular JJ B-adj.all	blockade NN B-noun.location	was VBD 0	studied VBN B-verb.cognition	in IN 0	patients NNS B-noun.person	undergoing VBG B-verb.emotion	surgery NN I-verb.emotion	. . 0	. . 0
DDI-DrugBank.d328.s20	Lithium NNP B-noun.person	, , 0	Valdecoxib NNP 0	40 CD 0	mg IN 0	BID NNP 0	for IN 0	7 CD B-adj.all	days NNS B-noun.person	produced VBD B-verb.creation	significant JJ B-adj.all	decreases NNS B-noun.event	in IN 0	lithium NN B-noun.animal	serum NN B-noun.phenomenon	clearance NN B-noun.phenomenon	( ( 0	25 CD B-adj.all	% NN 0	) ) 0	and CC 0	renal JJ B-adj.all	clearance NN B-noun.person	( ( 0	30 CD B-adj.all	% NN 0	) ) 0	with IN 0	a DT 0	34 CD 0	% NN 0	higher JJR B-adj.all	serum NN B-noun.person	exposure NN B-noun.person	compared VBN B-verb.cognition	to TO 0	lithium VB B-verb.social	alone RB I-verb.social	. . 0	. . 0
DDI-MedLine.d45.s1	The DT 0	growth NN 0	of IN 0	Pseudomonas NNP B-noun.other	aeruginosa NN I-noun.substance	, , 0	particularly RB B-adv.all	serotype JJ B-adj.all	O11 NN 0	, , 0	in IN 0	pentazocine NN 0	and CC 0	tripelennamine NN B-noun.act	. . 0
DDI-DrugBank.d499.s8	Therefore RB 0	, , 0	concurrent JJ B-adj.all	use NN 0	of IN 0	aspirin NN B-noun.food	and CC 0	ketoprofen NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d82.s4	At IN 0	stable JJ B-adj.all	As(V NN B-noun.location	) ) 0	concentrations NNS 0	greater JJR B-adj.all	than IN 0	1 CD B-adj.all	mM CD B-noun.quantity	, , 0	fractional JJ B-adj.all	mucosal JJ B-adj.all	cell NN B-noun.body	accumulation NN 0	of IN 0	As(V NNP B-noun.location	) ) 0	remains VBZ B-verb.change	constant JJ B-adj.all	, , 0	while IN 0	fractional JJ B-adj.all	transfer NN B-noun.person	to TO 0	the DT 0	body NN B-noun.object	declines NNS I-noun.object	. . 0	. . 0
DDI-MedLine.d102.s6	Endothelium SYM 0	- : 0	intact JJ B-adj.all	aortic JJ B-adj.all	rings NNS B-noun.artifact	from IN 0	high JJ B-adj.all	- : 0	estradiol NN B-noun.animal	rats NNS I-noun.animal	were VBD B-verb.stative	supersensitive JJ 0	to TO 0	noradrenaline VB B-verb.perception	when WRB 0	compared VBN B-verb.cognition	to TO 0	vehicle- VB B-verb.motion	, , 0	progesterone- NNP B-noun.person	and CC 0	progesterone NN B-noun.person	+ : 0	high JJ B-adj.all	- : 0	estradiol NN B-noun.act	- : 0	treated VBN B-verb.communication	rats NNS B-noun.animal	( ( 0	pD2 JJ 0	values NNS B-noun.attribute	= SYM B-adv.all	7.77+/-0.12 FW I-adv.all	, , 0	7.21+/-0.13 NNP B-noun.person	, , 0	6.93+/-0.04 NNP B-noun.person	and CC 0	7.22+/-0.18 NNP B-noun.person	, , 0	respectively RB B-adv.all	) ) 0	. . 0	. . 0
DDI-MedLine.d30.s2	Intermediate JJ B-adj.all	doses NNS B-noun.quantity	of IN 0	( ( 0	+ UH 0	) ) 0	-NANM NN B-noun.location	or CC 0	PCP NNP B-noun.group	produced VBD B-verb.creation	transient JJ B-adj.all	increases NNS B-noun.event	in IN 0	FI NNP 0	responding VBG B-verb.stative	in IN 0	monkeys NNS B-noun.animal	and CC 0	sustained VBD B-verb.contact	increases NNS B-noun.person	in IN 0	FI NNP 0	responding VBG B-verb.stative	in IN 0	pigeons NNS B-noun.animal	, , 0	. . 0
DDI-DrugBank.d165.s21	therefore RB B-adv.all	, , 0	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	phenytoin NN B-noun.substance	should MD 0	also RB B-adv.all	be VB 0	monitored VBN B-verb.perception	when WRB 0	it PRP 0	is VBZ 0	given VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	Itraconazole NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d88.s5	Leucovorin NNP B-noun.person	, , 0	The DT 0	concentration NN B-noun.event	of IN 0	5-fluorouracil NN 0	is VBZ 0	increased VBN B-verb.change	and CC 0	its PRP$ 0	toxicity NN B-noun.location	may MD 0	be VB 0	enhanced VBN B-verb.change	by IN 0	leucovorin NN B-noun.person	. . 0	. . 0
DDI-MedLine.d82.s2	By IN 0	this DT 0	procedure NN B-noun.act	, , 0	it PRP 0	was VBD 0	observed VBN B-verb.perception	that IN 0	arsenate NN B-noun.person	is VBZ 0	rapidly RB B-adv.all	and CC 0	essentially RB B-adv.all	completely RB B-adv.all	absorbed VBN B-verb.contact	( ( 0	80 CD 0	- : 0	95 CD 0	% NN 0	) ) 0	from IN 0	the DT 0	lumen NNS B-noun.person	at IN 0	As(V NNP B-noun.location	) ) 0	concentrations NNS B-noun.quantity	up IN 0	to TO 0	5 CD B-adj.all	mM CD B-noun.quantity	, , 0	declining VBG B-verb.communication	to TO 0	about IN 0	50 CD B-adj.all	% NN 0	absorption NN B-noun.act	at IN 0	50 CD B-adj.all	mM. NNP B-noun.quantity	. . 0
DDI-MedLine.d103.s2	Primary JJ B-adj.all	and CC 0	secondary JJ B-adj.all	magnesium NN B-noun.person	deficiencies NNS B-noun.person	constitute VBP B-verb.stative	the DT 0	sole JJ B-adj.all	indication NN B-noun.act	of IN 0	physiological JJ B-adj.pert	oral JJ B-adj.all	magnesium NN B-noun.person	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d414.s7	Therefore RB 0	, , 0	when WRB 0	EDECRIN NNP B-noun.person	and CC 0	non-_steroidal_anti-_inflammatory_agents NNS B-noun.person	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	the DT 0	patient NN B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	closely RB B-adv.all	to TO 0	determine VB B-verb.communication	if IN 0	the DT 0	desired VBN B-verb.emotion	effect NN 0	of IN 0	the DT 0	diuretic NN B-noun.person	is VBZ 0	obtained VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d307.s43	Therefore RB 0	, , 0	concurrent JJ B-adj.all	use NN 0	of IN 0	Trileptal NNP B-noun.person	with IN 0	hormonal_contraceptives NNS B-noun.artifact	may MD 0	render VB B-verb.possession	these DT 0	contraceptives VBZ B-verb.stative	less RBR B-adv.all	effective JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d48.s3	Diethyl_pyrocarbonate JJ B-adj.all	, , 0	at IN 0	pH $ 0	7.0 CD 0	, , 0	was VBD 0	used VBN B-verb.consumption	to TO 0	chemically RB 0	modify VB 0	exposed VBN B-verb.perception	histidine NN I-verb.perception	residues NNS B-noun.artifact	on IN 0	toxin_A. NNP B-noun.location	. . 0
DDI-DrugBank.d28.s3	However RB 0	, , 0	10 CD B-adj.all	patients NNS B-noun.person	who WP 0	switched VBD B-verb.motion	from IN 0	therapy NN B-noun.act	with IN 0	Interferon_beta JJ 0	to TO 0	COPAXONE NNP B-noun.group	_ , 0	did VBD 0	not RB B-adv.all	report VB B-verb.change	any DT 0	serious JJ B-adj.all	and CC 0	unexpected JJ B-adj.all	adverse JJ B-adj.all	reactions NNS B-noun.person	thought VBD B-verb.cognition	to TO 0	be VB 0	related VBN B-verb.cognition	to TO 0	treatment NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d14.s0	The DT 0	vasodilating VBG B-verb.change	effects NNS B-noun.phenomenon	of IN 0	nitroglycerin NN B-noun.animal	may MD 0	be VB B-verb.stative	additive JJ B-adj.all	with IN 0	those DT 0	of IN 0	other JJ 0	vasodilators NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d132.s2	Accordingly RB B-adv.all	, , 0	when WRB 0	diflunisal NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	with IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	, , 0	the DT 0	prothrombin NN B-noun.person	time NN B-noun.group	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	during IN 0	and CC 0	for IN 0	several JJ B-adj.all	days NNS B-noun.phenomenon	after IN 0	concomitant JJ B-adj.all	drug NN B-noun.person	administration NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d458.s7	Human JJ B-adj.all	pharmacokinetics NNS B-noun.person	data NNS B-noun.person	indicate VBP B-verb.communication	that IN 0	oral JJ B-adj.all	ketoconazole NN B-noun.person	potently RB B-adv.all	inhibits VBZ B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	cisapride NN 0	resulting VBG B-verb.stative	in IN 0	a DT 0	mean JJ B-adj.all	eight CD 0	- : 0	fold JJ B-adj.all	increase NN B-noun.act	in IN 0	AUC NNP 0	of IN 0	cisapride NN B-noun.location	. . 0	. . 0
DDI-MedLine.d119.s16	Although IN 0	this DT 0	effect NN B-noun.cognition	was VBD 0	noted VBN B-verb.perception	even RB B-adv.all	when WRB 0	cholestyramine NN B-noun.person	was VBD 0	given VBN B-verb.possession	4 CD B-adj.all	hours NNS B-noun.person	prior RB 0	to TO 0	fluvastatin VB B-verb.motion	, , 0	this DT 0	regimen NNS B-noun.person	did VBD 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	diminished JJ B-adj.all	efficacy NN B-noun.person	. . 0	. . 0
DDI-MedLine.d3.s7	Amprenavir NNP B-noun.person	significantly RB I-noun.person	increased VBD B-verb.change	the DT 0	area NN B-noun.body	under IN 0	the DT 0	curve NN B-noun.communication	at IN 0	steady JJ B-adj.all	state NN B-noun.state	( ( 0	AUC(ss VB 0	) ) 0	) ) 0	of IN 0	rifabutin NN B-noun.food	by IN 0	2.93-fold JJ B-noun.artifact	and CC 0	the DT 0	AUC(ss NNP B-noun.location	) ) 0	of IN 0	25-O JJ 0	- : 0	desacetylrifabutin NN B-noun.communication	by IN 0	13.3-fold JJ 0	. . 0	. . 0
DDI-DrugBank.d48.s10	If IN 0	antacid DT 0	therapy NN 0	is VBZ 0	needed VBN B-verb.consumption	, , 0	the DT 0	antacid NN B-noun.location	dose NN 0	should MD 0	be VB 0	administered VBN B-verb.possession	at IN 0	least JJS 0	2 CD B-adj.all	hours NNS B-noun.person	prior RB 0	to TO 0	or CC 0	2 CD B-adj.all	hours NNS B-noun.person	after IN 0	the DT 0	dose NN B-noun.quantity	of IN 0	SPRYCEL NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d485.s31	Prednisolone NNP B-noun.person	, , 0	Ethinyl_estradiol NN 0	may MD 0	inhibit VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	prednisolone NN B-noun.person	, , 0	leading VBG B-verb.motion	to TO 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d549.s0	In IN 0	studies NNS B-noun.artifact	in IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	, , 0	there EX 0	was VBD B-verb.stative	no DT 0	pharmacodynamic JJ B-adj.pert	interaction NN B-noun.act	between IN 0	intravenous JJ B-adj.all	iloprost NN B-noun.person	and CC 0	either DT 0	nifedipine NN B-noun.location	, , 0	diltiazem NN B-noun.person	, , 0	or CC 0	captopril NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d29.s13	Coadministration NN B-noun.person	of IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	diazepam NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	or CC 0	quinidine NN B-noun.attribute	did VBD 0	not RB B-adv.all	seem VB B-verb.perception	to TO 0	change VB B-verb.change	the DT 0	pharmacokinetic JJ B-adj.all	profile NN B-noun.attribute	of IN 0	esomeprazole NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d202.s16	Therefore RB 0	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	tricyclic_antidepressants NNS B-noun.plant	with IN 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	this DT 0	isoenzyme NN B-noun.attribute	, , 0	including VBG B-verb.change	other JJ 0	antidepressants NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	, , 0	carbamazepine NN 0	, , 0	and CC 0	Type_1C_antiarrhythmics NNS B-noun.person	( ( 0	eg UH 0	, , 0	propafenone NN B-noun.person	, , 0	flecainide NN 0	, , 0	and CC 0	encainide VB B-verb.social	) ) 0	, , 0	or CC 0	that WDT 0	inhibit VBP B-verb.stative	this DT 0	enzyme NN B-noun.cognition	( ( 0	eg UH 0	, , 0	quinidine NN B-noun.location	) ) 0	, , 0	should MD 0	be VB 0	approached VBN B-verb.communication	with IN 0	caution NN B-noun.cognition	. . 0	. . 0
DDI-MedLine.d131.s4	On IN 0	the DT 0	contrary NN B-noun.communication	, , 0	neurotensin NN B-noun.person	and CC 0	tuftsin NN B-noun.act	were VBD B-verb.stative	agonists NNS B-noun.person	in IN 0	induction NN 0	of IN 0	analgesia NN B-noun.animal	. . 0	. . 0
DDI-DrugBank.d516.s8	Caffeine NN B-noun.person	, , 0	Two CD 0	hundred CD 0	mg NN B-noun.quantity	of IN 0	caffeine NN B-noun.phenomenon	( ( 0	equivalent JJ B-adv.all	to TO 0	1 CD 0	to TO 0	3 CD B-adj.all	cups NNS B-noun.artifact	of IN 0	American JJ B-noun.other	coffee NN B-noun.artifact	) ) 0	was VBD 0	administered VBN B-verb.perception	to TO 0	16 CD B-adj.all	normal JJ B-adj.all	, , 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	who WP 0	had VBD 0	achieved VBN B-verb.consumption	steady JJ I-verb.consumption	- : 0	state NN B-adj.all	blood NN B-noun.body	concentrations NNS I-noun.body	of IN 0	lomefloxacin NN B-noun.food	after IN 0	being VBG 0	dosed VBN B-verb.social	at IN 0	400 CD 0	mg NN B-noun.quantity	qd NN 0	. . 0	. . 0
DDI-DrugBank.d3.s2	Ketorolac NNP B-noun.person	does VBZ 0	not RB B-adv.all	alter VB B-verb.change	digoxin NN B-noun.act	protein NN B-noun.substance	binding NN B-verb.contact	. . 0	. . 0
DDI-DrugBank.d373.s14	If IN 0	nifedipine JJ B-adj.all	therapy NN B-noun.person	is VBZ 0	initiated VBN B-verb.creation	in IN 0	a DT 0	patient NN B-noun.person	currently RB B-adv.all	receiving VBG B-verb.communication	cimetidine NN B-noun.person	, , 0	cautious JJ B-adj.all	titration NN B-noun.event	is VBZ 0	advised VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d548.s21	However RB 0	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	Duloxetine NNP B-noun.location	with IN 0	aluminum- NNP B-noun.person	and CC 0	magnesium NN B-noun.person	- : 0	containing VBG B-verb.stative	antacids NNS B-noun.substance	( ( 0	51 CD 0	mEq NNP 0	) ) 0	or CC 0	Duloxetine NNP B-noun.location	with IN 0	famotidine NN B-noun.group	, , 0	had VBD 0	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	rate NN B-noun.time	or CC 0	extent NN B-noun.attribute	of IN 0	duloxetine JJ B-adj.all	absorption NN B-noun.artifact	after IN 0	administration NN B-noun.time	of IN 0	a DT 0	40-mg JJ 0	oral JJ B-adj.all	dose NN B-noun.quantity	. . 0	. . 0
DDI-MedLine.d76.s10	Conjugation NN B-noun.person	at IN 0	NaCMC NNP B-noun.location	with IN 0	cysteine JJ B-adj.all	moieties NNS B-noun.person	significantly RB B-adv.all	improves VBZ B-verb.change	the DT 0	intestinal JJ B-adj.all	permeation NN B-noun.person	of IN 0	the DT 0	hydrophilic JJ B-adj.all	molecule NN B-noun.person	NaFlu NNP I-noun.person	and CC 0	the DT 0	model NN B-noun.person	peptide IN 0	drugs NNS B-noun.animal	bacitracin NN I-noun.animal	and CC 0	insulin NN B-noun.food	in IN B-adj.all	vitro NN I-adj.all	, , 0	therefore RB 0	this DT 0	conjugated JJ B-adj.all	system NN B-noun.body	maybe RB B-adv.all	useful JJ B-verb.consumption	for IN 0	peroral JJ B-adj.all	administration NN B-noun.time	of IN 0	peptide NN B-noun.food	drugs NNS I-noun.food	in IN 0	the DT 0	future NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d198.s16	Other JJ 0	Drug NNP B-noun.person	Interactions NNP I-noun.person	, , 0	No DT 0	pharmacokinetic JJ B-noun.person	interactions NNS I-noun.person	were VBD 0	observed VBN B-verb.perception	between IN 0	vardenafil NN B-noun.artifact	and CC 0	the DT 0	following VBG 0	drugs NNS B-noun.person	, , 0	glyburide NN 0	, , 0	warfarin NN B-noun.location	, , 0	digoxin NN B-noun.person	, , 0	Maalox NNP B-noun.person	, , 0	and CC 0	ranitidine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d314.s17	Estrogens NNS B-noun.artifact	, , 0	including VBG B-verb.change	oral JJ B-adj.all	contraceptives NNS B-noun.person	, , 0	Estrogens NNP B-noun.person	may MD 0	decrease VB B-verb.cognition	the DT 0	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	certain JJ B-noun.body	corticosteroids NNS I-noun.body	, , 0	thereby RB 0	increasing VBG B-verb.change	their PRP$ 0	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d270.s9	The DT 0	in FW 0	vitro FW 0	interaction NN 0	between IN 0	nevirapine JJ B-adj.all	and CC 0	the DT 0	antithrombotic_agent JJ B-adj.all	warfarin NN B-noun.communication	is VBZ B-verb.stative	complex JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d53.s15	Cyclosporine NNP B-noun.person	, , 0	hexobarbital JJ B-adj.all	and CC 0	phenytoin NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d289.s18	Therefore RB 0	, , 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	TRACLEER NNP B-noun.group	and CC 0	glyburide NN 0	is VBZ 0	contraindicated VBN B-verb.communication	, , 0	and CC 0	alternative JJ B-adj.all	hypoglycemic_agents NNS B-noun.group	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d141.s13	OTHER JJ 0	CONCOMITANT NNP B-noun.group	THERAPY NNP I-noun.group	, , 0	Although IN 0	specific JJ B-adj.all	interaction NN B-noun.act	studies NNS B-noun.artifact	were VBD B-verb.stative	not RB B-adv.all	performed VBN B-verb.social	, , 0	in IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	, , 0	cerivastatin_sodium NN B-noun.location	was VBD 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	angiotensin-_converting_enzyme_(ACE)_inhibitors NNS B-noun.person	, , 0	betablockers NNS B-noun.person	, , 0	calcium NN B-noun.person	- : 0	channel_blockers NNS B-noun.person	, , 0	diuretics NNS B-noun.person	, , 0	and CC 0	nonsteroidal_anti JJ B-noun.person	- : 0	inflammatory_drugs NNS B-noun.cognition	( ( 0	NSAIDs NNP B-noun.person	) ) 0	without IN 0	evidence NN B-noun.time	of IN 0	clinically RB B-adv.all	significant JJ B-adj.all	adverse JJ B-adj.all	interactions NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d141.s9	WARFARIN NNP 0	, , 0	Co- JJ 0	administration NN B-noun.time	of IN 0	warfarin NN B-noun.act	and CC 0	cerivastatin NN 0	to TO 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	did VBD 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	any DT 0	changes NNS B-noun.possession	in IN 0	prothrombin NN B-adj.all	time NN B-noun.time	or CC 0	clotting JJ B-adj.all	factor NN B-noun.person	VII NNP B-noun.group	when WRB 0	compared VBN B-verb.cognition	to TO 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	warfarin NN B-noun.act	and CC 0	placebo NN B-noun.plant	. . 0	. . 0
DDI-DrugBank.d98.s15	Magnesium NN B-noun.person	, , 0	Magnesium NNP B-noun.person	- : 0	containing VBG B-verb.stative	preparations NNS B-noun.substance	( ( 0	eg UH 0	, , 0	antacids NNS B-noun.location	) ) 0	may MD 0	cause VB B-verb.communication	hypermagnesemia NN B-noun.person	and CC 0	should MD 0	therefore RB 0	not RB B-adv.all	be VB 0	taken VBN B-verb.social	during IN 0	therapy NN 0	with IN 0	vitamin_D JJ 0	by IN 0	patients NNS B-noun.person	on IN 0	chronic JJ B-adj.all	renal JJ B-adj.all	dialysis NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d558.s18	In IN 0	the DT 0	DIAMOND NNP B-noun.group	trials NNS B-noun.communication	, , 0	1252 CD 0	patients NNS B-noun.person	were VBD 0	treated VBN B-verb.change	with IN 0	TIKOSYN NNP B-noun.group	and CC 0	diuretics NNS B-noun.person	concomitantly RB 0	of IN 0	whom WP 0	493 CD 0	died VBD B-verb.change	compared VBN I-verb.change	to TO 0	508 CD B-adj.all	deaths NNS B-noun.time	among IN 0	the DT 0	1248 CD 0	patients NNS B-noun.person	receiving VBG B-verb.communication	placebo NN B-noun.plant	and CC 0	diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d226.s0	Intravenous NNP B-noun.person	Adenocard NNP I-noun.person	( ( 0	adenosine NN 0	) ) 0	has VBZ 0	been VBN 0	effectively RB B-adv.all	administered VBN B-verb.possession	in IN 0	the DT 0	presence NN B-noun.person	of IN 0	other JJ 0	cardioactive JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	such JJ 0	as IN 0	quinidine NN B-noun.location	, , 0	beta JJ 0	- : 0	adrenergic_blocking_agents NNS B-noun.person	, , 0	calcium_channel_blocking_agents NNS B-noun.person	, , 0	and CC 0	angiotensin_converting_enzyme_inhibitors NNS B-noun.person	, , 0	without IN 0	any DT 0	change NN B-noun.possession	in IN 0	the DT 0	adverse JJ B-adj.all	reaction NN B-noun.process	profile NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d340.s11	therefore RB B-adv.all	, , 0	VIRACEPT NNP B-noun.group	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concurrently RB B-adv.all	with IN 0	terfenadine NN B-noun.artifact	because IN 0	of IN 0	the DT 0	potential NN B-noun.person	for IN 0	serious JJ B-adj.all	and/or NN B-noun.attribute	life NN I-noun.attribute	- : 0	threatening JJ B-verb.communication	cardiac JJ B-adj.all	arrhythmias NN B-noun.person	. . 0	. . 0
DDI-MedLine.d83.s15	Pharmacoeconomic JJ B-adj.pert	analyses NNS B-noun.act	indicate VBP B-verb.cognition	that IN 0	olanzapine NN B-noun.person	does VBZ 0	not RB B-adv.all	significantly RB B-adv.all	increase VB B-verb.change	, , 0	and CC 0	may MD 0	even RB 0	decrease VB B-verb.cognition	, , 0	the DT 0	overall JJ B-adj.all	direct JJ B-noun.relation	treatment NN I-noun.relation	costs NNS B-noun.person	of IN 0	schizophrenia NN B-noun.person	, , 0	compared VBN B-verb.cognition	with IN 0	haloperidol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d89.s4	Caffeine NN B-noun.person	administered VBD B-verb.communication	concurrently RB B-adv.all	with IN 0	ketoprofen NN B-noun.person	reduced VBD B-verb.change	the DT 0	urine NN B-noun.act	volume NN B-noun.artifact	in IN 0	4 CD B-adj.all	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d162.s11	Refer VB B-verb.cognition	to TO 0	the DT 0	package NN B-noun.artifact	insert NN B-noun.person	for IN 0	lithium NN B-noun.substance	preparations NNS B-noun.artifact	before IN 0	use NN 0	of IN 0	such JJ B-adj.all	preparations NNS B-noun.person	with IN 0	Hydrochlorothiazide NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d382.s35	Ketoconazole NNP B-noun.person	, , 0	When WRB 0	a DT 0	single JJ B-adj.all	125-mg JJ 0	dose NN B-noun.quantity	of IN 0	Aprepitant NNP B-noun.person	was VBD 0	administered VBN B-verb.possession	on IN 0	Day5 NN 0	of IN 0	a DT 0	. . 0
DDI-DrugBank.d314.s2	In IN 0	addition NN 0	, , 0	there EX 0	have VBP 0	been VBN B-verb.stative	cases NNS 0	reported VBN B-verb.communication	in IN 0	which WDT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	amphotericin_B JJ B-noun.possession	and CC 0	hydrocortisone NN B-noun.person	was VBD 0	followed VBN B-verb.stative	by IN 0	cardiac JJ B-adj.all	enlargement NN B-noun.person	and CC 0	congestive JJ B-adj.all	heart NN B-noun.person	failure NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d74.s4	Caution NN B-noun.person	should MD 0	also RB B-adv.all	be VB 0	applied VBN B-verb.consumption	for IN 0	other JJ 0	sympathomimetics NNS B-noun.person	, , 0	and CC 0	for IN 0	aminophylline NN B-noun.person	and CC 0	theophylline NN B-noun.person	and CC 0	tricyclic_antidepressants NNS B-noun.person	, , 0	which WDT 0	may MD 0	also RB 0	precipitate VB B-verb.communication	arrhythmias NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d537.s0	Bentiromide NNP B-noun.person	may MD 0	interact VB B-verb.change	with IN 0	acetaminophen NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Tylenol NNP B-noun.location	) ) 0	, , 0	chloramphenicol NN 0	( ( 0	e.g. UH 0	, , 0	Chloromycetin NNP B-noun.location	) ) 0	, , 0	local JJ B-adj.all	anesthetics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	benzocaine NN B-noun.person	and CC 0	lidocaine NN B-noun.location	) ) 0	, , 0	para NN B-noun.person	- : 0	aminobenzoic_acid JJ 0	( ( 0	PABA)-containing JJ B-adj.ppl	preparations NNS B-noun.substance	( ( 0	e.g. UH 0	, , 0	sunscreens VBZ B-verb.communication	and CC 0	some DT 0	multivitamins NNS B-noun.animal	) ) 0	, , 0	procainamide NN 0	( ( 0	e.g. UH 0	, , 0	Pronestyl NNP B-noun.location	) ) 0	, , 0	sulfonamides VBZ B-verb.stative	( ( 0	sulfa NN B-noun.substance	medicines NNS B-noun.artifact	) ) 0	, , 0	thiazide_diuretics NNS B-noun.person	( ( 0	use NN 0	of IN 0	these DT 0	medicines NNS B-noun.artifact	during IN 0	the DT 0	test NN B-adj.all	period NN B-noun.person	will MD 0	affect VB B-verb.change	the DT 0	test NN B-adj.all	results NNS B-noun.event	) ) 0	, , 0	and CC 0	pancreatic JJ B-adj.all	supplements NNS B-noun.artifact	( ( 0	use NN 0	of IN 0	pancreatic JJ B-adj.all	supplements NNS B-noun.artifact	may MD 0	give VB B-verb.possession	false JJ B-adj.all	test NN B-adj.all	results NNS B-noun.event	) ) 0	. . 0	. . 0
DDI-MedLine.d29.s3	To TO 0	determine VB B-verb.communication	whether IN 0	probenecid NN B-noun.person	has VBZ B-verb.possession	a DT 0	direct JJ B-noun.possession	effect NN 0	on IN 0	the DT 0	distribution NN B-noun.act	of IN 0	cloxacillin NN B-noun.food	, , 0	the DT 0	elimination NN B-noun.act	and CC 0	distribution NN B-noun.act	of IN 0	cloxacillin NN B-noun.phenomenon	was VBD 0	studied VBN B-verb.cognition	in IN 0	six CD 0	patients NNS B-noun.person	, , 0	five CD B-adj.all	lacking JJ B-adj.all	kidney NN B-noun.person	function NN B-noun.act	and CC 0	one CD 0	with IN 0	a DT 0	partially RB B-adv.all	impaired VBN B-verb.change	renal JJ B-adj.all	function NN B-noun.act	, , 0	in IN 0	the DT 0	presence NN B-noun.person	or CC 0	absence NN B-noun.act	of IN 0	probenecid NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d328.s40	Drugs NNS B-noun.person	whose WP$ 0	absorption NN B-noun.act	is VBZ B-verb.stative	sensitive JJ B-adj.all	to TO 0	pH ( 0	may MD 0	be VB B-verb.stative	negatively RB B-adv.all	impacted VBN B-verb.change	by IN 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	omeprazole NN B-noun.shape	and CC 0	valdecoxib NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d104.s1	Other JJ 0	CNS_depressant_drugs NNS B-noun.object	should MD 0	be VB 0	used VBN B-verb.consumption	with IN 0	caution NN B-noun.cognition	in IN 0	patients NNS B-noun.person	taking VBG B-verb.social	fenfluramine NN I-verb.social	, , 0	since IN 0	the DT 0	effects NNS B-noun.phenomenon	may MD 0	be VB B-verb.stative	additive JJ B-adj.all	. . 0	. . 0
DDI-DrugBank.d350.s14	When WRB 0	CANCIDAS NNP 0	is VBZ B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	inducers NNS B-noun.person	of IN 0	drug NN B-noun.phenomenon	clearance NN B-noun.attribute	, , 0	such JJ 0	as IN 0	efavirenz NN B-noun.person	, , 0	nevirapine NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	dexamethasone NN B-noun.person	, , 0	or CC 0	carbamazepine NN B-noun.communication	, , 0	use NN 0	of IN 0	a DT 0	daily JJ B-noun.event	dose NN 0	of IN 0	70 CD B-adj.all	mg NN B-noun.quantity	of IN 0	CANCIDAS NNP B-noun.group	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0
DDI-MedLine.d110.s0	18-Methoxycoronaridine NN 0	( ( 0	18-MC JJ 0	) ) 0	and CC 0	ibogaine NN B-noun.person	, , 0	comparison NN B-noun.person	of IN 0	antiaddictive JJ B-adj.all	efficacy NN B-noun.person	, , 0	toxicity NN B-noun.attribute	, , 0	and CC 0	mechanisms NNS B-noun.person	of IN 0	action NN B-noun.process	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d113.s1	Therefore RB 0	, , 0	when WRB 0	meclofenamate_sodium NN B-noun.person	is VBZ 0	given VBN B-verb.possession	to TO 0	a DT 0	patient NN B-noun.person	receiving VBG B-verb.perception	warfarin NN B-noun.act	, , 0	the DT 0	dosage NN B-noun.quantity	of IN 0	warfarin NN B-noun.location	should MD 0	be VB 0	reduced VBN B-verb.change	to TO 0	prevent VB B-verb.creation	excessive JJ B-adj.all	prolongation NN B-noun.act	of IN 0	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d150.s0	FLEXERIL NNP B-noun.group	may MD 0	have VB 0	life NN B-noun.person	- : 0	threatening JJ B-verb.communication	interactions NNS B-noun.person	with IN 0	MAO_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d328.s21	Lithium NNP 0	serum NN 0	concentrations NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.change	closely RB B-adj.all	when WRB 0	initiating VBG B-verb.communication	or CC 0	changing VBG B-verb.change	therapy NN 0	with IN 0	BEXTRA NNP B-noun.group	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.social	lithium NN I-verb.social	. . 0	. . 0
DDI-DrugBank.d158.s3	Antidepressants NNS B-noun.person	, , 0	tricyclic JJ B-adj.all	Amphetamines NNPS B-noun.person	may MD 0	enhance VB B-verb.change	the DT 0	activity NN B-noun.process	of IN 0	tricyclic_antidepressants NNS B-noun.plant	or CC 0	sympathomimetic_agents NNS B-noun.artifact	, , 0	. . 0
DDI-DrugBank.d307.s17	Influence NN B-noun.cognition	of IN 0	AED NNP B-noun.group	On IN I-noun.group	MHD NNP I-noun.group	Concentration NNP I-noun.group	( ( 0	Mean JJ 0	change NN 0	, , 0	90 CD B-adj.all	% NN 0	Confidence NNP B-noun.group	Interval NNP I-noun.group	) ) 0	. . 0
DDI-DrugBank.d495.s5	The DT 0	effects NNS B-noun.phenomenon	of IN 0	tricyclic_antidepressants NNS B-noun.person	on IN 0	clonidines NNS B-noun.artifact	analgesic JJ B-adj.all	actions NNS B-noun.act	are VBP B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d82.s16	Capsules NNP B-noun.person	INDOCIN NNP I-noun.person	50 CD B-adj.all	mg IN 0	t.i.d NNP B-noun.person	. . 0	produced VBN B-verb.creation	a DT 0	clinically RB B-adv.all	relevant JJ B-adj.all	elevation NN B-noun.act	of IN 0	plasma NN B-noun.plant	lithium NN B-noun.body	and CC 0	reduction NN B-noun.act	in IN 0	renal JJ B-adj.all	lithium NN B-noun.phenomenon	clearance NN B-noun.attribute	in IN 0	psychiatric JJ B-adj.all	patients NNS B-noun.person	and CC 0	normal JJ B-adj.all	subjects NNS B-noun.person	with IN 0	steady JJ B-adj.all	state NN B-noun.state	plasma NN B-noun.plant	lithium NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d143.s17	This DT 0	information NN B-noun.cognition	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	changing VBG B-verb.change	from IN 0	intravenous JJ B-adj.all	amiodarone NN 0	to TO 0	oral JJ B-adj.all	amiodarone NN 0	. . 0	. . 0
DDI-DrugBank.d176.s9	Antacids NNP B-noun.person	, , 0	In IN 0	a DT 0	clinical JJ B-adj.all	pharmacology NN B-noun.phenomenon	study NN B-noun.artifact	, , 0	coadministration NN B-noun.person	of IN 0	an DT 0	antacid NN B-noun.attribute	( ( 0	aluminum_hydroxide RB 0	, , 0	magnesium_hydroxide JJ 0	, , 0	and CC 0	simethicone NN 0	) ) 0	with IN 0	fosinopril NN 0	reduced VBN B-verb.change	serum NN B-noun.body	levels NNS B-noun.attribute	and CC 0	urinary JJ B-adj.all	excretion NN B-noun.act	of IN 0	fosinoprilat JJ 0	as IN 0	compared VBN B-verb.creation	with IN 0	fosinopril NN B-noun.body	administered VBN B-verb.perception	alone RB B-adv.all	, , 0	suggesting VBG B-verb.communication	that IN 0	antacids NNS B-noun.animal	may MD 0	impair VB B-verb.change	absorption NN B-noun.act	of IN 0	fosinopril NN 0	. . 0	. . 0
DDI-MedLine.d56.s8	Exposure NN B-noun.person	of IN 0	the DT 0	muscle NN B-noun.body	to TO 0	ouabain VB B-verb.consumption	( ( 0	10(-5 JJ 0	) ) 0	M NNP 0	) ) 0	markedly RB B-adv.all	increased VBD B-verb.change	the DT 0	PTX NNP B-noun.group	- : 0	induced VBN B-verb.creation	release NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d270.s18	Clarithromycin NN B-noun.person	exposure NN B-noun.person	was VBD B-verb.stative	significantly RB B-adv.all	decreased VBN B-verb.change	by IN 0	nevirapine NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d455.s4	In IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	have VBP 0	shown VBN B-verb.perception	no DT 0	binding JJ B-adj.pert	displacement NN B-noun.state	between IN 0	entacapone NN B-noun.person	and CC 0	other JJ 0	highly RB B-adv.all	bound VBN B-verb.contact	drugs NNS B-noun.artifact	, , 0	such JJ 0	as IN 0	warfarin NN 0	, , 0	salicylic_acid JJ 0	, , 0	phenylbutazone NN B-noun.person	, , 0	and CC 0	diazepam NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d143.s51	Other JJ 0	reported VBD B-verb.communication	interactions NNS B-noun.person	with IN 0	amiodarone NN 0	, , 0	Fentanyl NNP B-noun.person	( ( 0	CYP3A4 JJ B-adv.all	substrate NN I-adv.all	) ) 0	in IN 0	combination NN 0	with IN 0	amiodarone NN 0	may MD 0	cause VB B-verb.emotion	hypotension NN I-verb.emotion	, , 0	bradycardia NNS B-noun.person	, , 0	and CC 0	decreased VBD B-verb.change	cardiac JJ 0	output NN 0	. . 0	. . 0
DDI-DrugBank.d228.s1	Similarly RB B-adv.all	, , 0	ethanol NN B-noun.person	decreased VBD B-verb.change	the DT 0	rate NN B-noun.time	of IN 0	elimination NN B-noun.act	of IN 0	Antizol NNP B-noun.person	( ( 0	by IN 0	approximately RB B-adv.all	50 CD B-adj.all	% NN 0	) ) 0	by IN 0	the DT 0	same JJ B-adj.all	mechanism NN B-noun.object	. . 0	. . 0
DDI-DrugBank.d143.s34	because IN 0	of IN 0	this DT 0	, , 0	the DT 0	dosage NN B-noun.quantity	of IN 0	flecainide NN B-noun.plant	should MD 0	be VB 0	adjusted VBN B-verb.change	when WRB 0	these DT 0	drugs NNS B-noun.artifact	are VBP 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d306.s0	The DT 0	effectiveness NN B-noun.cognition	of IN 0	progestin NN B-noun.person	- : 0	only JJ B-adj.all	pills NNS B-noun.artifact	is VBZ 0	reduced VBN B-verb.change	by IN 0	hepatic JJ B-adj.all	enzyme NN B-noun.person	- : 0	inducing VBG B-verb.communication	drugs NNS B-noun.state	such JJ 0	as IN 0	the DT 0	anticonvulsants NNS B-noun.person	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	and CC 0	barbiturates NNS B-noun.artifact	, , 0	and CC 0	the DT 0	antituberculosis_drug JJ B-adj.all	rifampin NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d416.s0	Renal JJ B-adj.all	clearance NN B-noun.phenomenon	measurements NNS B-noun.attribute	of IN 0	PAH NNP B-noun.group	can MD 0	not RB B-adv.all	be VB 0	made VBN B-verb.social	with IN 0	any DT 0	significant JJ B-adj.all	accuracy NN B-noun.person	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	sulfonamides NNS B-noun.person	, , 0	procaine NN B-noun.person	, , 0	or CC 0	thiazolesulfone NN 0	. . 0	. . 0
DDI-DrugBank.d458.s19	When WRB 0	taken VBN 0	orally RB B-adv.all	, , 0	imidazole_compounds VBZ B-verb.stative	like IN 0	ketoconazole NN B-noun.person	may MD 0	enhance VB B-verb.change	the DT 0	anticoagulant JJ B-adj.all	effect NN B-noun.cognition	of IN 0	coumarin NN B-noun.person	- : 0	like IN 0	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d186.s0	An DT 0	encephalopathic JJ B-adj.all	syndrome NN B-noun.relation	( ( 0	characterized VBN B-verb.communication	by IN 0	weakness NN B-noun.artifact	, , 0	lethargy NN B-noun.communication	, , 0	fever NN B-noun.person	, , 0	tremulousness NN B-noun.plant	and CC 0	confusion NN B-noun.cognition	, , 0	extrapyramidal JJ B-adj.all	symptoms NNS B-noun.body	, , 0	leukocytosis NN B-noun.person	, , 0	elevated VBD B-verb.social	serum NN B-noun.person	enzymes NNS B-noun.person	, , 0	BUN NNP 0	, , 0	and CC 0	FBS NNP B-noun.group	) ) 0	followed VBN B-verb.stative	by IN 0	irreversible JJ B-adj.all	brain NN B-noun.person	damage NN 0	has VBZ 0	occurred VBN B-verb.cognition	in IN 0	a DT B-adj.all	few JJ I-adj.all	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	lithium NN B-noun.substance	plus IN 0	HALDOL NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d558.s8	In IN 0	an DT 0	analysis NN B-noun.communication	of IN 0	the DT 0	supraventricular JJ B-adj.all	arrhythmia NN B-noun.person	and CC 0	DIAMOND NNP B-noun.person	patient NN B-noun.person	populations NNS B-noun.person	, , 0	the DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	verapamil NN B-noun.food	with IN 0	dofetilide NN 0	was VBD 0	associated VBN B-verb.cognition	with IN 0	a DT 0	higher JJR B-adj.all	occurrence NN B-noun.state	of IN 0	torsade NN B-noun.person	de IN 0	pointes NNS B-noun.time	. . 0	. . 0
DDI-DrugBank.d312.s2	Irinotecan JJ B-adj.pert	concentrations NNS B-noun.person	were VBD B-verb.stative	similar JJ B-adj.all	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	bolus JJ B-adj.pert	- : 0	IFL NNP 0	alone RB 0	and CC 0	in IN 0	combination NN 0	with IN 0	AVASTIN NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d12.s0	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	anticoagulants NNS B-noun.person	are VBP 0	given VBN B-verb.possession	in IN 0	conjunction NN 0	with IN 0	Atromid NNP B-noun.person	- : 0	S. NN B-noun.time	. . 0
DDI-DrugBank.d208.s0	Benzthiazide NNP B-noun.person	may MD 0	interact VB B-verb.change	with IN 0	alcohol NN B-noun.food	, , 0	blood_thinners NNS B-noun.person	, , 0	decongestant_drugs NNS B-noun.time	( ( 0	allergy NN B-noun.attribute	, , 0	cold JJ B-noun.person	, , 0	and CC 0	sinus IN 0	medicines NNS B-noun.location	) ) 0	, , 0	diabetic JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	lithium NN B-noun.person	, , 0	norepinephrine NN B-noun.person	, , 0	NSAIDs NNP B-noun.person	like IN 0	Aleve NNP B-noun.person	or CC 0	Ibuprofen NNP B-noun.person	, , 0	and CC 0	high JJ B-adj.all	blood NN B-noun.phenomenon	pressure NN B-noun.act	medications NNS I-noun.act	. . 0	. . 0
DDI-DrugBank.d76.s31	Thus RB 0	patients NNS B-noun.person	receiving VBG B-verb.communication	oral JJ B-adj.all	anticoagulants NNS B-noun.person	and CC 0	Fluvoxamine NNP B-noun.person	Tablets NNPS I-noun.person	should MD 0	have VB 0	their PRP$ 0	prothrombin NN B-noun.person	time NN B-noun.person	monitored VBD B-verb.possession	and CC 0	their PRP$ 0	anticoagulant JJ B-adj.all	dose NN 0	adjusted VBN B-verb.change	accordingly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d477.s1	DIDREX NNP B-noun.group	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	other JJ B-adj.all	CNS_stimulants NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d170.s3	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	other JJ 0	CYP3A4 JJ B-adj.all	inhibitors NNS B-noun.attribute	such JJ 0	as IN 0	diltiazem NN B-noun.person	and CC 0	erythromycin NN B-noun.person	with IN 0	transdermal JJ B-adj.all	fentanyl NN B-noun.animal	may MD 0	also RB 0	result VB B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	fentanyl NN 0	plasma NN B-noun.substance	concentrations NNS I-noun.substance	, , 0	which WDT 0	could MD 0	increase VB B-verb.emotion	or CC 0	prolong JJ B-adj.all	adverse JJ B-adj.all	drug NN B-noun.phenomenon	effects NNS B-noun.phenomenon	and CC 0	may MD 0	cause VB B-verb.communication	serious JJ B-adj.all	respiratory JJ B-adj.pert	depression NN B-noun.process	. . 0	. . 0
DDI-DrugBank.d158.s17	Methenamine NN B-noun.person	therapy NN 0	Urinary NNP B-noun.location	excretion NN B-noun.act	of IN 0	amphetamines NNS B-noun.animal	is VBZ 0	increased VBN B-verb.change	, , 0	and CC 0	efficacy NN B-noun.person	is VBZ 0	reduced VBN B-verb.change	by IN 0	acidifying VBG B-verb.communication	agents NNS B-noun.person	used VBN B-verb.consumption	in IN 0	methenamine NN 0	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d82.s13	INDOCIN NNP B-noun.group	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	decrease VB B-verb.communication	the DT 0	tubular JJ B-adj.all	secretion NN B-noun.act	of IN 0	methotrexate NN B-noun.food	and CC 0	to TO 0	potentiate VB B-verb.communication	its PRP$ 0	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d317.s4	decreased VBN B-verb.change	levels NNS B-noun.state	of IN 0	anti NNS B-noun.person	- : 0	factor NN B-noun.person	Xa NNP I-noun.person	and CC 0	antithrombin_III NNP B-noun.person	, , 0	decreased VBD B-verb.change	antithrombin_III JJ B-adj.all	activity NN B-noun.state	, , 0	. . 0
DDI-DrugBank.d478.s5	If IN 0	concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	naratriptan JJ B-noun.group	and CC 0	an DT 0	SSRI NNP B-noun.group	is VBZ B-verb.stative	clinically RB B-adv.all	warranted VBN B-verb.communication	, , 0	appropriate JJ B-adj.all	observation NN B-noun.act	of IN 0	the DT 0	patient NN B-noun.person	is VBZ 0	advised VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d5.s1	Interactions NNS B-noun.person	between IN 0	treatments NNS B-noun.person	with IN 0	coumaphos NNS B-noun.person	, , 0	bishydroxycoumarin NN B-noun.person	( ( 0	an DT 0	anticoagulant NN B-noun.attribute	) ) 0	, , 0	trichlorfon NN B-noun.person	( ( 0	an DT 0	organophosphorous_compound NN B-noun.cognition	) ) 0	, , 0	and CC 0	phenobarbital_sodium NN B-noun.artifact	( ( 0	an DT 0	inducer NN B-noun.person	of IN 0	microsomal JJ B-adj.all	enzymes NNS B-noun.event	) ) 0	were VBD 0	investigated VBN B-verb.communication	in IN 0	sheep NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d334.s20	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	serum NN 0	lithium NN 0	levels NNS 0	be VB 0	monitored VBN B-verb.perception	frequently RB B-adv.all	if IN 0	PRINIVIL NNP B-noun.group	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	lithium NN B-noun.substance	. . 0	. . 0
DDI-MedLine.d18.s8	Analysis NN 0	of IN 0	the DT 0	concentration NN B-noun.event	of IN 0	budesonide NN 0	following VBG 0	ultracentrifugation NN B-noun.communication	indicated VBD B-verb.communication	that IN 0	there EX 0	is VBZ B-verb.stative	rapid JJ B-adj.all	equilibration NN B-noun.cognition	of IN 0	budesonide NN B-noun.cognition	between IN 0	the DT 0	Survanta NNP B-noun.other	and CC 0	aqueous JJ B-adj.all	phase NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d132.s23	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	diflunisal JJ B-adj.all	tablets NNS B-noun.artifact	and CC 0	other JJ 0	NSAIDs NNP B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.possession	due JJ 0	to TO 0	the DT 0	increased VBN B-verb.change	possibility NN B-noun.state	of IN 0	gastrointestinal JJ B-adj.all	toxicity NN B-noun.attribute	, , 0	with IN B-adv.all	little JJ I-adv.all	or CC 0	no DT 0	increase NN B-noun.act	in IN 0	efficacy NN B-noun.phenomenon	. . 0	. . 0
DDI-MedLine.d119.s18	Moreover RB B-adv.all	, , 0	additional JJ B-adj.all	interaction NN B-noun.act	studies NNS B-noun.artifact	with IN 0	niacin NN B-noun.person	and CC 0	propranolol NN B-noun.person	have VBP 0	not RB B-adv.all	demonstrated VBN B-verb.perception	any DT 0	effect NN B-noun.cognition	on IN 0	fluvastatin NN B-adj.all	plasma NN B-noun.state	levels NNS B-noun.state	, , 0	and CC 0	administration NN B-noun.person	to TO 0	a DT 0	patient JJ B-noun.person	population NN B-noun.person	chronically RB B-adv.all	receiving VBG B-verb.communication	digoxin NN B-noun.person	resulted VBD B-verb.contact	in IN 0	no DT 0	difference NN B-noun.cognition	in IN 0	the DT 0	extent NN B-noun.attribute	of IN 0	bioavailability NN B-noun.cognition	of IN 0	digoxin NN B-noun.substance	relative JJ B-adj.all	to TO 0	control VB B-verb.contact	data NNS B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d369.s3	The DT 0	response NN B-noun.communication	to TO 0	Factrel NNP B-noun.location	may MD 0	be VB 0	blunted VBN B-verb.cognition	by IN 0	phenothiazines NNS B-noun.artifact	and CC 0	dopamine_antagonists NNS B-noun.act	which WDT 0	cause VBP B-verb.creation	a DT 0	rise NN B-noun.attribute	in IN 0	prolactin NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d487.s7	The DT 0	effect NN B-noun.cognition	of IN 0	corticosteroids NNS B-noun.shape	on IN 0	oral JJ B-adj.all	anticoagulants NNS B-noun.person	is VBZ B-verb.stative	variable JJ B-adj.all	. . 0	. . 0
DDI-MedLine.d130.s4	Cisplatin NNP B-noun.person	was VBD 0	administered VBN B-verb.possession	over IN 0	the DT 0	last JJ B-adj.all	two CD 0	hours NNS 0	of IN 0	the DT 0	thiosulfate JJ B-adj.all	infusion NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d103.s26	Guardians NNPS B-noun.person	of IN 0	children NNS B-noun.person	who WP 0	have VBP 0	been VBN 0	prescribed VBN B-verb.communication	FORADIL NNP B-noun.group	should MD 0	be VB 0	alerted VBN B-verb.communication	to TO 0	the DT 0	general JJ B-adj.all	concern NN B-noun.feeling	regarding VBG B-verb.stative	asthma NN 0	therapy NN 0	compliance NN B-noun.communication	, , 0	especially RB B-adj.all	neglect NN B-noun.act	of IN 0	anti NNS B-noun.person	- : 0	inflammatory JJ B-adj.all	therapy NN B-noun.person	and CC 0	overuse NN B-noun.act	of IN 0	short JJ B-noun.body	- : 0	acting__beta2-agonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d246.s12	It PRP 0	is VBZ B-verb.stative	not RB B-adv.all	known VBN B-verb.cognition	if IN 0	the DT 0	effects NNS B-noun.phenomenon	of IN 0	butorphanol NN 0	are VBP 0	altered VBN B-verb.change	by IN 0	concomitant JJ B-adj.all	medications NNS B-noun.communication	that WDT 0	affect VBP B-verb.change	hepatic JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	drugs NNS B-noun.animal	( ( 0	erythromycin NN B-noun.person	, , 0	etc FW 0	. . 0	) ) 0	, , 0	but CC 0	physicians NNS B-noun.person	should MD 0	be VB B-verb.stative	alert JJ B-adj.all	to TO 0	the DT 0	possibility NN B-noun.state	that IN 0	a DT 0	smaller JJR B-adj.all	initial JJ B-adj.all	dose NN B-noun.act	and CC 0	longer JJR B-adj.all	intervals NNS B-noun.relation	between IN 0	doses NNS B-noun.location	may MD 0	be VB 0	needed VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d565.s28	The DT 0	effect NN B-noun.cognition	of IN 0	cyclosporine NN B-noun.person	on IN 0	diltiazem NN 0	plasma NN 0	concentrations NNS 0	has VBZ 0	not RB 0	been VBN 0	evaluated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d256.s0	Clindamycin NN B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	have VB B-verb.change	neuromuscular JJ B-adj.all	blocking VBG B-verb.change	properties NNS B-noun.attribute	that WDT 0	may MD 0	enhance VB B-verb.change	the DT 0	action NN B-noun.process	of IN 0	other JJ B-adj.all	neuromuscular_blocking_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d449.s0	Co SYM 0	- : 0	administration NN B-noun.time	with IN 0	antifungal_agents NNS B-noun.object	such JJ 0	as IN 0	ketoconazole NN B-noun.group	or CC 0	itraconazole NN B-noun.communication	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d503.s7	Exert NNP B-noun.person	particular JJ B-adj.all	caution NN B-noun.communication	in IN 0	combining VBG B-verb.creation	chlorprothixene NN I-verb.creation	with IN 0	other JJ B-adj.all	anticholinergic_drugs NNS B-noun.object	( ( 0	tricyclic_antidepressants NNS B-noun.person	and CC 0	antiparkinsonian_agents NNPS B-noun.location	) ) 0	, , 0	Particularly RB 0	the DT 0	elderly JJ B-noun.group	may MD 0	develop VB B-verb.cognition	delirium NN B-noun.person	, , 0	high JJ B-adj.all	fever NN B-noun.person	, , 0	severe JJ B-adj.all	obstipation NN B-noun.act	, , 0	even RB B-adv.all	ileus JJ B-adj.all	and CC 0	glaucoma NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d516.s12	Cimetidine NNP B-noun.person	, , 0	Cimetidine NNP B-noun.person	has VBZ 0	been VBN 0	demonstrated VBN B-verb.cognition	to TO 0	interfere VB B-verb.stative	with IN 0	the DT 0	elimination NN B-noun.act	of IN 0	other JJ 0	quinolones NNS B-noun.communication	. . 0	. . 0
DDI-DrugBank.d20.s12	Therefore RB 0	, , 0	when WRB 0	INSPRA NNP B-noun.group	and CC 0	NSAIDs NNP B-noun.person	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	patients NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	to TO 0	determine VB B-verb.communication	whether IN 0	the DT 0	desired VBN B-verb.emotion	effect NN 0	on IN 0	blood NN B-noun.act	pressure NN B-noun.act	is VBZ 0	obtained VBN B-verb.possession	. . 0	. . 0
DDI-MedLine.d94.s12	The DT 0	uptake NN B-noun.location	inhibitors NNS B-noun.person	cocaine NN B-noun.person	and CC 0	desipramine NN B-noun.person	( ( 0	3 CD B-adj.all	mumol NN B-noun.quantity	/ : 0	liter NN B-noun.animal	) ) 0	potentiated VBD B-verb.communication	the DT 0	positive JJ B-adj.all	inotropic JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	norepinephrine NN B-noun.person	in IN 0	nonfailing VBG B-verb.communication	myocardium NN B-noun.person	( ( 0	p IN 0	< $ 0	0.05 CD 0	) ) 0	but CC 0	not RB B-adv.all	in IN 0	functional JJ B-adj.all	class NN B-noun.group	IV NNP 0	myocardium NN 0	. . 0	. . 0
DDI-DrugBank.d216.s7	The DT 0	AUC NNP B-noun.group	of IN 0	eszopiclone NN 0	was VBD 0	increased VBN B-verb.change	2.2-fold JJ I-verb.change	by IN 0	coadministration NN B-noun.person	of IN 0	ketoconazole NN B-noun.shape	, , 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	, , 0	400 CD 0	mg NN B-noun.quantity	daily RB B-adv.all	for IN 0	5 CD B-adj.all	days NNS B-noun.act	. . 0	. . 0
DDI-MedLine.d49.s3	Gentamicin NNP B-noun.person	did VBD 0	not RB B-adv.all	interfere VB B-verb.stative	with IN 0	the DT 0	activity NN B-noun.process	of IN 0	clindamycin NN B-noun.phenomenon	within IN 0	the DT 0	range NN B-noun.location	of IN 0	concentrations NNS B-noun.person	tested VBN B-verb.social	( ( 0	0.1 CD 0	to TO 0	100 CD 0	mug NN B-noun.quantity	/ : 0	ml LS 0	) ) 0	, , 0	. . 0
DDI-DrugBank.d138.s2	Caution NN B-noun.person	in IN 0	using VBG B-verb.consumption	concomitant JJ B-adj.all	drugs NNS B-noun.state	such JJ 0	as IN 0	beta NNS B-noun.person	- : 0	blockers NNS B-noun.person	( ( 0	ophthalmic JJ B-adj.all	and CC 0	systemic JJ B-noun.body	) ) 0	, , 0	anti NNS B-noun.person	- : 0	hypertensives NNS B-noun.group	and/or CC I-noun.group	cardiac_glycosides VBZ I-noun.group	is VBZ 0	advised VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d165.s17	Rhabdomyolysis NNP B-noun.person	has VBZ 0	been VBN 0	observed VBN B-verb.perception	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitors NNS B-noun.person	administered VBD B-verb.perception	alone RB B-adv.all	( ( 0	at IN 0	recommended VBN B-verb.communication	dosages NNS B-noun.quantity	) ) 0	or CC 0	concomitantly RB B-adv.all	with IN 0	immunosuppressive_drugs NNS B-noun.artifact	including VBG B-verb.stative	cyclosporine NN 0	. . 0	. . 0
DDI-DrugBank.d135.s11	Other NNP B-noun.other	Chemotherapy NNP I-noun.other	Agents NNPS I-noun.other	In IN I-noun.other	a DT 0	separate JJ B-adj.all	study NN B-noun.artifact	, , 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	lapatinib NN B-noun.person	with IN 0	capecitabine NN B-noun.person	did VBD 0	not RB B-adv.all	meaningfully RB B-adv.all	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	agent NN B-noun.person	( ( 0	or CC 0	the DT 0	metabolites NNS B-noun.time	of IN 0	capecitabine NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d132.s21	In IN 0	some DT 0	patients NNS B-noun.person	the DT 0	combined VBN B-adj.all	use NN B-noun.process	of IN 0	indomethacin NN B-noun.act	and CC 0	diflunisal NN B-noun.person	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	fatal JJ B-adj.all	gastrointestinal JJ B-adj.pert	hemorrhage NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d550.s3	Although IN 0	the DT 0	clinical JJ B-adj.all	significance NN B-noun.communication	is VBZ B-verb.stative	not RB B-adj.all	known VBN I-adj.all	, , 0	it PRP 0	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	that IN 0	cefditoren_pivoxil NNP 0	be VB 0	taken VBN B-verb.cognition	concomitantly RB B-adv.all	with IN 0	H2_receptor_antagonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d499.s20	Therefore RB 0	, , 0	the DT 0	combination NN B-noun.event	of IN 0	ketoprofen NN B-noun.person	and CC 0	probenecid NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d495.s10	Epidural JJ B-adj.pert	clonidine NN B-noun.act	may MD 0	prolong VB B-verb.stative	the DT 0	duration NN 0	of IN 0	pharmacologic JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	epidural JJ B-adj.all	local JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	including VBG B-verb.stative	both DT 0	sensory JJ B-noun.person	and CC 0	motor NN B-noun.person	blockade NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d568.s28	However RB 0	, , 0	coadministration NN B-noun.person	of IN 0	escitalopram NN B-noun.cognition	( ( 0	20 CD B-adj.all	mg NN B-noun.quantity	) ) 0	and CC 0	ritonavir NN B-noun.person	( ( 0	600 CD 0	mg NN B-noun.quantity	) ) 0	, , 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	, , 0	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	escitalopram NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d380.s0	Buprenorphine NN B-noun.person	is VBZ 0	metabolized VBN B-verb.cognition	to TO 0	norbuprenorphine VB B-verb.communication	by IN 0	cytochrome JJ B-noun.person	CYP NNP I-noun.person	3A4 NNP I-noun.person	. . 0	. . 0
DDI-DrugBank.d485.s12	Anticonvulsants NNS B-noun.person	( ( 0	carbamazepine NN 0	, , 0	felbamate NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	phenytoin NN B-noun.person	, , 0	topiramate NN B-noun.location	) ) 0	, , 0	Increase NNP B-noun.person	the DT 0	metabolism NN B-noun.attribute	of IN 0	ethinyl_estradiol JJ 0	and/or CC 0	some DT 0	progestins NNS B-noun.person	, , 0	leading VBG B-verb.motion	to TO 0	possible JJ B-adj.all	decrease NN B-noun.state	in IN 0	contraceptive JJ B-adj.all	effectiveness NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d187.s11	Therophylline PRP 0	, , 0	A DT 0	recent JJ B-adj.all	study NN B-noun.communication	has VBZ 0	shown VBN B-verb.cognition	that DT 0	concomitan JJ B-adj.all	administration NN B-noun.person	of IN 0	isoniazid NN B-noun.food	and CC 0	theophylline PRP 0	may MD 0	cause VB B-verb.communication	elevated JJ B-adj.all	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	theophylline NN 0	, , 0	and CC 0	in IN 0	some DT 0	instances NNS B-noun.event	a DT 0	slight JJ B-adj.all	decrease NN B-noun.event	in IN 0	the DT 0	elimination NN B-noun.act	of IN 0	isoniazid NN B-noun.feeling	. . 0	. . 0
DDI-MedLine.d21.s8	An DT 0	oral JJ B-adj.all	glucose NN 0	overload NN 0	of IN 0	1 CD B-adj.all	ml NN B-noun.quantity	of IN 0	a DT 0	50 CD B-adj.all	% NN 0	glucose NN B-noun.substance	solution NN B-noun.phenomenon	was VBD 0	given VBN B-verb.possession	to TO 0	rats NNS B-noun.animal	and CC 0	blood NN B-noun.location	glucose NN B-noun.person	was VBD 0	determined VBN B-verb.communication	after IN 0	30 CD B-adj.all	, , 0	60 CD B-adj.all	and CC 0	90 CD B-adj.all	min NN B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d567.s13	Coumarin_Anticoagulants NNS B-noun.artifact	, , 0	In IN 0	a DT 0	small JJ B-adj.all	clinical JJ B-adj.all	trial NN B-noun.cognition	in IN 0	which WDT 0	lovastatin NN B-noun.person	was VBD 0	administered VBN B-verb.perception	to TO 0	warfarin VB B-verb.body	treated JJ B-adj.all	patients NNS B-noun.person	, , 0	no DT 0	effect NN B-noun.cognition	on IN 0	prothrombin NN B-noun.person	time NN B-noun.person	was VBD 0	detected VBN B-verb.perception	. . 0	. . 0
DDI-DrugBank.d197.s2	Specific JJ B-adj.all	studies NNS B-noun.group	have VBP 0	confirmed VBN B-verb.cognition	these DT 0	effects NNS B-noun.phenomenon	with IN 0	sevoflurane NN 0	, , 0	isoflurane NN B-noun.person	, , 0	propofol NN B-noun.person	, , 0	alfentanil RB 0	, , 0	and CC 0	midazolam NN B-noun.body	. . 0	. . 0
DDI-DrugBank.d207.s8	Phase NNP B-noun.person	II NNP I-noun.person	clinical JJ B-adj.all	trial NN B-noun.cognition	data NNS I-noun.cognition	, , 0	where WRB 0	IRESSA NNP B-noun.person	and CC 0	vinorelbine NN B-noun.plant	have VBP 0	been VBN 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	indicate VBP B-verb.cognition	that IN 0	IRESSA NNP B-noun.person	may MD 0	exacerbate VB B-verb.communication	the DT 0	neutropenic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	vinorelbine NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d231.s12	The DT 0	intake NN 0	of IN 0	furosemide NN B-noun.artifact	and CC 0	sucralfate NN B-noun.person	should MD 0	be VB 0	separated VBN B-verb.social	by IN 0	at IN 0	least JJS 0	two CD 0	hours NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d400.s6	Furosemide RB 0	, , 0	Clinical JJ B-noun.body	studies NNS I-noun.body	, , 0	as RB 0	well RB 0	as IN 0	post NN B-noun.person	- : 0	marketing NN B-noun.act	observations NNS B-noun.act	, , 0	have VBP 0	shown VBN B-verb.cognition	that IN 0	NSAIDs NNPS B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	natriuretic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	furosemide NN B-noun.artifact	and CC 0	thiazides NNS B-noun.person	in IN 0	some DT 0	patients NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d76.s1	The DT 0	purpose NN B-noun.attribute	of IN 0	this DT 0	study NN B-noun.artifact	was VBD 0	to TO 0	evaluate VB B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	sodium_carboxymethylcellulose JJ 0	( ( 0	NaCMC NNP 0	) ) 0	and CC 0	carboxymethylcellulose VB B-verb.communication	- : 0	cysteine NN B-noun.person	( ( 0	CMC NNP B-noun.group	- : 0	Cys NNP B-noun.person	) ) 0	conjugates VBZ B-verb.communication	on IN 0	the DT 0	intestinal JJ B-adj.all	permeation NN B-noun.person	of IN 0	sodium_fluorescein NN B-noun.communication	( ( 0	NaFlu NNP B-noun.person	) ) 0	and CC 0	model NN B-noun.person	peptide IN 0	drugs NNS B-noun.artifact	, , 0	bacitracin NN B-noun.person	and CC 0	insulin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d430.s0	Intravenous JJ B-adj.all	ranitidine NN B-noun.state	was VBD 0	shown VBN B-verb.perception	to TO 0	double VB B-verb.social	the DT 0	bioavailability NN B-noun.cognition	of IN 0	oral JJ B-adj.all	alendronate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d413.s19	However RB 0	, , 0	in IN 0	a DT 0	well RB 0	- : 0	controlled VBN B-verb.social	study NN B-noun.act	of IN 0	patients NNS B-noun.person	with IN 0	lymphoma NN B-noun.person	on IN 0	combination NN B-noun.person	therapy NN B-noun.person	, , 0	allopurinol NN B-noun.person	did VBD 0	not RB B-adv.all	increase VB B-verb.change	the DT 0	marrow NN B-noun.person	toxicity NN B-noun.person	of IN 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	cyclophosphamide NN 0	, , 0	doxorubicin NN B-noun.person	, , 0	bleomycin NN B-noun.person	, , 0	procarbazine NN B-noun.person	and/or CC 0	mechlorethamine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d568.s25	Ketoconazole NNP B-noun.person	; : 0	Combined VBN B-verb.cognition	administration NN B-noun.person	of IN 0	racemic JJ B-adj.all	citalopram NN B-noun.cognition	( ( 0	40 CD B-adj.all	mg NN B-noun.quantity	) ) 0	and CC 0	ketoconazole NN B-noun.person	( ( 0	200 CD 0	mg NN B-noun.quantity	) ) 0	decreased VBD B-verb.change	the DT 0	Cmax NNP B-noun.person	and CC 0	AUC NNP B-noun.group	of IN 0	ketoconazole NN B-noun.shape	by IN 0	21 CD B-adj.all	% NN 0	and CC 0	10 CD B-adj.all	% NN 0	, , 0	respectively RB B-adv.all	, , 0	and CC 0	did VBD 0	not RB B-adv.all	significantly RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	citalopram NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d458.s23	It PRP 0	is VBZ 0	suggested VBN B-verb.communication	to TO 0	monitor VB B-verb.perception	both DT 0	ketoconazole NN B-noun.group	and CC 0	phenytoin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d250.s4	The DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	sodium_cephalothin JJ B-adj.all	and CC 0	Coly NNP B-noun.person	- : 0	Mycin_M NNP B-noun.person	Parenteral NNP I-noun.person	should MD 0	be VB 0	avoided VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d217.s13	Some DT 0	quinolones NNS B-noun.communication	have VBP 0	also RB B-adv.all	been VBN 0	shown VBN B-verb.perception	to TO 0	interfere VB B-verb.stative	with IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	caffeine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d145.s0	Plasma NN B-noun.person	levels NNS B-noun.state	of IN 0	anticonvulsant_agents NNS B-noun.object	may MD 0	become VB B-verb.stative	subtherapeutic JJ B-adj.all	during IN 0	cisplatin NN B-noun.person	therapy NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d388.s2	Exaggerated JJ B-adj.all	hypertensive JJ B-adj.all	responses NNS B-noun.act	have VBP 0	been VBN 0	reported VBN B-verb.communication	from IN 0	the DT 0	combined VBN B-adj.all	use NN B-noun.process	of IN 0	beta JJ B-adj.pert	- : 0	adrenergic_antagonists NNS B-noun.person	and CC 0	alpha NN B-noun.person	- : 0	adrenergic_stimulants NNS B-noun.person	, , 0	including VBG B-verb.change	those DT 0	contained VBN B-verb.stative	in IN 0	proprietary JJ B-adj.all	cold JJ B-noun.person	remedies NNS I-noun.person	and CC 0	vasoconstrictive JJ B-adj.all	nasal JJ B-adj.all	drops NNS B-noun.shape	. . 0	. . 0
DDI-DrugBank.d141.s6	Therefore RB 0	, , 0	it PRP 0	would MD 0	be VB 0	expected VBN B-verb.cognition	that IN 0	a DT 0	dosing NN B-noun.person	schedule NN B-noun.person	of IN 0	cerivastatin_sodium NN 0	given VBN B-verb.possession	at IN 0	bedtime NN B-noun.location	and CC 0	cholestyramine NN B-noun.act	given VBN B-verb.possession	before IN 0	the DT 0	evening NN 0	meal NN B-noun.attribute	would MD 0	not RB B-adv.all	result VB B-verb.stative	in IN 0	a DT 0	significant JJ B-adj.all	decrease NN B-noun.state	in IN 0	the DT 0	clinical JJ B-adj.all	effect NN B-noun.cognition	of IN 0	cerivastatin_sodium NN B-noun.location	. . 0	. . 0
DDI-DrugBank.d143.s56	Cholestyramine NN B-noun.person	increases VBZ B-verb.change	enterohepatic JJ B-adj.all	elimination NN B-noun.act	of IN 0	amiodarone NN B-noun.person	and CC 0	may MD 0	reduce VB B-verb.change	its PRP$ 0	serum NN B-noun.body	levels NNS B-noun.attribute	and CC 0	t1/2 NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d225.s12	All DT 0	subjects NNS B-noun.person	received VBD B-verb.possession	glipizide NN 0	alone RB 0	and CC 0	following VBG 0	treatment NN B-noun.communication	with IN 0	100 CD 0	mg NN B-noun.quantity	of IN 0	fluconazole NN B-noun.substance	as IN 0	a DT 0	single JJ B-adj.all	daily JJ B-noun.event	oral JJ B-adj.all	dose NN B-noun.quantity	for IN 0	seven CD 0	days NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d221.s2	Although IN 0	the DT 0	specific JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	was VBD B-verb.stative	not RB B-adv.all	studied VBN B-verb.cognition	in IN 0	a DT 0	clinical JJ B-adj.all	trial NN B-noun.cognition	, , 0	there EX 0	have VBP 0	been VBN B-verb.stative	more JJR B-noun.quantity	than IN 0	50 CD B-adj.all	episodes NNS B-noun.quantity	of IN 0	concomitant JJ B-adj.all	use NN 0	of IN 0	antifibrinolytic JJ B-adj.all	therapies NNS B-noun.cognition	( ( 0	i.e. FW B-adv.all	, , 0	tranexamic_acid NN 0	, , 0	aminocaproic_acid JJ 0	) ) 0	and CC 0	NovoSeven NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d324.s28	Drugs NNS B-noun.other	That IN I-noun.other	Inhibit NNP I-noun.other	Both NNP I-noun.other	Aldehyde NNP I-noun.other	Oxidase NNP I-noun.other	and CC 0	CYP3A4 NNP B-noun.person	Cimetidine NNP I-noun.person	, , 0	Cimetidine NNP B-noun.person	inhibits VBZ B-verb.possession	both DT 0	aldehyde JJ B-adj.all	oxidase NN B-noun.cognition	( ( 0	in IN 0	vitro NN B-noun.location	) ) 0	and CC 0	CYP3A4 NNP B-noun.person	( ( 0	in IN 0	vitro NN B-noun.animal	and CC 0	in IN 0	vivo NN B-noun.location	) ) 0	, , 0	the DT 0	primary JJ B-adj.all	and CC 0	secondary JJ B-adj.all	enzymes NNS B-noun.person	, , 0	respectively RB B-adv.all	, , 0	responsible JJ B-adj.all	for IN 0	zaleplon NN B-noun.artifact	metabolism NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d107.s4	Non SYM 0	- : 0	steroidal_Anti SYM 0	- : 0	inflammatory_Agents NNS B-noun.person	, , 0	In IN 0	some DT 0	patients NNS B-noun.person	with IN 0	compromised JJ B-adj.all	renal JJ B-adj.all	function NN B-noun.act	who WP 0	are VBP 0	being VBG 0	treated VBN B-verb.change	with IN 0	nonsteroidal_anti JJ B-noun.person	- : 0	inflammatory_drugs NNS B-noun.time	, , 0	the DT 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	enalapril NN B-noun.time	may MD 0	result VB B-verb.stative	in IN 0	a DT 0	further JJ B-adj.all	deterioration NN B-noun.cognition	of IN 0	renal JJ B-adj.all	function NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d219.s27	Drug NN 0	/ '' 0	Laboratory NNP B-noun.other	Test NNP I-noun.other	Interactions NNPS I-noun.other	The DT 0	urine NN B-noun.act	of IN 0	patients NNS B-noun.person	who WP 0	take VBP B-verb.cognition	Lodine NN B-noun.person	can MD 0	give VB B-verb.creation	a DT 0	false JJ B-adj.all	- : 0	positive JJ B-adj.all	reaction NN B-noun.process	for IN 0	urinary JJ B-adj.all	bilirubin NN B-noun.person	( ( 0	urobilin NN B-noun.substance	) ) 0	due JJ 0	to TO 0	the DT 0	presence NN B-noun.person	of IN 0	phenolic JJ B-adj.all	metabolites NNS B-noun.event	of IN 0	etodolac NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d559.s1	Butalbital NNP B-noun.person	, , 0	acetaminophen NN B-noun.person	and CC 0	caffeine NN B-noun.act	may MD 0	enhance VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	, , 0	other JJ 0	narcotic_analgesics NNS B-noun.person	, , 0	alcohol NN B-noun.person	, , 0	general JJ B-adj.all	anesthetics NNS B-noun.person	, , 0	tranquilizers NNS B-noun.person	such JJ 0	as IN 0	chlordiazepoxide NN 0	, , 0	sedative JJ B-adj.all	- : 0	hypnotics NNS B-noun.person	, , 0	or CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	, , 0	causing VBG B-verb.communication	increased VBN B-verb.change	CNS NNP 0	depression NN 0	. . 0	. . 0
DDI-MedLine.d87.s0	ADL_8 SYM 0	- : 0	2698 CD 0	, , 0	a DT 0	trans-3,4-dimethyl-4-(3-hydroxyphenyl NN B-noun.event	) ) 0	piperidine NN 0	, , 0	prevents VBZ B-verb.communication	gastrointestinal JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	intravenous JJ B-adj.all	morphine NN B-noun.attribute	without IN 0	affecting VBG B-verb.competition	analgesia NN I-verb.competition	. . 0	_ PRP 0	. . 0
DDI-MedLine.d113.s0	Acid SYM 0	- : 0	catalyzed VBN B-verb.communication	ethanolysis NN B-noun.person	of IN 0	temazepam NN B-noun.food	in IN 0	anhydrous JJ B-adj.all	and CC 0	aqueous JJ B-adj.all	ethanol NN B-noun.event	solutions NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d90.s1	Evoked JJ 0	hind NN 0	limb NN 0	digital JJ B-adj.all	extensor NN 0	tension NN 0	( ( 0	hoof JJ 0	twitch NN 0	) ) 0	was VBD 0	maintained VBN B-verb.stative	at IN 0	40 CD B-adj.all	% NN 0	of IN 0	baseline NN B-noun.person	for IN 0	1 CD B-adj.all	h NN 0	by IN 0	atracurium JJ B-adj.all	infusion NN B-noun.cognition	in IN 0	7 CD B-adj.all	horses NNS B-noun.act	anaesthetised VBN B-verb.cognition	with IN 0	halothane NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d246.s2	In IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	a DT 0	1-mg JJ B-adj.all	dose NN B-noun.quantity	of IN 0	butorphanol NN 0	administered VBN B-verb.possession	as IN 0	STADOL_NS NNS B-noun.group	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	a DT 0	single JJ B-adj.all	6-mg JJ B-noun.group	subcutaneous JJ B-adj.all	dose NN B-noun.event	of IN 0	sumatriptan NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d237.s2	Antibiotics NNS B-noun.person	, , 0	In IN 0	vitro NN B-noun.artifact	and/or CC 0	in IN 0	vivo JJ B-adj.all	data NNS B-noun.cognition	show VBP B-verb.communication	that DT 0	clarithromycin NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	and CC 0	troleandomycin NN B-noun.person	markedly RB B-adv.all	inhibit VBP B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	cisapride NN B-noun.location	, , 0	which WDT 0	can MD 0	result VB B-verb.stative	in IN 0	an DT 0	increase NN B-noun.act	in IN 0	plasma NN B-noun.substance	cisapride NN 0	levels NNS B-noun.state	and CC 0	prolongation NN B-noun.act	of IN 0	the DT 0	QT NNP 0	interval NN 0	on IN 0	the DT 0	ECG NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d236.s27	Propoxyphene NNP B-noun.person	, , 0	In IN 0	cases NNS B-noun.state	of IN 0	propoxyphene NN B-noun.person	overdosage NN B-noun.person	, , 0	amphetamine JJ 0	CNS NNP 0	stimulation NN 0	is VBZ 0	potentiated VBN B-verb.possession	and CC 0	fatal JJ B-adj.all	convulsions NNS B-noun.person	can MD 0	occur VB B-verb.cognition	. . 0	. . 0
DDI-MedLine.d99.s11	The DT 0	clearance NN B-noun.act	by IN 0	means NNS B-noun.person	of IN 0	4-hydroxytolbutamide JJ 0	and CC 0	carboxytolbutamide NN B-noun.person	was VBD B-verb.stative	significantly RB B-adv.all	reduced VBN B-verb.change	in IN 0	both DT 0	groups NNS B-noun.group	( ( 0	ie UH 0	, , 0	from IN 0	901 CD B-adj.all	mL SYM B-noun.quantity	/ : 0	h PRP 0	to TO 0	318 CD B-adj.all	mL SYM B-noun.quantity	/ FW 0	h FW 0	in IN 0	the DT 0	group NN B-noun.group	that WDT 0	received VBD B-verb.possession	150 CD 0	mg NN B-noun.quantity	of IN 0	tolbutamide NN 0	per IN 0	day NN B-noun.animal	and CC 0	from IN 0	723 CD B-adj.all	mL SYM B-noun.quantity	/ : 0	h PRP 0	to TO 0	457 CD B-adj.all	mL SYM B-noun.quantity	/ FW 0	h FW 0	in IN 0	the DT 0	group NN B-noun.group	that WDT 0	received VBD B-verb.possession	75 CD 0	mg NN B-noun.quantity	of IN 0	tolbutamide NN 0	per IN 0	day NN B-noun.animal	) ) 0	. . 0	. . 0
DDI-DrugBank.d356.s4	In IN 0	some DT 0	patients NNS B-noun.person	, , 0	the DT 0	administration NN B-noun.time	of IN 0	a DT 0	non NN B-noun.person	- : 0	steroidal_anti SYM 0	- : 0	inflammatory_agent NN B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	diuretic JJ B-adj.all	, , 0	natriuretic JJ B-adj.all	, , 0	and CC 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	loop NN B-noun.location	, , 0	potassium NN B-noun.person	- : 0	sparing NN B-verb.communication	and CC 0	thiazide_diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d568.s39	Concomitant NNP B-noun.person	Administration NNP I-noun.person	with IN 0	Racemic NNP B-noun.person	Citalopram NNP I-noun.person	Citalopram NNP I-noun.person	; : 0	Since IN 0	escitalopram NN B-noun.act	is VBZ B-verb.stative	the DT 0	active JJ B-adj.all	isomer NN B-noun.person	of IN 0	racemic JJ B-adj.all	citalopram NN B-noun.cognition	( ( 0	Celexa NNP B-noun.location	) ) 0	, , 0	the DT 0	two CD 0	agents NNS B-noun.person	should MD 0	not RB 0	be VB 0	coadministered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d467.s3	Furthermore RB B-adv.all	, , 0	rifampin NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	and CC 0	other JJ 0	inducers NNS B-noun.person	of IN 0	cytochrome NN B-noun.person	P450 NN I-noun.person	3A4 WDT 0	may MD 0	cause VB B-verb.communication	a DT 0	reduction NN B-noun.act	in IN 0	plasma NN B-noun.plant	bexarotene NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d435.s0	Exemestane NNP B-noun.person	is VBZ B-verb.stative	extensively RB B-adv.all	metabolized VBN B-verb.cognition	by IN 0	CYP NNP B-noun.person	3A4 NNP I-noun.person	, , 0	but CC 0	coadministration NN B-noun.person	of IN 0	ketoconazole NN B-noun.shape	, , 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	CYP NNP B-noun.person	3A4 NNP I-noun.person	, , 0	has VBZ B-verb.possession	no DT 0	significant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	exemestane NN B-noun.person	pharmacokinetics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d352.s4	Concurrent JJ B-adj.all	use NN 0	of IN 0	phenothiazines NNS B-noun.animal	may MD 0	antagonize VB B-verb.cognition	the DT 0	anorectic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	diethylpropion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d485.s43	ETHANOL NN 0	/ IN 0	NUTRITION NNP B-noun.group	/ POS 0	HERB NNP B-noun.group	INTERACTIONS NNP I-noun.group	, , 0	Food NNP B-noun.location	, , 0	CNS NNP 0	effects NNS B-noun.phenomenon	of IN 0	caffeine NN B-noun.act	may MD 0	be VB 0	enhanced VBN B-verb.communication	if IN 0	combination_hormonal_contraceptives NNS B-noun.person	are VBP 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	caffeine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d249.s10	Oral NNP B-noun.person	Hypoglycemics NNP I-noun.person	, , 0	Diclofenac NNP B-noun.person	does VBZ 0	not RB B-adv.all	alter VB B-verb.change	glucose JJ B-adj.all	metabolism NN B-noun.artifact	in IN 0	normal JJ B-adj.all	subjects NNS B-noun.person	nor CC 0	does VBZ 0	it PRP 0	alter VB B-verb.change	the DT 0	effects NNS B-noun.phenomenon	of IN 0	oral JJ B-adj.all	hypoglycemic_agents NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d271.s0	Physiological JJ B-noun.body	changes NNS I-noun.body	resulting VBG B-verb.stative	from IN 0	smoking VBG B-verb.consumption	cessation NN I-verb.consumption	, , 0	with IN 0	or CC 0	without IN 0	nicotine JJ B-adj.all	replacement NN B-noun.person	, , 0	may MD 0	alter VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	certain JJ B-adj.all	concomitant JJ B-adj.all	medications NNS B-noun.person	, , 0	such JJ 0	as IN 0	tricyclic_antidepressants NNS B-noun.person	and CC 0	theophylline PRP 0	. . 0	. . 0
DDI-MedLine.d85.s7	Misonidazole NNP B-noun.person	reduced VBD B-verb.change	the DT 0	antitumour JJ B-adj.all	activity NN B-noun.state	of IN 0	oral JJ B-adj.all	CCNU NNP B-noun.group	by IN 0	dose NN B-noun.substance	modifying NN B-noun.artifact	factors NNS B-noun.person	( ( 0	DMF NNP 0	) ) 0	of IN 0	0.58 CD 0	- : 0	0.71 CD 0	. . 0	. . 0
DDI-MedLine.d13.s8	However RB 0	, , 0	the DT 0	absolute JJ B-adj.all	number NN B-noun.quantity	of IN 0	alcohol NN B-noun.person	- : 0	related JJ B-adj.all	deaths NNS B-noun.person	is VBZ B-verb.stative	far RB B-adv.all	greater JJR B-adj.all	than IN 0	the DT 0	number NN B-noun.quantity	of IN 0	deaths NNS B-noun.person	in IN 0	amphetamine JJ B-adj.all	or CC 0	heroin NN B-noun.person	users NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d132.s1	This DT 0	may MD 0	occur VB B-verb.cognition	because IN 0	diflunisal NN B-noun.person	competitively RB B-adv.all	displaces VBZ B-verb.communication	coumarins NNS B-noun.person	from IN 0	protein NN B-noun.animal	binding JJ B-verb.contact	sites NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d277.s27	Interaction NN B-noun.act	of IN 0	GABITRIL NNP B-noun.group	with IN 0	Highly NNP B-noun.other	Protein NNP I-noun.other	Bound NNP I-noun.other	Drugs NNP I-noun.other	, , 0	In IN 0	vitro NN B-noun.animal	data NNS B-noun.cognition	showed VBD B-verb.communication	that IN 0	tiagabine NN B-noun.state	is VBZ B-verb.stative	96 CD B-adj.all	% NN 0	bound NN 0	to TO 0	human JJ B-adj.all	plasma NN B-noun.person	protein NN B-noun.person	and CC 0	therefore RB B-adv.all	has VBZ B-verb.possession	the DT 0	potential NN B-noun.person	to TO 0	interact VB B-verb.contact	with IN 0	other JJ 0	highly RB B-adv.all	protein VBP 0	bound VBN B-verb.contact	compounds NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d76.s7	Terfenadine NN B-noun.person	, , 0	astemizole NN B-noun.person	and CC 0	cisapride NN B-noun.act	are VBP B-verb.stative	all DT 0	metabolized VBN B-verb.cognition	by IN 0	the DT 0	cytochrome NN B-noun.person	P450IIIA4 JJ I-noun.person	isozyme NN I-noun.person	, , 0	and CC 0	it PRP 0	has VBZ 0	been VBN 0	demonstrated VBN B-verb.cognition	that IN 0	ketoconazole NN B-noun.person	, , 0	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	IIIA4 NN B-noun.food	, , 0	blocks VBZ B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	these DT 0	drugs NNS B-noun.artifact	, , 0	resulting VBG B-verb.stative	in IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	parent JJ B-adj.all	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d22.s3	Therefore RB 0	you PRP 0	may MD 0	need VB 0	to TO 0	take VB B-verb.motion	a DT 0	vitamin_B12 JJ B-adj.all	supplement NN B-noun.artifact	while IN 0	taking VBG B-verb.social	aminosalicylic_acid JJ I-verb.social	. . 0	. . 0
DDI-DrugBank.d210.s18	Thus RB 0	, , 0	when WRB 0	VIOXX NNP B-noun.group	and CC 0	lithium NN B-noun.person	are VBP 0	administered VBN B-verb.possession	concurrently RB B-adv.all	, , 0	subjects NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	carefully RB B-adv.all	for IN 0	signs NNS B-noun.communication	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d467.s2	On IN 0	the DT 0	basis NN B-noun.cognition	of IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	bexarotene NN B-noun.person	by IN 0	cytochrome JJ B-noun.person	P450 JJ I-noun.person	3A4 NN I-noun.person	, , 0	ketoconazole NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	gemfibrozil NN B-noun.artifact	, , 0	grapefruit NN B-adj.all	juice NN B-noun.person	, , 0	and CC 0	other JJ 0	inhibitors NNS B-noun.person	of IN 0	cytochrome NN B-noun.person	P450 NN I-noun.person	3A4 WDT 0	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	lead VB B-verb.cognition	to TO 0	an DT 0	increase NN B-noun.act	in IN 0	plasma NN B-noun.plant	bexarotene NN B-noun.body	concentrations NNS I-noun.body	. . 0	. . 0
DDI-MedLine.d83.s11	In IN 0	addition NN 0	, , 0	olanzapine NN B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	associated VBN B-verb.cognition	with IN 0	a DT 0	risk NN 0	of IN 0	agranulocytosis NN B-noun.state	as RB 0	seen VBN B-verb.perception	with IN 0	clozapine NN B-noun.attribute	or CC 0	clinically RB B-adj.all	significant JJ B-adj.all	hyperprolactinaemia NN B-noun.state	as RB 0	seen VBN B-verb.perception	with IN 0	risperidone NN B-noun.attribute	or CC 0	prolongation NN B-noun.act	of IN 0	the DT 0	QT NNP 0	interval NN 0	. . 0	. . 0
DDI-DrugBank.d154.s2	Because IN 0	Nalfon NNP B-noun.person	has VBZ 0	not RB 0	been VBN 0	shown VBN B-verb.perception	to TO 0	produce VB B-verb.cognition	any DT 0	additional JJ B-adj.all	effect NN B-noun.cognition	beyond IN 0	that DT 0	obtained VBD B-verb.stative	with IN 0	aspirin NN B-noun.state	alone RB I-noun.state	and CC 0	because IN 0	aspirin NN B-noun.person	increases VBZ B-verb.change	the DT 0	rate NN B-noun.time	of IN 0	excretion NN B-noun.act	of IN 0	Nalfon NNP B-noun.person	, , 0	the DT 0	concomitant JJ B-adj.all	use NN 0	of IN 0	Nalfon NNP B-noun.person	and CC 0	salicylates NNS B-noun.person	is VBZ B-verb.stative	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d386.s10	While IN 0	all PDT 0	the DT 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	, , 0	e.g. NNP B-noun.person	, , 0	fluoxetine NN B-noun.person	, , 0	seriraline NN B-noun.person	, , 0	and CC 0	paroxetine NN B-noun.person	, , 0	inhibit VBP B-verb.stative	P450 JJ 0	2D6 NN 0	, , 0	they PRP 0	may MD 0	vary VB B-verb.stative	in IN 0	the DT 0	extent NN B-noun.attribute	of IN 0	inhibition NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d17.s3	In IN 0	seven CD B-adj.all	experiments NNS B-noun.event	reactions NNS B-noun.motive	to TO 0	norepinephrine VB B-verb.communication	and CC 0	oxytocin NN B-noun.person	were VBD B-verb.stative	PGF2alpha NNP 0	. . 0	. . 0
DDI-DrugBank.d172.s15	Because IN 0	of IN 0	its PRP$ 0	lack NN B-noun.state	of IN 0	platelet NN B-noun.phenomenon	effects NNS B-noun.phenomenon	, , 0	CELEBREX NNP B-noun.group	is VBZ B-verb.stative	not RB I-verb.stative	a DT 0	substitute NN B-noun.person	for IN 0	aspirin NN B-noun.person	for IN 0	cardiovascular JJ B-adj.all	prophylaxis NN B-noun.artifact	. . 0	. . 0
DDI-MedLine.d21.s10	Fluoxetine NNP B-noun.person	and CC 0	moclobemide NN B-noun.person	increased VBD B-verb.change	blood NN B-noun.location	glucose NN B-noun.person	at IN 0	different JJ B-adj.all	times NNS B-noun.event	after IN 0	the DT 0	glucose NN B-noun.communication	overload NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d485.s2	Acetaminophen NNP B-noun.person	, , 0	May MD 0	increase VB B-verb.change	plasma NN 0	concentration NN 0	of IN 0	synthetic_estrogens NNS B-noun.artifact	, , 0	possibly RB B-adv.all	by IN 0	inhibiting VBG B-verb.possession	conjugation NN B-noun.possession	. . 0	. . 0
DDI-MedLine.d3.s11	Amprenavir NNP B-noun.person	plus CC 0	rifampin NN B-noun.location	was VBD B-verb.stative	well RB 0	tolerated VBN 0	. . 0	. . 0
DDI-DrugBank.d119.s2	Probenecid NNP B-noun.person	___ NNP I-noun.person	Prolonged NNP I-noun.person	action NN B-noun.process	of IN 0	etomidate NN B-noun.person	. . 0
DDI-DrugBank.d103.s4	Corticosteroids NNS B-noun.person	, , 0	Methylxanthines NNPS B-noun.person	and CC 0	Diuretics NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	xanthine_derivatives NNS B-noun.person	, , 0	steroids NNS B-noun.communication	, , 0	or CC 0	diuretics NNS B-noun.person	may MD 0	potentiate VB B-verb.stative	a DT 0	possible JJ B-adj.all	hypokalemic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	_ . 0	beta2-agonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d434.s1	Use NN 0	in IN 0	Conjunction NNP B-noun.other	with IN I-noun.other	Other JJ I-noun.other	Antiepileptic_Drugs NNS I-noun.other	, , 0	The DT 0	addition NN 0	of IN 0	Felbatol NNP B-noun.person	_ ( 0	to TO 0	antiepileptic_drugs NNS B-noun.location	( ( 0	AEDs NNP B-noun.group	) ) 0	affects VBZ B-verb.stative	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	AEDs NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d104.s0	Fenfluramine NNP B-noun.person	may MD 0	increase VB B-verb.body	slightly RB B-adv.all	the DT 0	effect NN B-noun.cognition	of IN 0	antihypertensive_drugs NNS B-noun.object	, , 0	e.g. NNP B-noun.person	, , 0	guanethidine NN B-noun.person	, , 0	methyldopa NN B-noun.person	, , 0	reserpine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d303.s1	No DT 0	information NN B-noun.cognition	is VBZ B-verb.stative	available JJ B-adj.all	about IN 0	the DT 0	interaction NN B-noun.act	of IN 0	cephalexin NN B-noun.food	and CC 0	metformin NN B-noun.substance	following VBG B-verb.stative	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	either DT 0	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d132.s10	This DT 0	effect NN B-noun.cognition	is VBZ B-verb.stative	small JJ B-adj.all	with IN 0	occasional JJ B-adj.all	doses NNS B-noun.act	of IN 0	antacids NNS B-noun.object	, , 0	but CC 0	may MD 0	be VB B-verb.stative	clinically RB B-adv.all	significant JJ B-adj.all	when WRB 0	antacids NNS B-noun.animal	are VBP 0	used VBN B-verb.consumption	on IN 0	a DT 0	continuous JJ B-adj.all	schedule NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d368.s0	DIAMOX NN B-noun.attribute	modifies NNS B-noun.animal	phenytoin VBP B-verb.consumption	metabolism NN I-verb.consumption	with IN 0	increased VBN B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	of IN 0	phenytoin NN B-noun.food	. . 0	. . 0
DDI-MedLine.d8.s6	When WRB 0	combined VBN B-verb.creation	with IN 0	ofloxacin NN B-noun.person	, , 0	KRM-1648 NNP B-noun.person	exhibited VBD B-verb.perception	strong JJ B-adj.all	synergistic JJ B-adj.all	activity NN B-noun.state	while IN 0	only RB B-adv.all	additive JJ B-adj.all	effects NNS B-noun.phenomenon	were VBD 0	observed VBN B-verb.perception	with IN 0	the DT 0	combination NN B-noun.event	of IN 0	rifampicin NN B-noun.substance	( ( 0	or CC 0	rifabutin NN B-noun.body	) ) 0	and CC 0	ofloxacin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d236.s18	Haloperidol NNP B-noun.person	, , 0	Haloperidol NNP B-noun.person	blocks VBZ B-verb.change	dopamine NN 0	and CC 0	norepinephrine JJ B-adj.all	reuptake NN B-noun.person	, , 0	thus RB 0	inhibiting VBG B-verb.change	the DT 0	central JJ B-noun.body	stimulant JJ I-noun.body	effects NNS B-noun.phenomenon	of IN 0	amphetamines NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d143.s27	Antiarrhythmics NNS B-noun.person	, , 0	Other JJ 0	antiarrhythmic JJ B-adj.all	drugs NNS B-noun.artifact	, , 0	such JJ 0	as IN 0	quinidine NN B-noun.location	, , 0	procainamide NN B-noun.person	, , 0	disopyramide NN 0	, , 0	and CC 0	phenytoin NN B-noun.person	, , 0	have VBP 0	been VBN 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	amiodarone NN 0	. . 0	. . 0
DDI-DrugBank.d139.s8	Warfarin SYM 0	- : 0	Vitamin_K NN B-noun.person	can MD 0	antagonize VB B-verb.cognition	the DT 0	effect NN B-noun.cognition	of IN 0	warfarin NN B-noun.act	. . 0
DDI-DrugBank.d364.s15	Although IN 0	not RB B-adv.all	studied VBN B-verb.cognition	with IN 0	alosetron RB 0	, , 0	inhibition NN 0	of IN 0	N NNP 0	- : 0	acetyltransferase NN B-noun.act	may MD 0	have VB 0	clinically RB B-adv.all	relevant JJ B-adj.all	consequences NNS B-noun.food	for IN 0	drugs NNS B-noun.object	such JJ 0	as IN 0	isoniazid NN B-noun.person	, , 0	procainamide NN B-noun.person	, , 0	and CC 0	hydralazine NN B-noun.person	. . 0	. . 0
DDI-MedLine.d16.s0	Interaction NN B-noun.act	of IN 0	ketamine NN B-noun.person	and CC 0	halothane NN B-noun.person	in IN 0	rats NNS B-noun.animal	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d42.s7	Dolasetron_mesylate NN B-noun.artifact	did VBD 0	not RB B-adv.all	inhibit VB B-verb.change	the DT 0	antitumor NN B-noun.phenomenon	activity NN B-noun.process	of IN 0	four CD B-adj.all	chemotherapeutic_agents NNS B-noun.group	( ( 0	cisplatin NN B-noun.person	, , 0	5-fluorouracil NN 0	, , 0	doxorubicin NN B-noun.person	, , 0	cyclophosphamide NN 0	) ) 0	in IN 0	four CD 0	murine NN B-noun.act	models NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d475.s0	No DT 0	interactions NNS B-noun.motive	have VBP 0	been VBN 0	observed VBN B-verb.perception	between IN 0	nizatidine NN B-noun.person	and CC 0	theophylline PRP 0	, , 0	chlordiazepoxide NN 0	, , 0	lorazepam NN B-noun.person	, , 0	lidocaine NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	and CC 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d78.s14	In IN 0	addition NN 0	, , 0	other JJ 0	quinolones NNS B-noun.communication	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	decrease VB B-verb.communication	the DT 0	CYP3A4-mediated JJ B-adj.all	metabolism NN B-noun.attribute	of IN 0	cyclosporine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d165.s23	Therefore RB 0	, , 0	prothrombin NN B-noun.person	time NN B-noun.group	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	Itraconazole NNP B-noun.person	and CC 0	coumarin NN B-noun.person	- : 0	like IN 0	drugs NNS B-noun.person	simultaneously RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d340.s35	Ethinyl_Estradiol NN B-noun.artifact	and CC 0	Norethindrone NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	VIRACEPT NNP 0	with IN 0	OVCON-35 NN B-noun.person	resulted VBD B-verb.communication	in IN 0	a DT 0	47 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	ethinyl_estradiol NN 0	and CC 0	an DT 0	18 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	norethindrone JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d395.s20	Theophylline PRP 0	, , 0	Enoxacin NNP B-noun.person	is VBZ B-verb.stative	a DT 0	potent JJ B-adj.all	inhibitor NN B-noun.person	of IN 0	the DT 0	cytochrome NN B-noun.person	P-450 NN I-noun.person	isozymes VBZ B-verb.change	responsible JJ B-adj.all	for IN 0	the DT 0	metabolism NN B-noun.attribute	of IN 0	methylxanthines NNS B-noun.object	. . 0	. . 0
DDI-MedLine.d58.s8	Thus RB 0	, , 0	the DT 0	selective JJ B-adj.all	regulation NN B-noun.act	of IN 0	voltage NN B-noun.act	- : 0	dependent JJ B-noun.person	Ca(2 NN I-noun.person	+ '' 0	) ) 0	subtypes NNS B-noun.quantity	by IN 0	ginsenosides NNS B-noun.person	in IN 0	bovine NN 0	chromaffin NN B-adj.all	cell NN B-noun.body	could MD 0	be VB B-verb.stative	the DT 0	cellular JJ B-adj.all	basis NN B-noun.cognition	of IN 0	antistress JJ B-adj.all	effects NNS B-noun.phenomenon	induced VBN B-verb.creation	by IN 0	ginseng NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d550.s2	H2-Receptor_Antagonists NNS B-noun.person	, , 0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	intravenously RB B-adv.all	administered VBN B-verb.possession	famotidine NN 0	( ( 0	20 CD B-adj.all	mg NN B-noun.quantity	) ) 0	reduced VBD B-verb.change	the DT 0	oral JJ B-adj.all	absorption NN B-noun.process	of IN 0	a DT 0	single JJ 0	400 CD 0	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	cefditoren_pivoxil NN B-noun.body	administered VBN B-verb.body	following VBG B-verb.stative	a DT 0	meal NN B-noun.food	, , 0	as IN 0	evidenced VBN B-verb.communication	by IN 0	a DT 0	27 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	mean JJ B-adj.all	Cmax NNP B-noun.person	and CC 0	a DT 0	22 CD B-adj.all	% NN 0	decrease NN B-noun.act	in IN 0	mean JJ B-adj.all	AUC NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d8.s4	Cimetidine NNP B-noun.person	reduces VBZ B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	ALFENTA NNP B-noun.other	. . 0	. . 0
DDI-MedLine.d42.s9	however RB 0	, , 0	patients NNS B-noun.person	with IN 0	moderate JJ B-adj.all	to TO 0	severe VB B-verb.contact	cardiovascular JJ B-adj.all	disease NN B-noun.state	or CC 0	those DT 0	taking VBG B-verb.social	nitrate JJ B-adj.all	therapy NN B-noun.person	are VBP B-verb.stative	at IN 0	increased VBN B-verb.social	risk NN I-verb.social	for IN 0	potentially RB B-adv.all	serious JJ B-adj.all	cardiovascular JJ B-adj.all	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	with IN 0	sildenafil NN B-noun.attribute	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d32.s0	Theophylline PRP 0	, , 0	Twelve CD 0	healthy JJ B-adj.all	male NN B-noun.person	volunteers NNS B-noun.person	were VBD 0	administered VBN B-verb.possession	one CD 0	200-mg JJ 0	ceftibuten NN B-noun.artifact	capsule NN I-noun.artifact	twice RB 0	daily RB 0	for IN 0	6 CD B-adj.all	days NNS B-noun.time	. . 0	. . 0
DDI-MedLine.d84.s5	Synergism NN B-noun.artifact	was VBD 0	observed VBN B-verb.perception	when WRB 0	GL NNP 0	was VBD 0	combined VBN B-verb.change	with IN 0	cefazolin NN B-noun.body	against IN 0	Bacillus NN B-noun.other	subtilis NNS B-noun.state	and CC 0	Klebsiella NNP B-noun.person	oxytoca NN I-noun.person	. . 0	. . 0
DDI-MedLine.d102.s3	injection NN B-noun.act	of IN 0	vehicle NN B-noun.communication	( ( 0	corn NN B-noun.substance	oil NN I-noun.substance	, , 0	0.1 CD 0	mL CD B-noun.quantity	/ DT 0	day NN B-noun.location	) ) 0	, , 0	estradiol NN 0	( ( 0	10 CD B-adj.all	microg NNS B-noun.quantity	/ ) 0	kg RB 0	/ JJ 0	day NN 0	or CC 0	4 CD B-adj.all	mg FW B-noun.quantity	/ FW 0	kg FW 0	/ FW 0	day NN 0	) ) 0	and/or CC 0	progesterone NN B-noun.substance	( ( 0	20 CD 0	mg FW 0	/ FW 0	kg FW 0	/ FW 0	day NN 0	) ) 0	, , 0	for IN 0	eight CD B-adj.all	days NNS B-noun.phenomenon	. . 0	. . 0
DDI-DrugBank.d414.s6	In IN 0	some DT 0	patients NNS B-noun.person	, , 0	the DT 0	administration NN B-noun.time	of IN 0	a DT 0	non-_steroidal_antiinflammatory_agent NN B-noun.person	can MD 0	reduce VB B-verb.change	the DT 0	diuretic JJ B-adj.all	, , 0	natriuretic JJ B-adj.all	, , 0	and CC 0	antihypertensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	loop NN B-noun.location	, , 0	potassium-_sparing VBG B-verb.motion	and CC 0	thiazide_diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d237.s18	astemizole NN B-noun.attribute	, , 0	bepridil NN B-noun.person	, , 0	sparfloxacin NN B-noun.person	, , 0	and CC 0	terodiline NN B-noun.person	. . 0	. . 0
DDI-MedLine.d21.s6	Imipramine NNP B-noun.person	( ( 0	5 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	, , 0	moclobemide RB 0	( ( 0	30 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	, , 0	clonazepam NN B-noun.person	( ( 0	0.25 CD 0	mg PRP B-noun.quantity	/ : 0	kg LS 0	) ) 0	, , 0	fluoxetine NN B-noun.person	( ( 0	20 CD 0	mg PRP 0	/ : 0	kg LS 0	) ) 0	sertraline NN 0	( ( 0	30 CD B-adj.all	mg NN B-noun.quantity	/ : 0	kg LS 0	) ) 0	or CC 0	vehicle NN B-noun.communication	was VBD 0	administered VBN B-verb.possession	. . 0	. . 0
DDI-DrugBank.d43.s7	A DT 0	21 CD 0	( ( 0	17)% JJ 0	decrease NN B-noun.state	in IN 0	the DT 0	steady JJ B-noun.artifact	- : 0	state NN B-adj.all	AUC NNP 0	of IN 0	ganciclovir NN B-noun.person	was VBD 0	observed VBN B-verb.perception	when WRB 0	VIDEX NNP B-noun.group	was VBD 0	administered VBN B-verb.possession	2 CD B-adj.all	hours NNS B-noun.person	prior RB 0	to TO 0	ganciclovir NN B-noun.person	, , 0	but CC 0	not RB B-adv.all	when WRB 0	the DT 0	two CD 0	drugs NNS B-noun.person	were VBD 0	administered VBN B-verb.perception	simultaneously RB B-adv.all	( ( 0	n UH 0	= $ 0	12 CD B-adj.all	) ) 0	. . 0	. . 0
DDI-DrugBank.d210.s23	Oral NNP B-noun.group	Contraceptives NNP I-noun.group	Rofecoxib NNP I-noun.group	did VBD 0	not RB B-adv.all	have VB B-verb.change	any DT 0	clinically RB B-adv.all	important JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	ethinyl_estradiol NN B-noun.food	and CC 0	norethindrone NN B-noun.person	. . 0	. . 0
DDI-MedLine.d133.s1	BACKGROUND NN 0	, , 0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	combined VBN B-verb.change	administration NN B-noun.time	of IN 0	bombesin NN B-noun.food	and CC 0	verapamil_hydrochloride RB 0	( ( 0	verapamil NN B-noun.event	) ) 0	, , 0	a DT 0	calcium_channel_blocker NN B-noun.person	, , 0	on IN 0	the DT 0	incidence NN B-noun.event	of IN 0	peritoneal JJ B-adj.pert	metastasis NN B-noun.cognition	of IN 0	intestinal JJ B-adj.all	adenocarcinomas NNS B-noun.communication	induced VBN B-verb.creation	by IN 0	azoxymethane NN B-noun.person	( ( 0	AOM NNP 0	) ) 0	and CC 0	the DT 0	labeling VBG B-verb.contact	index NN I-verb.contact	of IN 0	intestinal JJ B-adj.all	cancers NNS B-noun.person	were VBD 0	investigated VBN B-verb.communication	in IN 0	male NN 0	Wistar NNP B-noun.person	rats NNS I-noun.person	. . 0	. . 0
DDI-DrugBank.d88.s0	Antacid NNP B-noun.person	, , 0	The DT 0	effect NN B-noun.cognition	of IN 0	an DT 0	aluminum_hydroxide- NNP B-noun.person	and CC 0	magnesium_hydroxide JJ B-noun.group	- : 0	containing VBG B-verb.communication	antacid NN B-noun.attribute	( ( 0	Maalox NNP B-noun.person	) ) 0	_ , 0	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	capecitabine NN B-noun.location	was VBD 0	investigated VBN B-verb.communication	in IN 0	12 CD B-adj.all	cancer NN B-noun.state	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d107.s17	It PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	serum NN 0	lithium NN 0	levels NNS 0	be VB 0	monitored VBN B-verb.perception	frequently RB B-adv.all	if IN 0	enalapril NN B-noun.person	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	lithium NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d194.s0	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	administering VBG B-verb.creation	ETOPOPHOS NNP I-verb.creation	with IN 0	drugs NNS B-noun.artifact	that WDT 0	are VBP 0	known VBN B-verb.cognition	to TO 0	inhibit VB B-verb.change	phosphatase NN B-noun.group	activities NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	levamisole_hydrochloride NN B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d81.s6	propranolol NN B-noun.person	to TO 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	under IN 0	steady JJ B-adj.all	- : 0	state NN B-noun.location	conditions NNS B-noun.person	had VBD 0	no DT 0	relevant JJ B-adj.all	effect NN B-noun.cognition	on IN 0	either DT 0	drug NN B-noun.person	s VBZ 0	bioavailability NN B-noun.cognition	, , 0	AUC NNP B-noun.group	and CC 0	Cmax NNP B-noun.person	, , 0	differences NNS B-noun.person	were VBD B-verb.stative	_ $ 0	20 CD B-adj.all	% NN 0	between IN 0	isradipine JJ 0	given VBN B-verb.possession	singly RB B-adv.all	and CC 0	in IN 0	combination NN 0	with IN 0	propranolol NN B-noun.person	, , 0	and CC 0	between IN 0	propranolol NN B-noun.person	given VBN B-verb.possession	singly RB B-adv.all	and CC 0	in IN 0	combination NN 0	with IN 0	isradipine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d415.s7	Caution NN B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	if IN 0	ibuprofen VBN 0	is VBZ 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	methotrexate NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d277.s16	Theophylline PRP 0	, , 0	A DT 0	single JJ B-adj.all	10 CD B-adj.all	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	tiagabine NN B-noun.artifact	did VBD 0	not RB B-adv.all	affect VB B-verb.change	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	theophylline NN 0	at IN 0	steady JJ B-adj.all	state NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d235.s2	Increased VBN B-verb.change	toxicity NN B-noun.attribute	( ( 0	CNS NNP 0	depression NN B-noun.process	) ) 0	, , 0	CNS_depressants NNS B-noun.person	, , 0	MAO_inhibitors NNS B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	phenothiazines NNS B-noun.body	. . 0	. . 0
DDI-DrugBank.d45.s7	Patients NNS B-noun.person	with IN 0	Crohn NNP B-noun.person	s PRP$ 0	disease NN B-noun.person	who WP 0	received VBD B-verb.possession	immunosuppressants NNS B-noun.person	tended VBD B-verb.social	to TO 0	experience VB B-verb.change	fewer JJR B-adj.all	infusion NN B-noun.act	reactions NNS B-noun.motive	compared VBN 0	to TO 0	patients NNS B-noun.person	on IN 0	no DT 0	immunosuppressants NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d63.s5	On IN 0	the DT 0	other JJ B-adj.all	hand NN B-noun.communication	, , 0	intrathecal JJ B-adj.all	naloxone NN B-noun.person	( ( 0	12 CD 0	- : 0	120 CD 0	micrograms NNS B-noun.quantity	) ) 0	had VBD 0	only RB B-adv.all	a DT 0	very RB B-adv.all	weak JJ B-adj.all	effect NN B-noun.cognition	on IN 0	the DT 0	tail NN B-noun.body	- : 0	flick NN 0	inhibition NN 0	induced VBN B-verb.creation	by IN 0	intraventricular JJ B-adj.all	morphine NN B-noun.phenomenon	( ( 0	40 CD B-adj.all	micrograms NNS B-noun.quantity	) ) 0	. . 0	. . 0
DDI-DrugBank.d119.s6	Aminophylline NNP B-noun.person	____ NNP I-noun.person	Etomidate NNP I-noun.person	antagonism NN B-noun.attribute	. . 0
DDI-DrugBank.d288.s12	In IN 0	order NN 0	to TO 0	avoid VB B-verb.social	the DT 0	occurrence NN B-noun.state	of IN 0	severe JJ B-adj.all	hypersensitivity NN B-noun.act	reactions NNS I-noun.act	, , 0	all DT 0	patients NNS B-noun.person	treated VBD B-verb.social	with IN 0	TAXOL NNP B-noun.group	should MD 0	be VB 0	premedicated VBN B-verb.creation	with IN 0	corticosteroids NNS B-noun.person	( ( 0	such JJ 0	as IN 0	dexamethasone NN 0	) ) 0	, , 0	diphen RB B-adv.all	- : 0	hydramine NN B-noun.person	and CC 0	H2_antagonists NNS B-noun.person	( ( 0	such JJ 0	as IN 0	cimetidine NN B-noun.person	or CC 0	ranitidine NN B-noun.location	) ) 0	. . 0	. . 0
DDI-DrugBank.d81.s9	Rifampicin NNP B-noun.person	, , 0	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	a DT 0	six CD 0	- : 0	day NN B-noun.person	course NN B-noun.group	of IN 0	rifampicin NN B-noun.person	at IN 0	600 CD 0	mg RB 0	/ JJ 0	day NN 0	followed VBN B-verb.stative	by IN 0	a DT 0	single JJ B-noun.communication	5 CD B-adj.all	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	isradipine NN B-noun.person	resulted VBD B-verb.communication	in IN 0	a DT 0	reduction NN B-noun.act	in IN 0	isradipine JJ B-adj.all	levels NNS B-noun.attribute	to TO 0	below IN 0	detectable JJ B-adj.all	limits NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d21.s13	Again RB 0	, , 0	sertraline NN B-noun.person	neutralized VBD B-verb.change	the DT 0	increase NN B-noun.event	in IN 0	glycemia NN B-noun.animal	after IN 0	glucose DT 0	overload NN B-noun.artifact	both DT 0	in IN 0	diabetic NN B-noun.person	and CC 0	non NN B-noun.person	- : 0	diabetic JJ B-adj.all	rats NNS B-noun.animal	. . 0	. . 0
DDI-DrugBank.d422.s4	When WRB 0	digoxin NN B-noun.person	and CC 0	BREVIBLOC NNP B-noun.person	were VBD B-verb.stative	concomitantly RB B-adv.all	administered VBN B-verb.body	intravenously RB B-adv.all	to TO 0	normal JJ B-adj.all	volunteers NNS B-noun.person	, , 0	there EX 0	was VBD B-verb.stative	a DT 0	10 CD B-adj.all	- : 0	20 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	digoxin NN 0	blood NN B-noun.location	levels NNS B-noun.state	at IN 0	some DT 0	time NN B-noun.time	points NNS B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d62.s0	Dexbrompheniramine NN B-noun.person	can MD 0	interact VB B-verb.change	with IN 0	alcohol NN B-noun.feeling	or CC 0	other JJ B-adj.all	CNS_depressants NNS B-noun.person	( ( 0	may MD 0	potentiate VB B-verb.communication	the DT 0	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	either CC 0	these DT 0	medications NNS B-noun.artifact	or CC 0	antihistamines NNS B-noun.attribute	) ) 0	, , 0	anticholinergics NNS B-noun.person	or CC 0	other JJ B-adj.all	medications NNS B-noun.person	with IN 0	anticholinergic JJ B-adj.all	activity NN B-noun.state	( ( 0	anticholinergic JJ B-adj.pert	effects NNS B-noun.phenomenon	may MD 0	be VB 0	potentiated VBN B-verb.cognition	when WRB 0	these DT 0	medications NNS B-noun.artifact	are VBP 0	used VBN B-verb.consumption	concurrently RB B-adv.all	with IN 0	antihistamines NNS B-noun.attribute	) ) 0	, , 0	and CC 0	monoamine_oxidase_(MAO)_inhibitors NNS B-noun.person	( ( 0	concurrent JJ B-adj.all	use NN 0	with IN 0	antihistamines NNS B-noun.object	may MD 0	prolong VB B-verb.perception	and CC 0	intensify VB B-verb.change	the DT 0	anticholinergic JJ B-adj.all	and CC 0	CNS NNP B-noun.group	depressant JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	antihistamines NNS B-noun.attribute	) ) 0	. . 0	. . 0
DDI-DrugBank.d441.s2	Adrenergic_Agents NNS B-noun.person	, , 0	Some DT 0	individuals NNS 0	receiving VBG B-verb.change	ZYVOX NNP B-noun.group	may MD 0	experience VB B-verb.change	a DT 0	reversible JJ B-adj.all	enhancement NN B-noun.person	of IN 0	the DT 0	pressor NN B-noun.person	response NN B-noun.communication	to TO 0	indirect VB B-verb.creation	- : 0	acting VBG B-verb.stative	sympathomimetic_agents NNS I-verb.stative	, , 0	vasopressor NN B-noun.person	or CC 0	dopaminergic_agents NNS B-noun.group	. . 0	. . 0
DDI-DrugBank.d196.s34	Because IN 0	of IN 0	the DT 0	potential NN B-noun.person	for IN 0	adverse JJ B-adj.all	reactions NNS B-noun.person	from IN 0	the DT 0	drugs NNS B-noun.artifact	in IN 0	nursing NN B-verb.emotion	infants NNS B-noun.person	, , 0	a DT 0	decision NN B-noun.act	must MD 0	be VB 0	made VBN B-verb.social	whether IN 0	to TO 0	discontinue VB B-verb.emotion	nursing NN I-verb.emotion	or CC 0	discontinue NN B-noun.group	PEGASYS NNP B-noun.group	and CC 0	COPEGUS NNP B-noun.group	treatment NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d81.s7	Cimetidine NNP B-noun.person	, , 0	In IN 0	a DT 0	study NN B-noun.artifact	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	a DT 0	one CD 0	- : 0	week NN B-noun.time	course NN 0	of IN 0	cimetidine NN B-noun.person	at IN 0	400 CD 0	mg IN 0	b.i.d NNP B-noun.person	. . 0	with IN 0	a DT 0	single JJ B-noun.communication	5 CD B-adj.all	mg NN B-noun.quantity	dose NN B-noun.quantity	of IN 0	isradipine NN B-noun.person	on IN 0	the DT 0	sixth JJ B-adj.all	day NN B-noun.person	showed VBD B-verb.communication	an DT 0	increase NN B-noun.act	in IN 0	isradipine JJ B-adj.all	mean JJ B-adj.all	peak JJ B-adj.all	plasma NN B-noun.substance	concentrations NNS B-noun.relation	( ( 0	36 CD 0	% NN 0	) ) 0	and CC 0	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	area NN B-noun.body	under IN 0	the DT 0	curve NN B-noun.communication	( ( 0	50 CD B-adj.all	% NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d299.s5	Propanolol NNP B-noun.person	, , 0	The DT 0	pharmacokinetics NNS B-noun.time	of IN 0	almotriptan JJ B-noun.animal	were VBD B-verb.stative	not RB B-adv.all	affected VBN B-verb.change	by IN 0	coadministration NN B-noun.person	of IN 0	propranolol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d532.s2	These DT 0	medications NNS B-noun.communication	have VBP 0	included VBN B-verb.stative	heparin NN 0	, , 0	warfarin NN B-noun.location	, , 0	beta JJ 0	- : 0	adrenergic_receptor_blockers NNS B-noun.person	, , 0	calcium_channel_antagonists NNS B-noun.person	, , 0	angiotensin_converting_enzyme_inhibitors NNS B-noun.person	, , 0	intravenous JJ B-adj.all	and CC 0	oral JJ B-adj.all	nitrates NNS B-noun.time	, , 0	ticlopidine NN B-noun.location	, , 0	and CC 0	aspirin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d331.s3	- : 0	Lithium NN B-noun.person	, , 0	Lithium NNP B-noun.location	should MD 0	generally RB 0	not RB 0	be VB 0	given VBN B-verb.possession	with IN 0	diuretics NNS B-noun.person	( ( 0	such JJ 0	as IN 0	bumetanide NN 0	) ) 0	because IN 0	they PRP 0	reduce VBP B-verb.change	its PRP$ 0	renal JJ B-adj.all	clearance NN B-noun.act	and CC 0	add VB B-verb.communication	a DT 0	high JJ B-adj.all	risk NN 0	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-MedLine.d128.s10	On IN 0	the DT 0	other JJ B-adj.all	hand NN B-noun.communication	, , 0	the DT 0	enhanced JJ B-adj.all	secretion NN B-noun.act	of IN 0	colonic JJ B-adj.all	fluid NN B-noun.state	by IN 0	dmPGE2 NNP B-noun.person	, , 0	given VBN B-verb.possession	intraluminally RB B-adv.all	, , 0	was VBD B-verb.stative	only JJ B-adv.all	half NN B-noun.quantity	of IN 0	that DT 0	in IN 0	control NN B-noun.animal	rats NNS B-noun.animal	, , 0	whereas IN 0	the DT 0	colonic JJ B-adj.pert	transit NN B-noun.act	- : 0	enhancing VBG B-verb.stative	effect NN 0	of IN 0	dmPGE2 NNP B-noun.person	in IN 0	cecectomized VBN B-verb.social	rats NNS B-noun.person	was VBD B-verb.stative	more RBR B-adv.all	pronounced JJ B-adj.all	than IN 0	in IN 0	control NN B-noun.animal	rats NNS B-noun.animal	at IN 0	15 CD B-adj.all	but CC 0	not RB B-adv.all	at IN 0	30 CD B-adj.all	min NN B-noun.communication	after IN 0	its PRP$ 0	administration NN B-noun.time	. . 0	. . 0
DDI-DrugBank.d427.s14	Therefore RB 0	, , 0	cyclosporine JJ B-adj.all	serum NN B-noun.body	levels NNS B-noun.attribute	should MD 0	be VB 0	monitored VBN B-verb.perception	and CC 0	appropriate JJ B-adj.all	cyclosporine JJ B-adj.all	dosage NN B-noun.artifact	adjustments NNS B-noun.person	made VBN B-verb.social	when WRB 0	these DT 0	drugs NNS B-noun.artifact	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d521.s5	- : 0	a DT 0	beta NN B-noun.person	- : 0	blocker NN B-adj.all	such JJ 0	as IN 0	propranolol NN B-noun.person	( ( I-noun.person	Inderal NNP I-noun.person	) ) 0	, , 0	atenolol NN 0	( ( 0	Tenormin NNP 0	) ) 0	, , 0	acebutolol NN B-noun.person	( ( 0	Sectral NNP B-noun.location	) ) 0	, , 0	metoprolol NN B-noun.person	( ( 0	Lopressor NNP 0	) ) 0	, , 0	and CC 0	others NNS 0	, , 0	. . 0
DDI-MedLine.d42.s5	RESULTS NNS B-noun.artifact	, , 0	Sildenafil NNP B-noun.person	has VBZ 0	demonstrated VBN B-verb.perception	effectiveness NN B-noun.cognition	in IN 0	men NNS B-noun.person	with IN 0	erectile JJ B-adj.all	dysfunction NN B-noun.communication	associated VBN B-verb.cognition	with IN 0	prostatectomy NN B-noun.person	, , 0	radiation NN B-noun.act	therapy NN 0	, , 0	diabetes VBZ B-verb.communication	mellitus NN B-noun.person	, , 0	certain JJ B-adj.all	neurologic JJ B-adj.all	disorders NNS B-noun.person	, , 0	and CC 0	drug NN B-noun.person	therapy NN 0	( ( 0	eg UH 0	, , 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	[ POS 0	SSRIs NNP B-noun.group	] NNP I-noun.group	) ) 0	. . 0	. . 0
DDI-DrugBank.d413.s23	Monitoring NN B-noun.person	of IN 0	cyclosporine JJ B-adj.all	levels NNS B-noun.attribute	and CC 0	possible JJ B-adj.all	adjustment NN B-noun.person	of IN 0	cyclosporine JJ B-adj.all	dosage NN B-noun.artifact	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	these DT 0	drugs NNS B-noun.artifact	are VBP B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d482.s3	Caution NN B-noun.person	should MD 0	be VB 0	exercised VBN B-verb.social	when WRB 0	taking VBG B-verb.cognition	this DT 0	medicine NN B-noun.attribute	certain JJ B-adj.all	antibiotics NNS B-noun.person	, , 0	such JJ 0	as IN 0	erythromycin NN B-noun.person	, , 0	clarithromycin NN B-noun.person	, , 0	or CC 0	azithromycin NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d106.s1	Ranitidine JJ 0	150 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	did VBD 0	not RB B-adv.all	interact VB B-verb.change	significantly RB B-adv.all	with IN 0	nisoldipine NN B-noun.person	( ( 0	AUC NNP 0	was VBD 0	decreased VBN B-verb.change	by IN 0	15 CD B-adj.all	- : 0	20 CD B-adj.all	% NN 0	) ) 0	. . 0	. . 0
DDI-MedLine.d47.s1	The DT 0	in FW 0	vitro FW 0	anti FW 0	- : 0	cryptosporidial JJ B-adj.all	activity NN B-noun.process	of IN 0	buforin_II NNP B-noun.person	alone RB I-noun.person	and CC 0	in IN 0	combination NN 0	with IN 0	azithromycin NN B-noun.person	and CC 0	minocycline NN B-noun.person	was VBD 0	investigated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d328.s8	ACE NNP B-noun.person	- : 0	inhibitors NNS B-noun.person	, , 0	Reports NNS B-noun.person	suggest VBP B-verb.communication	that IN 0	NSAIDs NNP B-noun.person	may MD 0	diminish VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	ACE NNP B-noun.group	- : 0	inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d216.s2	Lorazepam NNP B-noun.person	, , 0	Coadministration NNP B-noun.person	of IN 0	single JJ B-adj.all	doses NNS B-noun.event	of IN 0	eszopiclone NN B-noun.communication	3 CD B-adj.all	mg NN B-noun.quantity	and CC 0	lorazepam NN B-noun.communication	2 CD B-adj.all	mg NN B-noun.quantity	did VBD 0	not RB B-adv.all	have VB 0	clinically RB B-adv.all	relevant JJ B-adj.pert	effects NNS B-noun.phenomenon	on IN 0	the DT 0	pharmacodynamics NNS B-noun.time	or CC 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	drug NN B-noun.person	. . 0	. . 0
DDI-MedLine.d129.s0	Green_tea_polyphenols NNS B-noun.artifact	as IN 0	potent JJ B-adj.all	enhancers NNS B-noun.person	of IN 0	glucocorticoid JJ B-adj.all	- : 0	induced VBN B-verb.creation	mouse NN B-noun.animal	mammary JJ B-adj.all	tumor NN B-noun.animal	virus NN I-noun.animal	gene NN B-noun.state	expression NN B-noun.communication	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d437.s13	Laboratory NNP B-noun.person	Tests NNPS I-noun.person	, , 0	The DT 0	combination NN B-noun.event	of IN 0	Amprenavir NNP B-noun.person	and CC 0	low JJ B-adj.all	- : 0	dose NN B-noun.person	ritonavir NN B-noun.person	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	elevations NNS B-noun.person	of IN 0	cholesterol NN B-noun.act	and CC 0	triglycerides NNS B-noun.person	, , 0	SGOT NNP B-noun.group	( ( 0	AST NNP 0	) ) 0	, , 0	and CC 0	SGPT NNP B-noun.group	( ( 0	ALT NNP 0	) ) 0	in IN 0	some DT 0	patients NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d27.s1	In IN B-adj.all	vitro NN I-adj.all	studies NNS B-noun.group	show VBP B-verb.change	significant JJ B-adj.all	inhibition NN B-noun.attribute	of IN 0	the DT 0	formation NN B-noun.act	of IN 0	oxidized JJ B-adj.all	irbesartan JJ B-adj.all	metabolites NNS B-noun.person	with IN 0	the DT 0	known VBN B-adj.all	cytochrome NN B-noun.person	CYP NNP I-noun.person	2C9 CC 0	substrates NNS B-noun.time	/ POS 0	inhibitors NNS B-noun.person	sulphenazole NN B-noun.person	, , 0	tolbutamide NN 0	and CC 0	nifedipine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d61.s0	In IN 0	clinical JJ B-adj.all	studies NNS B-noun.communication	, , 0	Tilade NNP B-noun.person	has VBZ 0	been VBN B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	other JJ 0	anti NNS B-noun.person	- : 0	asthma NN B-noun.person	medications NNS I-noun.person	, , 0	including VBG B-verb.change	inhaled VBN B-verb.body	and CC 0	oral JJ B-adj.all	bronchodilators NNS B-noun.person	, , 0	and CC 0	inhaled JJ B-adj.all	corticosteroids NNS B-noun.person	, , 0	with IN 0	no DT 0	evidence NN B-noun.attribute	of IN 0	increased JJ B-adj.all	frequency NN B-noun.person	of IN 0	adverse JJ B-adj.all	events NNS B-noun.state	or CC 0	laboratory NN B-noun.body	abnormalities NNS I-noun.body	. . 0	. . 0
DDI-MedLine.d49.s6	Combinations NNS B-noun.person	of IN 0	clindamycin NN B-noun.person	and CC 0	gentamicin NN B-noun.state	were VBD B-verb.stative	indifferent JJ B-adj.all	for IN 0	29 CD B-adj.all	strains NNS B-noun.communication	and CC 0	synergistic NN B-noun.person	for IN 0	33 CD 0	strains NNS B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d172.s6	Clinical JJ B-adj.all	studies NNS B-noun.communication	with IN 0	celecoxib NN B-noun.artifact	have VBP 0	identified VBN B-verb.cognition	potentially RB B-adv.all	significant JJ B-adj.all	interactions NNS B-noun.person	with IN 0	fluconazole NN B-noun.attribute	and CC 0	lithium NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d316.s12	In IN 0	controlled VBN B-verb.social	clinical JJ B-adj.all	trials NNS B-noun.communication	, , 0	however RB 0	, , 0	beta_blockers NNS B-noun.person	including VBG B-verb.social	metoprolol NN B-noun.act	were VBD B-verb.stative	concurrently RB B-adv.all	administered VBN B-verb.possession	with IN 0	felodipine NN B-noun.person	and CC 0	were VBD B-verb.stative	well RB 0	tolerated VBN 0	. . 0	. . 0
DDI-DrugBank.d169.s1	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	10 CD B-adj.all	mg NN B-noun.quantity	of IN 0	lenalidomide NN B-noun.person	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	the DT 0	single JJ B-adj.all	dose NN B-noun.person	pharmacokinetics NNS B-noun.person	of IN 0	R- : 0	and CC 0	S-_warfarin NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d567.s12	Amiodarone NNP B-noun.person	or CC 0	Verapamil NNP B-noun.location	, , 0	The DT 0	risk NN 0	of IN 0	myopathy JJ B-adj.all	/ CD 0	rhabdomyolysis NN B-noun.quantity	is VBZ 0	increased VBN B-verb.change	when WRB 0	either RB 0	amiodarone JJ 0	or CC 0	verapamil NN B-noun.artifact	is VBZ 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	a DT 0	closely RB B-adj.all	related JJ B-adj.all	member NN B-noun.person	of IN 0	the DT 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitor_class NN B-noun.group	( ( 0	see VB B-verb.social	WARNINGS NNS B-noun.act	, , 0	Myopathy NNP B-noun.person	/ NNP I-noun.person	Rhabdomyolysis NNP I-noun.person	) ) 0	. . 0	. . 0
DDI-MedLine.d79.s1	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	indinavir NN B-noun.person	and CC 0	didanosine NN B-noun.person	significantly RB B-adv.all	reduces VBZ B-verb.change	the DT 0	level NN B-noun.state	of IN 0	exposure NN B-noun.cognition	to TO 0	indinavir NN B-noun.person	, , 0	but CC 0	it PRP 0	is VBZ B-verb.stative	unclear JJ B-adj.all	how WRB 0	soon RB 0	after IN 0	didanosine JJ B-adj.all	administration NN 0	indinavir NN 0	may MD 0	be VB 0	given VBN B-verb.possession	safely RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d462.s1	Vecuronium NNP B-noun.person	, , 0	When WRB 0	used VBN B-verb.consumption	in IN 0	the DT 0	perioperative JJ B-adj.all	period NN B-noun.person	, , 0	piperacillin NN B-noun.person	has VBZ 0	been VBN 0	implicated VBN B-verb.communication	in IN 0	the DT 0	prolongation NN B-noun.act	of IN 0	the DT 0	neuromuscular JJ B-adj.all	blockade NN B-noun.attribute	of IN 0	vecuronium NN B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d307.s4	Although IN 0	inhibition NN 0	of IN 0	CYP NNP B-noun.person	3A4/5 NNP I-noun.person	by IN 0	OXC NNP 0	and CC 0	MHD NNP B-noun.group	did VBD 0	occur VB B-verb.stative	at IN 0	high JJ B-adj.all	concentrations NNS B-noun.artifact	, , 0	it PRP 0	is VBZ B-verb.stative	not RB B-adv.all	likely JJ B-adj.all	to TO 0	be VB B-verb.stative	of IN 0	clinical JJ B-adj.all	significance NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d59.s0	The DT 0	effects NNS B-noun.phenomenon	of IN 0	ERGOMAR NNP B-noun.group	may MD 0	be VB 0	potentiated VBN B-verb.communication	by IN 0	triacetyloleandomycin NN B-noun.communication	which WDT 0	inhibits VBZ B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	ergotamine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d373.s0	Beta SYM 0	- : 0	adrenergic_Blocking_Agents NNS B-noun.person	, , 0	Experience NNP B-noun.person	in IN 0	over IN 0	1400 CD 0	patients NNS B-noun.person	in IN 0	a DT 0	non NN B-noun.person	- : 0	comparative JJ B-adj.all	clinical JJ B-adj.all	trial NN B-noun.cognition	has VBZ 0	shown VBN B-verb.cognition	that DT 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	nifedipine NN B-noun.person	and CC 0	beta JJ B-noun.body	- : 0	blocking_agents NNS B-noun.person	is VBZ B-verb.stative	usually RB B-adv.all	well RB 0	tolerated VBN 0	, , 0	but CC 0	there EX 0	have VBP 0	been VBN B-verb.stative	occasional JJ B-adj.all	literature NN B-noun.act	reports NNS B-noun.artifact	suggesting VBG B-verb.communication	that IN 0	the DT 0	combination NN B-noun.group	may MD 0	increase VB B-verb.change	the DT 0	likelihood NN B-noun.location	of IN 0	congestive JJ B-adj.all	heart NN B-noun.person	failure NN B-noun.person	, , 0	severe JJ B-adj.all	hypotension NN B-noun.state	or CC 0	exacerbation NN B-noun.act	of IN 0	angina NN 0	. . 0	. . 0
DDI-DrugBank.d124.s1	Several JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	studies NNS B-noun.artifact	have VBP 0	been VBN 0	completed VBN B-verb.change	with IN 0	both DT 0	INVIRASE NNP B-noun.group	and CC 0	FORTOVASE NNP B-noun.act	. . 0	. . 0
DDI-DrugBank.d526.s4	Digitalis_glycosides NNS 0	enhanced VBN B-verb.change	possibility NN B-noun.state	of IN 0	arrhythmias NNS B-noun.communication	or CC 0	digitalis PRP$ 0	toxicity NN B-noun.attribute	associated VBN B-verb.cognition	with IN 0	hypokalemia NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d487.s4	Corticosteroids NNS B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	chronic JJ B-adj.pert	high JJ B-adj.all	dose NN 0	aspirin NN 0	. . 0	. . 0
DDI-MedLine.d2.s1	Studies NNS B-noun.person	in IN 0	rats NNS B-noun.animal	have VBP 0	shown VBN B-verb.cognition	that DT 0	neomycin JJ B-adj.all	administration NN B-noun.person	attenuates VBZ B-verb.contact	certain JJ B-adj.all	types NNS B-noun.person	of IN I-noun.person	adrenocortical_steroid JJ I-noun.person	dependent JJ B-adj.all	hypertension NN B-noun.person	, , 0	including VBG B-verb.change	ACTH NNP 0	hypertension NN 0	. . 0	. . 0
DDI-DrugBank.d179.s1	Sulfapyridine NN 0	may MD 0	interact VB B-verb.change	with IN 0	any DT 0	of IN 0	the DT 0	following NN 0	, , 0	; : 0	Acetaminophen NNP B-noun.person	( ( 0	e.g. UH 0	, , 0	Tylenol NNP B-noun.location	) ) 0	( ( 0	with IN 0	long JJ B-noun.body	- : 0	term NN B-noun.time	, , 0	high JJ B-noun.group	- : 0	dose NN 0	use NN 0	) ) 0	or CC 0	. . 0
DDI-MedLine.d132.s0	The DT 0	emerging VBG B-verb.change	roles NNS B-noun.act	of IN 0	non NN B-noun.person	- : 0	nucleoside_reverse_transcriptase_inhibitors NNS B-noun.person	in IN 0	antiretroviral JJ B-adj.all	therapy NN B-noun.act	. . 0	. . 0
DDI-MedLine.d3.s12	Amprenavir NNP B-noun.person	plus CC 0	rifabutin NN B-noun.location	was VBD B-verb.stative	poorly RB B-adv.all	tolerated VBN B-verb.communication	, , 0	and CC 0	5 CD 0	of IN 0	11 CD B-adj.all	subjects NNS B-noun.person	discontinued VBN B-verb.stative	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d415.s12	Lithium NNP B-noun.person	, , 0	Ibuprofen NNP B-noun.person	produced VBD B-verb.creation	an DT 0	elevation NN B-noun.act	of IN 0	plasma NN B-noun.plant	lithium NN B-noun.body	levels NNS B-noun.attribute	and CC 0	a DT 0	reduction NN B-noun.act	in IN 0	renal JJ B-adj.all	lithium NN B-noun.phenomenon	clearance NN B-noun.attribute	in IN 0	a DT 0	study NN B-noun.artifact	of IN 0	eleven CD 0	normal JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d75.s3	The DT 0	percentage NN B-noun.possession	of IN 0	neurons NNS B-noun.person	hyperpolarized VBN B-verb.communication	by IN 0	mu- JJ 0	, , 0	delta(1)- NNP B-noun.group	, , 0	and CC 0	kappa NN B-noun.person	- : 0	selective_opioids NNS B-noun.person	was VBD B-verb.stative	significantly RB B-adv.all	reduced VBN B-verb.change	when WRB 0	1 CD B-adj.all	% NN 0	but CC 0	not RB B-adv.all	< JJ 0	. . 0
DDI-DrugBank.d458.s27	After IN 0	the DT 0	coadministration NN B-noun.person	of IN 0	200 CD 0	mg IN 0	oral JJ B-adj.all	ketoconazole NN B-noun.attribute	twice RB B-adv.all	daily JJ B-adj.all	and CC 0	one CD 0	20 CD B-adj.all	mg DT B-noun.quantity	dose NN B-noun.quantity	of IN 0	loratadine NN 0	to TO 0	11 CD 0	subjects NNS B-noun.person	, , 0	the DT 0	AUC NNP B-noun.group	and CC 0	Cmax NNP B-noun.person	of IN 0	loratadine NN B-noun.person	averaged VBD B-verb.creation	302 CD 0	% NN 0	( ( 0	_ $ 0	142 CD 0	S.D. NNP 0	) ) 0	and CC 0	251 CD 0	% NN 0	( ( 0	_ $ 0	68 CD 0	S.D. NNP 0	) ) 0	, , 0	respectively RB B-adv.all	, , 0	of IN 0	those DT 0	obtained VBN B-verb.creation	after IN 0	co SYM 0	- : 0	treatment NN B-noun.plant	with IN 0	placebo NN B-noun.plant	. . 0	. . 0
DDI-DrugBank.d506.s6	Norpace NN B-noun.person	does VBZ 0	not RB B-adv.all	increase VB B-verb.change	serum NN B-noun.body	digoxin NN I-noun.body	levels NNS B-noun.state	. . 0	. . 0
DDI-DrugBank.d307.s48	Results NNS B-noun.person	with IN 0	warfarin NN B-noun.person	wshow VBP B-verb.communication	no DT 0	evidence NN B-noun.attribute	of IN 0	interaction NN B-noun.act	with IN 0	either DT 0	single JJ B-noun.location	or CC 0	repeated VBN B-verb.communication	doses NNS B-noun.quantity	of IN 0	Trileptal NNP B-noun.person	. . 0	. . 0
DDI-DrugBank.d279.s10	It PRP 0	would MD 0	be VB 0	expected VBN B-verb.cognition	that IN 0	laxative JJ B-adj.all	use NN 0	during IN 0	therapy NN 0	with IN 0	CAMPTOSAR NNP B-noun.group	would MD 0	worsen VB B-verb.emotion	the DT 0	incidence NN B-noun.communication	or CC 0	severity NN B-noun.attribute	of IN 0	diarrhea NN B-noun.person	, , 0	but CC 0	this DT 0	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d223.s16	Inhibitors NNS B-noun.person	or CC 0	substrates NNS B-noun.substance	of IN 0	CYP2D6 NNP B-noun.person	( ( 0	i.e. FW B-adv.all	, , 0	quinidine NN B-noun.location	, , 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	[ POS 0	SSRIs NNP B-noun.group	] NNP I-noun.group	) ) 0	may MD 0	increase VB B-verb.change	the DT 0	plasma NN B-noun.substance	concentration NN B-noun.event	of IN 0	doxepin NN B-noun.communication	when WRB 0	administered VBN B-verb.communication	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d495.s8	There EX 0	is VBZ B-verb.stative	one CD 0	reported VBN B-verb.communication	case NN B-noun.state	of IN 0	a DT 0	patient NN B-noun.person	with IN 0	acute JJ B-adj.all	delirium NN B-noun.person	associated VBN B-verb.cognition	with IN 0	the DT 0	simultaneous JJ B-adj.all	use NN B-noun.act	of IN 0	fluphenazine NN B-noun.substance	and CC 0	oral JJ B-adj.all	clonidine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d36.s0	Caution NN B-noun.person	is VBZ 0	advised VBN B-verb.communication	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	concomitant JJ B-adj.all	high JJ B-noun.group	- : 0	dose NN 0	aspirin NN 0	and CC 0	carbonic_anhydrase_inhibitors NNS B-noun.person	, , 0	as IN 0	anorexia NN 0	, , 0	tachypnea NN B-noun.person	, , 0	lethargy NN B-noun.communication	and CC 0	coma NN B-noun.person	have VBP 0	been VBN 0	rarely RB B-adv.all	reported VBN B-verb.communication	due JJ 0	to TO 0	a DT 0	possible JJ B-adj.all	drug NN B-noun.artifact	interaction NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d75.s8	Anagrelide RB 0	alone RB 0	had VBD 0	no DT 0	effect NN B-noun.cognition	on IN 0	platelet NN B-noun.artifact	aggregation NN I-noun.artifact	, , 0	but CC 0	did VBD 0	slightly RB B-adv.all	enhance VB B-verb.social	the DT 0	inhibition NN B-noun.attribute	of IN 0	platelet NN B-noun.phenomenon	aggregation NN I-noun.phenomenon	by IN 0	aspirin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d176.s0	Diuretics NNS B-noun.person	, , 0	Patients NNPS B-noun.person	on IN 0	diuretics NNS B-noun.person	, , 0	especially RB B-adv.all	those DT 0	with IN 0	intravascular JJ B-adj.all	volume NN B-noun.artifact	depletion NN I-noun.artifact	, , 0	may MD 0	occasionally RB 0	experience VB B-verb.social	an DT 0	excessive JJ B-adj.all	reduction NN B-noun.process	of IN 0	blood NN B-noun.phenomenon	pressure NN I-noun.phenomenon	after IN 0	initiation NN B-noun.time	of IN 0	therapy NN 0	with IN 0	fosinopril_sodium JJ 0	. . 0	. . 0
DDI-DrugBank.d232.s0	After IN 0	multiple JJ B-adj.all	dosing NN B-noun.act	, , 0	interferon_beta-1a NNP B-noun.person	( ( 0	AVONEX NNP B-noun.group	_ $ 0	30 CD B-adj.all	mcg NN 0	IM NNP 0	once RB B-adv.all	weekly JJ I-adv.all	) ) 0	reduced VBD B-verb.change	TYSABRI NNP B-noun.group	_ , 0	clearance NN B-noun.act	by IN 0	approximately RB B-noun.time	30 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d55.s0	Isoproterenol_hydrochloride JJ B-adj.all	injection NN B-noun.event	and CC 0	epinephrine NN B-noun.location	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	simultaneously RB B-adv.all	because IN 0	both DT 0	drugs NNS B-noun.artifact	are VBP B-verb.stative	direct JJ B-adj.all	cardiac JJ I-adj.all	stimulants NNS B-noun.artifact	and CC 0	their PRP$ 0	combined VBN B-verb.change	effects NNS B-noun.phenomenon	may MD 0	induce VB B-verb.cognition	serious JJ B-adj.all	arrhythmias NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d198.s15	Consequently RB B-adv.all	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	not RB B-adv.all	to TO 0	exceed VB B-verb.stative	a DT 0	single JJ B-adj.all	2.5 CD 0	mg IN 0	Vardenafil NNP B-noun.person	dose NN I-noun.person	in IN 0	a DT 0	72-hour JJ 0	period NN B-noun.time	when WRB 0	used VBN B-verb.consumption	in IN 0	combination NN 0	with IN 0	ritonavir NN B-noun.person	. . 0	. . 0
DDI-MedLine.d107.s1	Little NNP B-noun.person	has VBZ 0	been VBN 0	studied VBN B-verb.cognition	of IN 0	the DT 0	adverse JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	the DT 0	exposure NN B-noun.cognition	of IN 0	the DT 0	liver NN 0	to TO 0	the DT 0	interaction NN B-noun.act	of IN 0	ethanol NN 0	with IN 0	its PRP$ 0	congeners NNS B-noun.person	and CC 0	acetaldehyde NN B-noun.person	, , 0	coexisting VBG B-verb.stative	in IN 0	the DT 0	contents NNS B-noun.group	of IN 0	alcoholic JJ B-adj.all	beverages NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d397.s5	Concurrent JJ B-adj.all	use NN 0	of IN 0	erythromycin NN B-noun.food	and CC 0	ergotamine NN B-noun.act	or CC 0	dihydroergotamine NN B-noun.person	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	in IN 0	some DT 0	patients NNS B-noun.person	with IN 0	acute JJ B-adj.all	ergot NN B-noun.person	toxicity NN B-noun.person	characterized VBN B-verb.communication	by IN 0	severe JJ B-adj.all	peripheral JJ B-adj.pert	vasospasm NN B-noun.cognition	and CC 0	dysesthesia NN B-noun.state	. . 0	. . 0
DDI-MedLine.d127.s6	Concomitantly RB B-adv.all	given VBN B-verb.possession	thiazide_diuretics NNS B-noun.artifact	did VBD 0	not RB B-adv.all	interfere VB B-verb.stative	with IN 0	the DT 0	absorption NN B-noun.artifact	of IN 0	a DT 0	tablet NN B-noun.group	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d34.s0	Although IN 0	acid NN B-noun.person	- : 0	base NN B-noun.person	and CC 0	electrolyte NN B-noun.person	disturbances NNS B-noun.person	were VBD B-verb.stative	not RB B-adv.all	reported VBN B-verb.communication	in IN 0	the DT 0	clinical JJ B-adj.all	trials NNS B-noun.person	with IN 0	dorzolamide NN 0	, , 0	these DT 0	disturbances NNS B-noun.artifact	have VBP 0	been VBN 0	reported VBN B-verb.communication	with IN 0	oral JJ B-adj.all	carbonic_anhydrase_inhibitors NNS B-noun.person	and CC 0	have VB 0	, , 0	in IN 0	some DT 0	instances NNS B-noun.artifact	, , 0	resulted VBD B-verb.stative	in IN 0	drug NN 0	interactions NNS 0	( ( 0	e.g. UH 0	, , 0	toxicity NN B-noun.attribute	associated VBN B-verb.cognition	with IN 0	high JJ B-noun.group	- : 0	dose NN 0	salicylate NN 0	therapy NN 0	) ) 0	. . 0	. . 0
DDI-DrugBank.d382.s22	Midazolam NNP B-noun.person	, , 0	Aprepitant NNP B-noun.person	increased VBD B-verb.change	the DT 0	AUC NNP B-noun.group	of IN 0	midazolam NN B-noun.food	, , 0	a DT 0	sensitive JJ B-noun.person	CYP3A4 NNP I-noun.person	substrate NN I-noun.person	, , 0	by IN 0	2.3-fold JJ B-noun.other	on IN I-noun.other	Day NNP I-noun.other	1 CD I-noun.other	and CC I-noun.other	3.3-fold JJ I-noun.other	on IN I-noun.other	Day NNP I-noun.other	5 CD I-noun.other	, , 0	when WRB 0	a DT 0	single JJ B-adj.all	oral JJ B-adj.all	dose NN B-noun.quantity	of IN 0	midazolam NN B-noun.communication	2 CD B-adj.all	mg NN B-noun.quantity	was VBD 0	coadministered VBN B-verb.contact	on IN 0	Day NNP 0	1 CD 0	and CC 0	Day NNP 0	5 CD 0	of IN 0	a DT 0	regimen NNS B-noun.person	of IN 0	Aprepitant JJ 0	125 CD 0	mg NN B-noun.quantity	on IN 0	Day NNP 0	1 CD 0	and CC 0	80 CD 0	mg RB 0	/ JJ 0	day NN 0	on IN 0	Days NNS B-noun.time	2 CD 0	through IN 0	5 CD 0	. . 0	. . 0
DDI-DrugBank.d404.s8	Ketoconazole NNP B-noun.person	, , 0	Ketoconazole NNP B-noun.person	may MD 0	inhibit VB B-verb.possession	both DT 0	synthetic JJ B-adj.all	and CC 0	catabolic JJ B-adj.all	enzymes NNS B-noun.event	of IN 0	vitamin_D. NNP B-noun.person	. . 0
DDI-DrugBank.d314.s19	Drugs NNS B-noun.artifact	which WDT 0	inhibit VBP B-verb.change	CYP NNP B-noun.group	3A4 NNP I-noun.group	( ( 0	e.g. UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	macrolide_antibiotics NNS B-noun.person	such JJ 0	as IN 0	erythromycin NN 0	) ) 0	have VBP B-verb.stative	the DT 0	potential NN B-noun.person	to TO 0	result VB B-verb.stative	in IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	corticosteroids NNS B-noun.food	. . 0	. . 0
DDI-DrugBank.d269.s5	When WRB 0	concomitant JJ B-adj.all	treatment NN B-noun.communication	with IN 0	agents_with_b SYM 0	- : 0	blocking_properties NNS B-noun.group	and CC 0	clonidine NN B-noun.person	is VBZ B-verb.stative	to TO 0	be VB 0	terminated VBN B-verb.change	, , 0	the DT 0	b SYM 0	- : 0	blocking_agent NN B-noun.group	should MD 0	be VB 0	discontinued VBN B-verb.cognition	first RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d382.s4	Aprepitant NNP B-noun.person	has VBZ 0	been VBN 0	shown VBN B-verb.perception	to TO 0	induce VB B-verb.cognition	the DT 0	metabolism NN B-noun.attribute	of IN 0	S(-)_warfarin NNP B-noun.person	and CC 0	tolbutamide NN 0	, , 0	which WDT 0	are VBP 0	metabolized VBN B-verb.cognition	through IN 0	CYP2C9 NNP B-noun.other	. . 0	. . 0
DDI-DrugBank.d450.s7	Rifampin NNP B-noun.person	may MD 0	decrease VB B-verb.cognition	serum NN 0	digoxin NN 0	concentration NN B-noun.event	, , 0	especially RB B-adv.all	in IN 0	patients NNS B-noun.person	with IN 0	renal JJ B-adj.all	dysfunction NN B-noun.act	, , 0	by IN 0	increasing VBG B-verb.change	the DT 0	non NN B-noun.person	- : 0	renal JJ B-adj.all	clearance NN B-noun.act	of IN 0	digoxin NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d165.s3	Coadministration NN B-noun.person	of IN 0	terfenadine NN 0	with IN 0	Itraconazole NNP B-noun.person	has VBZ 0	led VBN B-verb.stative	to TO 0	elevated JJ B-adj.all	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	terfenadine NN B-noun.artifact	, , 0	resulting VBG B-verb.stative	in IN 0	rare JJ B-adj.all	instances NNS B-noun.time	of IN 0	life- NN 0	threatening VBG B-verb.communication	cardiac JJ B-noun.person	dysrhythmias NNS I-noun.person	and CC 0	one CD 0	death NN 0	. . 0	. . 0
DDI-MedLine.d128.s15	N SYM 0	- : 0	methyllevallorphan NN B-noun.person	( ( 0	5 CD 0	mg FW 0	/ FW 0	kg FW 0	, , 0	s.c NNP B-noun.person	. . 0	) ) 0	completely RB B-adv.all	antagonized VBN B-verb.cognition	the DT 0	inhibitory JJ B-adj.all	effect NN B-noun.cognition	of IN 0	loperamide NN B-noun.food	and CC 0	partly RB B-adv.all	antagonized VBN B-verb.communication	the DT 0	effect NN B-noun.cognition	of IN 0	morphine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d269.s10	Due JJ 0	to TO 0	wide VB B-verb.possession	interindividual JJ B-noun.possession	variability NN I-noun.possession	in IN 0	the DT 0	dose NN B-noun.communication	adjustment NN B-noun.communication	required VBN B-verb.stative	, , 0	it PRP 0	is VBZ 0	recommended VBN B-verb.communication	that IN 0	cyclosporine JJ B-adj.all	concentrations NNS B-noun.person	be VB 0	monitored VBN B-verb.perception	closely RB B-adv.all	after IN 0	initiation NN B-noun.time	of IN 0	carvedilol NN B-noun.act	therapy NN B-noun.act	and CC 0	that IN 0	the DT 0	dose NN B-noun.quantity	of IN 0	cyclosporine NN 0	be VB 0	adjusted VBN B-verb.change	as IN 0	appropriate JJ B-noun.person	. . 0	. . 0
DDI-DrugBank.d412.s9	Labetalol_HCl NN B-noun.artifact	blunts NNS B-noun.artifact	the DT 0	reflex JJ B-adj.all	tachycardia NNS B-noun.person	produced VBN B-verb.creation	by IN 0	nitroglycerin NN B-noun.person	without IN 0	preventing VBG B-verb.creation	its PRP$ 0	hypotensive JJ B-adj.all	effect NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d64.s6	Drugs NNS B-noun.artifact	that WDT 0	have VBP 0	been VBN 0	reported VBN B-verb.communication	to TO 0	diminish VB B-verb.change	oral JJ B-adj.all	anticoagulant JJ B-adj.all	response NN B-noun.communication	, , 0	ie UH 0	, , 0	decreased VBD B-verb.communication	prothrom NN B-noun.person	- : 0	bin NN 0	time NN 0	response NN B-noun.communication	, , 0	in IN 0	man NN 0	significantly RB B-adv.all	include VBP B-verb.change	, , 0	adrenocortical_steroids NNS B-noun.person	, , 0	. . 0
DDI-DrugBank.d85.s0	The DT 0	use NN 0	of IN 0	NSAIDs NNP B-noun.person	in IN 0	patients NNS B-noun.person	who WP 0	are VBP 0	receiving VBG B-verb.communication	ACE_inhibitors NNS B-noun.person	may MD 0	potentiate VB B-verb.stative	renal JJ B-adj.all	disease NN B-noun.process	states NNS B-noun.location	. . 0	. . 0
DDI-DrugBank.d453.s0	Cytosine_arabinoside RB 0	, , 0	a DT 0	cytostatic_agent NN B-noun.person	, , 0	has VBZ 0	been VBN 0	reported VBN B-verb.communication	to TO 0	inactivate VB B-verb.communication	the DT 0	antifungal JJ B-adj.all	activity NN B-noun.process	of IN 0	flucytosine NN B-noun.phenomenon	by IN 0	competitive JJ B-adj.all	inhibition NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d77.s15	While IN 0	all PDT 0	the DT 0	selective_serotonin_reuptake_inhibitors NNS B-noun.person	( ( 0	SSRIs NNP 0	) ) 0	, , 0	e. FW 0	g. FW 0	, , 0	fluoxetine NN B-noun.person	, , 0	sertraline NN B-noun.person	, , 0	and CC 0	paroxetine NN B-noun.person	, , 0	inhibit VBP B-verb.stative	P450 JJ 0	2D6 NN 0	, , 0	they PRP 0	may MD 0	vary VB B-verb.stative	in IN 0	the DT 0	extent NN B-noun.attribute	of IN 0	inhibition NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d411.s2	Levothyroxine_Sodium NN B-noun.state	Absorption NNP B-noun.person	, , 0	The DT 0	following VBG 0	agents NNS B-noun.person	may MD 0	bind VB B-verb.social	and CC 0	decrease VB B-verb.change	absorption NN B-noun.act	of IN 0	levothyroxine_sodium NN B-noun.state	from IN 0	the DT 0	gastrointestinal JJ B-adj.all	tract NN B-noun.body	, , 0	aluminum_hydoxide RB 0	, , 0	cholestyramine JJ B-adj.all	resin NN B-noun.artifact	, , 0	colestipol_hydrochloride NN 0	, , 0	ferrous_sulfate NNP B-noun.person	, , 0	sodium_polystyrene_sulfonate JJ B-adj.all	, , 0	soybean NN 0	flour NN 0	( ( 0	e.g. UH 0	, , 0	infant JJ B-adj.all	formula NN B-noun.attribute	) ) 0	, , 0	sucralfate NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d299.s11	Although IN 0	the DT 0	interaction NN B-noun.act	between IN 0	almotriptan JJ B-adj.all	and CC 0	other JJ B-adj.all	potent JJ B-noun.person	CYP3A4 JJ I-noun.person	inhibitors NNS I-noun.person	( ( 0	e.g. UH 0	, , 0	itraconazole NN B-noun.person	, , 0	ritonavir NN B-noun.person	, , 0	and CC 0	erythromycin NN B-noun.body	) ) 0	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	, , 0	increased VBD B-verb.change	exposures NNS B-noun.person	to TO 0	almotriptan VB B-verb.change	may MD 0	be VB 0	expected VBN B-verb.cognition	when WRB 0	almotriptan RB 0	is VBZ 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	with IN 0	these DT 0	medications NNS B-noun.artifact	. . 0	. . 0
DDI-MedLine.d125.s7	However RB 0	, , 0	administration NN B-noun.person	of IN 0	4-methylpyrazole JJ 0	( ( 0	90 CD 0	mg IN 0	kg(-1 NNP 0	) ) 0	body NN 0	weight NN B-noun.attribute	) ) 0	to TO 0	rats NNS B-noun.communication	2 CD B-adj.all	hours NNS B-noun.person	prior RB 0	to TO 0	1,3-difluoroacetone JJ 0	( ( 0	100 CD 0	mg IN 0	kg(-1 NNP 0	) ) 0	body NN 0	weight NN B-noun.attribute	) ) 0	was VBD B-verb.stative	ineffective JJ B-adj.all	in IN 0	preventing VBG B-verb.creation	( ( 0	-)-erythro UH 0	- : 0	fluorocitrate JJ B-adj.all	synthesis NN B-noun.cognition	and CC 0	did VBD 0	not RB B-adv.all	diminish JJ B-adj.all	fluoride NN B-noun.cognition	or CC 0	citrate JJ B-adj.all	accumulation NN B-noun.person	in IN 0	vivo NN B-noun.animal	. . 0	. . 0
DDI-MedLine.d86.s2	Several JJ 0	clinically RB B-adv.all	important JJ B-adj.all	interactions NNS B-noun.communication	have VBP 0	previously RB B-adv.all	been VBN 0	reported VBN B-verb.communication	for IN 0	other JJ B-adj.all	immunosuppressive_drugs NNS B-noun.plant	that WDT 0	are VBP 0	metabolized VBN B-verb.cognition	by IN 0	the DT 0	same JJ B-adj.all	enzyme NN B-noun.person	and CC 0	for IN 0	calcium_antagonists NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d82.s2	Therefore RB 0	, , 0	diflunisal JJ B-adj.all	and CC 0	INDOCIN NNP B-noun.group	should MD 0	not RB 0	be VB 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d3.s9	Probenecid NNP B-noun.person	, , 0	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	TORADOL NNP B-noun.person	ORAL NNP I-noun.person	and CC 0	probenecid NN B-noun.person	resulted VBD B-verb.communication	in IN 0	decreased JJ B-adj.all	clearance NN B-noun.person	of IN 0	ketorolac NN B-noun.food	and CC 0	significant JJ B-adj.all	increases NNS B-noun.event	in IN 0	ketorolac NN B-noun.animal	plasma NN I-noun.animal	levels NNS B-noun.attribute	( ( 0	total JJ B-adj.all	AUC NNP B-noun.group	increased VBD B-verb.change	approximately RB B-adv.all	threefold RB 0	from IN 0	5.4 CD 0	to TO 0	17.8 CD 0	m FW 0	g FW 0	/ FW 0	h FW 0	/ : 0	mL LS 0	) ) 0	and CC 0	terminal JJ B-noun.artifact	half NN I-noun.artifact	- : 0	life NN B-noun.person	increased VBD B-verb.change	approximately RB B-adv.all	twofold JJ B-adj.all	from IN 0	6.6 CD 0	to TO 0	15.1 CD 0	hours NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d503.s0	Chlorprothixene NNP B-noun.person	may MD 0	increase VB B-verb.change	the DT 0	plasma NN B-noun.person	- : 0	level NN B-noun.attribute	of IN 0	concomitantly RB B-adv.all	given VBN B-verb.possession	lithium NN B-noun.substance	. . 0	. . 0
DDI-DrugBank.d196.s0	Treatment NN B-noun.person	with IN 0	PEGASYS NNP B-noun.group	once RB B-adv.all	weekly RB I-adv.all	for IN 0	4 CD B-adj.all	weeks NNS B-noun.time	in IN 0	healthy JJ B-adj.all	subjects NNS B-noun.person	was VBD 0	associated VBN B-verb.cognition	with IN 0	an DT 0	inhibition NN B-noun.attribute	of IN 0	P450 JJ B-noun.phenomenon	1A2 JJ I-noun.phenomenon	and CC 0	a DT 0	25 CD B-adj.all	% NN 0	increase NN B-noun.event	in IN 0	theophylline DT 0	AUC NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d515.s0	The DT 0	physician NN B-noun.communication	should MD 0	be VB B-verb.stative	alert JJ B-adj.all	for IN 0	possible JJ B-adj.all	combined VBN B-verb.possession	drug NN B-noun.person	actions NNS B-noun.person	, , 0	desirable JJ B-adj.all	or CC 0	undesirable JJ B-adj.all	, , 0	involving VBG B-verb.stative	ifosfamide RB 0	even RB 0	though IN 0	ifosfamide NN 0	has VBZ 0	been VBN 0	used VBN B-verb.consumption	successfully RB B-adv.all	concurrently RB B-adv.all	with IN 0	other JJ 0	drugs NNS B-noun.artifact	, , 0	including VBG B-verb.change	other JJ 0	cytotoxic JJ B-adj.all	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d186.s3	As IN 0	with IN 0	other JJ B-adj.all	antipsychotic_agents NNS B-noun.location	, , 0	it PRP 0	should MD 0	be VB 0	noted VBN B-verb.communication	that IN 0	HALDOL NNP B-noun.group	may MD 0	be VB B-verb.stative	capable JJ B-adj.all	of IN 0	potentiating VBG B-verb.stative	CNS_depressants NNS 0	such JJ 0	as IN 0	anesthetics NNS B-noun.person	, , 0	opiates NNS B-noun.person	, , 0	and CC 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d258.s1	Although IN 0	increased VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.relation	( ( 0	AUC NNP B-noun.group	0 CD B-noun.quantity	- : 0	24 CD B-adj.all	hrs NNS B-noun.artifact	) ) 0	of IN 0	loratadine NN B-noun.location	and/or CC 0	descarboethoxyloratadine NN B-noun.person	were VBD 0	observed VBN B-verb.perception	following VBG B-verb.stative	coadministration NN B-noun.person	of IN 0	loratadine NN 0	with IN 0	each DT 0	of IN 0	these DT 0	drugs NNS B-noun.artifact	in IN 0	normal JJ B-adj.all	volunteers NNS B-noun.person	( ( 0	n UH 0	= $ 0	24 CD B-adj.all	in IN 0	each DT 0	study NN B-noun.artifact	) ) 0	, , 0	there EX 0	were VBD B-verb.stative	no DT 0	clinically RB B-adj.all	relevant JJ B-adj.pert	changes NNS B-noun.relation	in IN 0	the DT 0	safety NN B-noun.person	profile NN B-noun.quantity	of IN 0	loratadine NN B-noun.location	, , 0	as IN 0	assessed VBN B-verb.communication	by IN 0	electrocardiographic JJ B-adj.pert	parameters NNS B-noun.person	, , 0	clinical JJ B-adj.all	laboratory NN B-noun.artifact	tests NNS I-noun.artifact	, , 0	vital JJ B-adj.all	signs NNS B-noun.communication	, , 0	and CC 0	adverse JJ B-adj.all	events NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d480.s19	In IN 0	a DT 0	study NN B-noun.artifact	of IN 0	schizophrenic JJ B-adj.all	patients NNS B-noun.person	who WP 0	received VBD B-verb.possession	clozapine NN B-noun.artifact	under IN 0	steady JJ B-adj.all	state NN B-noun.state	conditions NNS I-noun.state	, , 0	fluvoxamine NN B-noun.substance	or CC 0	paroxetine NN B-noun.person	was VBD 0	added VBN B-verb.change	in IN 0	16 CD B-adj.all	and CC 0	14 CD B-adj.all	patients NNS B-noun.person	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d548.s9	Therefore RB 0	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	Duloxetine NNP B-noun.location	with IN 0	other JJ 0	drugs NNS B-noun.artifact	that WDT 0	are VBP B-verb.stative	extensively RB B-adv.all	metabolized VBN B-verb.cognition	by IN 0	this DT 0	isozyme NN B-noun.attribute	and CC 0	which WDT 0	have VBP B-verb.stative	a DT 0	narrow JJ B-adj.all	therapeutic JJ B-adj.all	index NN B-noun.communication	, , 0	including VBG B-verb.change	certain JJ B-adj.all	antidepressants NNS B-noun.attribute	( ( 0	tricyclic_antidepressants NNS B-noun.person	[ POS 0	TCAs NNPS B-noun.other	] : 0	, , 0	such JJ 0	as IN 0	nortriptyline NN B-noun.person	, , 0	amitriptyline NN B-noun.person	, , 0	and CC 0	imipramine NN B-noun.act	) ) 0	, , 0	phenothiazines NNS B-noun.body	and CC 0	Type_1C_antiarrhythmics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	propafenone NN B-noun.person	, , 0	flecainide NN 0	) ) 0	, , 0	should MD 0	be VB 0	approached VBN B-verb.communication	with IN 0	caution NN B-noun.cognition	. . 0	. . 0
DDI-DrugBank.d512.s7	Dose DT 0	adjustment NN B-noun.communication	of IN 0	Sensipar NNP B-noun.person	may MD 0	be VB 0	required VBN B-verb.stative	and CC 0	PTH NNP B-noun.group	and CC 0	serum NN B-noun.body	calcium NN I-noun.body	concentrations NNS B-noun.attribute	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	if IN 0	a DT 0	patient JJ B-noun.person	initiates NNS I-noun.person	or CC 0	discontinues VBZ B-verb.creation	therapy NN I-verb.creation	with IN 0	a DT 0	strong JJ B-adj.all	CYP3A4 JJ B-adj.all	inhibitor NN B-noun.person	( ( 0	e.g. UH 0	, , 0	ketoconazole NN B-noun.person	, , 0	erythromycin NN B-noun.person	, , 0	itraconazole NN B-noun.person	, , 0	. . 0
DDI-DrugBank.d509.s8	Inhibitors NNS B-noun.person	of IN 0	CYP3A4 NNP B-noun.person	( ( 0	eg UH 0	, , 0	ketoconazole NN B-noun.artifact	) ) 0	or CC 0	CYP2D6 NNP B-noun.person	( ( 0	eg UH 0	, , 0	quinidine NN B-noun.location	, , 0	fluoxetine NN B-noun.person	, , 0	or CC 0	paroxetine NN B-noun.location	) ) 0	can MD 0	inhibit VB B-verb.change	aripiprazole JJ B-adj.all	elimination NN B-noun.act	and CC 0	cause VB 0	increased VBN B-verb.change	blood NN B-noun.body	levels NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d196.s33	The DT 0	effect NN B-noun.cognition	of IN 0	orally RB B-adv.all	ingested JJ B-adj.all	peginterferon NN B-noun.person	or CC 0	ribavirin VB B-verb.motion	from IN 0	breast NN B-noun.person	milk NN B-noun.person	on IN 0	the DT 0	nursing NN B-noun.artifact	infant NN I-noun.artifact	has VBZ 0	not RB 0	been VBN 0	evaluated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d395.s25	Nevertheless RB B-adv.all	, , 0	the DT 0	prothrombin NN B-adj.all	time NN B-noun.time	or CC 0	other JJ 0	suitable JJ B-adj.all	coagulation NN 0	test NN 0	should MD 0	be VB 0	monitored VBN B-verb.perception	when WRB 0	warfarin NN B-noun.state	or CC 0	its PRP$ 0	derivatives NNS B-noun.event	and CC 0	enoxacin NN B-noun.person	are VBP 0	given VBN B-verb.possession	concomitantly RB B-adv.all	. . 0	. . 0
DDI-MedLine.d120.s1	Among IN 0	the DT 0	polyene_antibiotics NNS B-noun.other	, , 0	many JJ 0	, , 0	like IN 0	filipin NN B-noun.person	, , 0	can MD 0	not RB B-adv.all	be VB 0	used VBN B-verb.consumption	clinically RB B-adv.all	because IN 0	they PRP 0	are VBP B-verb.stative	toxic JJ B-adj.all	, , 0	. . 0
DDI-DrugBank.d97.s73	Immunosuppressants NNS B-noun.person	, , 0	cyclosporine NN B-noun.person	, , 0	tacrolimus NN B-noun.person	, , 0	sirolimus NN 0	. . 0
DDI-DrugBank.d41.s14	Rifampin NNP B-noun.person	, , 0	Following VBG 0	concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	ARAVA NNP B-noun.group	to TO 0	subjects NNS B-noun.person	receiving VBG B-verb.change	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	rifampin NN B-noun.food	, , 0	M1 CC 0	peak JJ B-adj.all	levels NNS B-noun.state	were VBD 0	increased VBN B-verb.change	( ( 0	~40 CD 0	% NN 0	) ) 0	over IN 0	those DT 0	seen VBN B-verb.perception	when WRB 0	ARAVA NNP B-noun.group	was VBD 0	given VBN B-verb.possession	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d223.s14	It PRP 0	is VBZ B-verb.stative	desirable JJ B-adj.all	to TO 0	monitor VB B-verb.creation	TCA NNP B-noun.group	plasma NN B-noun.plant	levels NNS B-noun.body	whenever WRB 0	a DT 0	TCA NNP B-noun.group	is VBZ 0	going VBG 0	to TO 0	be VB B-verb.stative	co SYM 0	- : 0	administered VBN B-verb.communication	with IN 0	another DT 0	drug NN B-noun.person	known VBN B-verb.cognition	to TO 0	be VB B-verb.stative	an DT 0	inhibitor NN B-noun.person	of IN 0	P450 JJ B-noun.artifact	2D6 NN I-noun.artifact	. . 0	. . 0
DDI-DrugBank.d237.s17	certain JJ B-adj.all	antipsychotic_medications NNS B-noun.attribute	( ( 0	such JJ 0	as IN 0	sertindole NN B-noun.event	) ) 0	, , 0	. . 0
DDI-DrugBank.d236.s21	Methenamine NN B-noun.person	therapy NN B-noun.person	, , 0	Urinary NNP B-noun.location	excretion NN B-noun.act	of IN 0	amphetamines NNS B-noun.animal	is VBZ 0	increased VBN B-verb.change	, , 0	and CC 0	efficacy NN B-noun.person	is VBZ 0	reduced VBN B-verb.change	, , 0	by IN 0	acidifying_agents NNS B-noun.person	used VBN B-verb.consumption	in IN 0	methenamine NN 0	therapy NN 0	. . 0	. . 0
DDI-DrugBank.d158.s11	Antihypertensives NNPS B-noun.person	, , 0	Amphetamines NNPS B-noun.person	may MD 0	antagonize VB B-verb.cognition	the DT 0	hypotensive JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	antihypertensives NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d210.s28	Adequate JJ B-adj.all	monitoring NN B-noun.person	of IN 0	theophylline JJ 0	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	should MD 0	be VB 0	considered VBN B-verb.cognition	when WRB 0	therapy NN 0	with IN 0	VIOXX NNP B-noun.group	is VBZ 0	initiated VBN B-verb.possession	or CC 0	changed VBN B-verb.change	in IN 0	patients NNS B-noun.person	receiving VBG B-verb.communication	theophylline PRP 0	. . 0	. . 0
DDI-DrugBank.d456.s6	Other JJ 0	CYP3A4 JJ B-adj.all	inducers NNS B-noun.person	include VBP B-verb.change	, , 0	but CC 0	are VBP 0	not RB B-adv.all	limited VBN B-verb.change	to TO 0	, , 0	rifabutin NN B-noun.person	, , 0	rifapentine NN B-noun.person	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	phenobarbital JJ B-adj.all	and CC 0	St. NNP B-noun.group	Johns NNP I-noun.group	Wort NNP I-noun.group	. . 0	. . 0
DDI-DrugBank.d103.s2	Concomitant JJ B-adj.all	administration NN B-noun.time	of IN 0	other JJ B-adj.all	sympathomimetic_agents NNS B-noun.location	may MD 0	potentiate VB B-verb.communication	the DT 0	undesirable JJ B-adj.all	effects NNS B-noun.phenomenon	of IN 0	FORADIL NNP B-noun.group	. . 0	. . 0
DDI-DrugBank.d480.s15	Phenytoin NN B-noun.person	, , 0	nicotine NN B-noun.person	, , 0	and CC 0	rifampin NN B-noun.person	may MD 0	decrease VB B-verb.change	Clozapine JJ B-adj.all	plasma NN B-noun.substance	levels NNS B-noun.state	, , 0	resulting VBG B-verb.stative	in IN 0	a DT 0	decrease NN B-noun.event	in IN 0	effectiveness NN 0	of IN 0	a DT 0	previously RB B-adv.all	effective JJ B-adj.all	Clozapine NNP B-noun.other	dose NN B-noun.event	. . 0	. . 0
DDI-MedLine.d135.s3	In IN 0	the DT 0	present JJ B-adj.all	study NN B-noun.artifact	, , 0	the DT 0	atypical_antipsychotic JJ B-adj.all	clozapine NN B-noun.phenomenon	was VBD 0	tested VBN B-verb.social	in IN 0	combination NN 0	with IN 0	an DT 0	active JJ B-adj.all	dose NN B-noun.act	of IN 0	PCP NNP B-noun.group	in IN 0	two CD 0	- : 0	lever NN B-noun.person	drug NN B-noun.person	discrimination NN B-noun.person	and CC 0	mixed JJ B-adj.all	signalled VBN B-verb.social	- : 0	unsignalled JJ B-adj.all	differential JJ B-adj.all	- : 0	reinforcement NN B-noun.person	- : 0	of IN 0	- : 0	low JJ B-adj.all	- : 0	rates NNS B-noun.time	( ( 0	DRL NNP 0	) ) 0	procedures NNS B-noun.quantity	. . 0	. . 0
DDI-DrugBank.d179.s6	- : 0	Carbamazepine NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Tegretol NNP B-noun.location	) ) 0	or CC 0	. . 0
DDI-DrugBank.d223.s12	Concomitant JJ B-adj.all	use NN 0	of IN 0	tricyclic_antidepressants NNS B-noun.plant	with IN 0	drugs NNS B-noun.artifact	that WDT 0	can MD 0	inhibit VB B-verb.possession	cytochrome JJ B-noun.person	P450 NN I-noun.person	2D6 WDT 0	may MD 0	require VB B-verb.stative	lower JJR B-adj.all	doses NNS B-noun.person	than IN 0	usually RB B-adv.all	prescribed VBN B-verb.communication	for IN 0	either CC 0	the DT 0	tricyclic_antidepressant JJ B-adj.all	or CC 0	the DT 0	other JJ B-adj.all	drug NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d521.s8	- : 0	a DT 0	phenothiazine NN 0	such JJ 0	as IN 0	chlorpromazine NN 0	( ( 0	Thorazine NNP 0	) ) 0	, , 0	fluphenazine NN B-noun.person	( ( 0	Prolixin NNP B-noun.person	, , 0	Permitil NNP B-noun.person	) ) 0	, , 0	prochlorperazine NN B-noun.person	( ( 0	Compazine NNP B-noun.person	) ) 0	, , 0	promethazine NN B-noun.person	( ( 0	Phenergan NNP B-noun.person	) ) 0	, , 0	and CC 0	others NNS 0	, , 0	. . 0
DDI-DrugBank.d64.s90	Drugs NNS B-noun.artifact	that WDT 0	reduce VBP B-verb.change	the DT 0	number NN B-noun.quantity	of IN 0	blood NN B-noun.act	platelets NNS B-noun.artifact	by IN 0	causing VBG B-verb.creation	bone NN 0	marrow NN 0	depression NN B-noun.act	( ( 0	such JJ 0	as IN 0	antineoplastic_agents NNS B-noun.location	) ) 0	or CC 0	drugs NNS B-noun.artifact	which WDT 0	inhibit VBP B-verb.stative	platelet NN I-verb.stative	function NN B-noun.act	( ( 0	eg UH 0	, , 0	aspirin NN B-noun.person	and CC 0	other JJ 0	non NN B-noun.person	- : 0	steroidal_anti SYM 0	- : 0	inflammatory_drugs NNS B-noun.time	, , 0	dipyridamole NN B-noun.person	, , 0	hydrochloroquine NN B-noun.person	, , 0	clofibrate NN B-noun.person	, , 0	dextran NN B-noun.process	) ) 0	may MD 0	increase VB B-verb.change	the DT 0	bleeding NN B-noun.act	tendency NN B-noun.attribute	produced VBN B-verb.creation	by IN 0	anticoagulants NNS B-noun.person	without IN 0	altering VBG B-verb.change	prothrombin NN B-noun.person	time NN B-noun.person	determinations NNS I-noun.person	. . 0	. . 0
DDI-DrugBank.d507.s1	The DT 0	administration NN B-noun.time	of IN 0	guanfacine NN 0	concomitantly RB B-adv.all	with IN 0	known VBN B-verb.cognition	microsomal JJ B-adj.all	enzyme NN B-noun.person	inducer NN B-noun.person	( ( 0	phenobarbital JJ B-adv.all	or CC 0	phenytoin NN B-noun.substance	) ) 0	to TO 0	two CD 0	patients NNS B-noun.person	with IN 0	renal JJ B-adj.all	impairment NN B-noun.person	reportedly RB B-adv.all	resulted VBD B-verb.stative	in IN 0	significant JJ B-adj.all	reductions NNS B-noun.group	in IN 0	elimination NN B-noun.artifact	half NN B-noun.person	- : 0	life NN B-noun.person	and CC 0	plasma NN B-noun.substance	concentration NN B-noun.event	. . 0	. . 0
DDI-DrugBank.d196.s36	PEGASYS NNP B-noun.group	contains VBZ B-verb.stative	benzyl_alcohol NN 0	. . 0	. . 0
DDI-DrugBank.d123.s12	Omeprazole NNP B-noun.person	, , 0	The DT 0	rate NN B-noun.time	and CC 0	extent NN B-noun.act	of IN 0	absorption NN B-noun.process	of IN 0	ciprofloxacin NN B-noun.person	was VBD B-verb.stative	bioequivalent NN B-noun.person	when WRB 0	Proquin_XR NN B-noun.person	was VBD 0	given VBN B-verb.possession	alone RB B-adv.all	or CC 0	when WRB 0	Proquin_XR NN B-noun.person	was VBD 0	given VBN B-verb.possession	2 CD B-adj.all	hours NNS B-noun.person	after IN 0	omeprazole NN B-noun.person	at IN 0	the DT 0	dose NN B-noun.communication	that WDT 0	maximally RB B-adv.all	suppresses VBZ B-verb.possession	gastric JJ B-adj.pert	acid NN B-noun.act	secretion NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d529.s6	Concurrent JJ B-adj.all	use NN 0	of IN 0	flurbiprofen NN B-noun.person	and CC 0	aspirin NN B-noun.person	is VBZ B-verb.stative	therefore RB 0	not RB B-adv.all	recommended VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d483.s1	If IN 0	CEFOTAN NNP B-noun.group	and CC 0	an DT 0	aminoglycoside NN B-noun.artifact	are VBP 0	used VBN B-verb.consumption	concomitantly RB B-adv.all	, , 0	renal JJ B-adj.all	function NN B-noun.act	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.perception	, , 0	because IN 0	nephrotoxicity NN B-noun.act	may MD 0	be VB 0	potentiated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d485.s17	Benzodiazepines NNS B-noun.person	, , 0	Combination NNP B-noun.group	hormonal_contraceptives NNPS I-noun.group	may MD 0	decrease VB B-verb.cognition	the DT 0	clearance NN B-noun.act	of IN 0	some DT 0	benzodiazepines NNS 0	( ( 0	alprazolam NN B-noun.person	, , 0	chlordiazepoxide NN 0	, , 0	diazepam NN B-noun.person	) ) 0	and CC 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	others NNS 0	( ( 0	lorazepam NN B-noun.person	, , 0	oxazepam NN B-noun.person	, , 0	temazepam NN B-noun.artifact	) ) 0	. . 0	. . 0
DDI-MedLine.d90.s3	Atracurium NNP B-noun.person	was VBD B-verb.stative	again RB B-adv.all	given VBN B-verb.possession	by IN 0	infusion NN 0	to TO 0	maintain VB B-verb.consumption	40 CD B-adj.all	% NN 0	twitch NN B-noun.act	for IN 0	a DT 0	second JJ B-adj.all	hour NN B-noun.communication	, , 0	then RB B-adv.all	2 CD B-adj.all	mg NN B-noun.quantity	gentamycin NN 0	/ '' 0	kg IN 0	bwt PRP 0	were VBD 0	given VBN B-verb.possession	i.v NNP 0	. . 0	. . 0
DDI-MedLine.d16.s4	The DT 0	reduction NN B-noun.act	in IN 0	MAC NNP B-noun.other	was VBD 0	correlated VBN B-verb.creation	with IN 0	brain NN B-noun.food	levels NNS B-noun.attribute	of IN 0	ketamine NN B-noun.state	or CC 0	metabolite VB B-verb.cognition	I PRP 0	, , 0	suggesting VBG B-verb.communication	a DT 0	ketamine NN B-noun.person	, , 0	metabolite VBP B-verb.cognition	I PRP 0	potency VBP B-verb.communication	ration NN B-noun.time	of IN 0	3,1 CD 0	. . 0	. . 0
DDI-DrugBank.d382.s20	therefore RB B-adv.all	, , 0	the DT 0	efficacy NN B-noun.phenomenon	of IN 0	oral JJ B-adj.all	contraceptives NNS B-noun.artifact	during IN 0	administration NN B-noun.time	of IN 0	Aprepitant NNP B-noun.person	may MD 0	be VB 0	reduced VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d565.s15	Patients NNS B-noun.person	currently RB B-adv.all	receiving VBG B-verb.perception	diltiazem NN I-verb.perception	therapy NN 0	should MD 0	be VB 0	carefully RB B-adv.all	monitored VBN B-verb.contact	for IN 0	a DT 0	change NN B-noun.act	in IN 0	pharmacological JJ B-adj.all	effect NN B-noun.cognition	when WRB 0	initiating VBG B-verb.communication	and CC 0	discontinuing VBG B-verb.motion	therapy NN 0	with IN 0	cimetidine NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d179.s35	- : 0	Ethotoin NN B-noun.person	( ( 0	e.g. UH 0	, , 0	Peganone NNP 0	) ) 0	or CC 0	. . 0
DDI-DrugBank.d487.s6	Aspirin NNP B-noun.person	should MD 0	be VB 0	used VBN B-verb.consumption	cautiously RB B-adv.all	in IN 0	conjunction NN 0	with IN 0	cortico NN B-noun.person	- : 0	steroids NNS B-noun.communication	in IN 0	patients NNS B-noun.person	suffering VBG B-verb.body	from IN 0	hypopro NN B-noun.person	- : 0	thrombinemia NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d569.s1	In IN 0	clinical JJ B-adj.all	trials NNS B-noun.cognition	in IN 0	patients NNS B-noun.person	undergoing VBG B-verb.social	PTCA NNP B-noun.group	/ POS 0	PCI NNP B-noun.group	, , 0	co SYM 0	- : 0	administration NN B-noun.time	of IN 0	Angiomax NNP B-noun.person	with IN 0	heparin NN B-noun.person	, , 0	warfarin NN B-noun.location	, , 0	thrombolytics NNS B-noun.person	or CC 0	glycoprotein NN B-noun.person	IIb NNP I-noun.person	/ NNP I-noun.person	IIIa NNP I-noun.person	inhibitors NNS B-noun.person	was VBD 0	associated VBN B-verb.cognition	with IN 0	increased VBN B-verb.change	risks NNS 0	of IN 0	major JJ B-adj.all	bleeding JJ B-adj.all	events NNS B-noun.plant	compared VBN B-verb.change	to TO 0	patients NNS B-noun.person	not RB 0	receiving VBG B-verb.communication	these DT 0	concomitant JJ B-adj.all	medications NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d531.s5	Drugs NNS B-noun.artifact	which WDT 0	induce VBP B-verb.cognition	CYP3A4 JJ B-noun.phenomenon	activity NN B-noun.process	( ( 0	eg UH 0	, , 0	phenobarbital JJ B-adj.all	, , 0	rifampin NN B-noun.person	, , 0	rifabutin NN 0	) ) 0	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	efavirenz NN 0	resulting VBG B-verb.stative	in IN 0	lowered VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d411.s4	Thyroid NNP B-noun.person	Physiology NNP I-noun.person	, , 0	The DT 0	following VBG 0	agents NNS B-noun.person	may MD 0	alter VB B-verb.change	thyroid JJ B-noun.body	hormone NN I-noun.body	or CC 0	TSH NNP B-noun.group	levels NNS B-noun.artifact	, , 0	generally RB B-adv.all	by IN 0	effects NNS B-noun.phenomenon	on IN 0	thyroid JJ B-noun.body	hormone NN I-noun.body	synthesis NN B-noun.event	, , 0	secretion NN B-noun.act	, , 0	distribution NN B-noun.act	, , 0	metabolism NN B-noun.artifact	, , 0	hormone NN 0	action NN B-noun.process	, , 0	or CC 0	elimination NN B-noun.act	, , 0	or CC 0	altered JJ B-verb.change	TSH NNP 0	secretion NN 0	, , 0	aminoglutethimide IN 0	, , 0	p SYM 0	- : 0	aminosalicylic_acid JJ 0	, , 0	amiodarone NN 0	, , 0	androgens NNS B-noun.person	and CC 0	related VBN B-verb.creation	anabolic JJ B-adj.all	hormones NNS B-noun.animal	, , 0	complex JJ B-adj.all	anions NNS B-noun.animal	( ( 0	thiocyanate JJ 0	, , 0	perchlorate NN B-noun.person	, , 0	pertechnetate VBP B-verb.social	) ) 0	, , 0	antithyroid_drugs NNS B-noun.object	, , 0	b SYM 0	- : 0	adrenergic_blocking_agents NNS B-noun.person	, , 0	carbamazepine NN 0	, , 0	chloral_hydrate NNP B-noun.person	, , 0	diazepam NN B-noun.person	, , 0	dopamine NN B-noun.person	and CC 0	dopamine_agonists NNS B-noun.person	, , 0	ethionamide NN 0	, , 0	glucocorticoids NNS B-noun.person	, , 0	heparin NN B-noun.person	, , 0	hepatic JJ B-adj.all	enzyme NN B-noun.person	inducers NNS I-noun.person	, , 0	insulin NN B-noun.person	, , 0	iodinated VBD B-verb.change	cholestographic JJ B-adj.all	agents NNS B-noun.person	, , 0	iodine NN B-noun.person	- : 0	containing_compounds NNS B-noun.other	, , 0	levodopa NN B-noun.person	, , 0	lovastatin NN B-noun.person	, , 0	lithium NN B-noun.person	, , 0	6-mercaptopurine JJ 0	, , 0	metoclopramide NN B-noun.attribute	, , 0	mitotane NN B-noun.person	, , 0	nitroprusside NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	phenytoin NN B-noun.person	, , 0	resorcinol NN B-noun.person	, , 0	rifampin NN B-noun.person	, , 0	somatostatin NN 0	analogs NNS B-noun.animal	, , 0	sulfonamides VBZ B-verb.motion	, , 0	sulfonylureas NNS B-noun.location	, , 0	thiazide JJ 0	diuretics NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d417.s0	Netilmicin NNP B-noun.group	should MD 0	not RB 0	be VB 0	administered VBN B-verb.possession	concomitantly RB B-adv.all	with IN 0	potent JJ B-adj.all	loop_diuretics NNS B-noun.group	such JJ 0	as IN 0	furosemide NN B-noun.artifact	and CC 0	ethacrynic_acid JJ 0	as IN 0	the DT 0	potential NN B-noun.person	for IN 0	ototoxicity NN 0	is VBZ 0	enhanced VBN B-verb.change	by IN 0	the DT 0	combination NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d82.s9	When WRB 0	INDOCIN NNP 0	is VBZ 0	given VBN B-verb.possession	to TO 0	patients NNS B-noun.person	receiving VBG B-verb.communication	probenecid NN B-noun.person	, , 0	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	indomethacin NN B-noun.animal	are VBP B-verb.stative	likely JJ B-adj.all	to TO 0	be VB 0	increased VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d5.s14	In IN 0	a DT 0	study NN B-noun.artifact	of IN 0	15 CD B-adj.all	male JJ B-adj.all	subjects NNS B-noun.person	( ( 0	ages VBZ B-verb.stative	19 CD 0	to TO 0	35 CD 0	years NNS B-noun.time	) ) 0	who WP 0	were VBD B-verb.stative	extensive JJ B-adj.all	metabolizers NNS B-noun.person	of IN 0	the DT 0	CYP2D6 JJ B-adj.all	isoenzyme NN I-adj.all	, , 0	daily JJ B-adj.pert	doses NNS B-noun.event	of IN 0	bupropion NN B-noun.act	given VBN B-verb.possession	as IN 0	150 CD 0	mg NN B-noun.quantity	twice RB 0	daily RB 0	followed VBN B-verb.stative	by IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.event	of IN 0	50 CD B-adj.all	mg IN 0	desipramine NN B-noun.person	increased VBD B-verb.change	the DT 0	Cmax NNP B-noun.person	, , 0	AUC NNP 0	, , 0	and CC 0	t1/2 NNP B-noun.person	of IN 0	desipramine NN B-noun.phenomenon	by IN 0	an DT 0	average NN B-noun.act	of IN 0	approximately RB B-adj.all	2- JJ 0	, , 0	5- : 0	and CC 0	2-fold JJ B-noun.artifact	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d3.s7	Although IN 0	these DT 0	results NNS B-noun.event	do VBP 0	not RB B-adv.all	indicate VB B-verb.communication	a DT 0	significant JJ B-adj.all	interaction NN B-noun.relation	between IN 0	TORADOL NNP B-noun.person	and CC 0	warfarin NN B-noun.act	or CC 0	heparin NN B-noun.substance	, , 0	the DT 0	administration NN B-noun.time	of IN 0	TORADOL NNP B-noun.person	to TO 0	patients NNS B-noun.person	taking VBG B-verb.social	anticoagulants NNS B-noun.attribute	should MD 0	be VB 0	done VBN B-verb.social	extremely RB B-adv.all	cautiously RB B-adv.all	, , 0	and CC 0	patients NNS B-noun.person	should MD 0	be VB B-verb.stative	closely RB B-adj.all	monitored VBN I-adj.all	. . 0	. . 0
DDI-DrugBank.d526.s19	Anabolic_steroids NNS B-noun.animal	( ( 0	particularly RB B-adv.all	C-17 NN 0	alkylated VBD B-verb.stative	androgens NNS 0	such JJ 0	as IN 0	oxymetholone NN 0	, , 0	methandrostenolone NN B-noun.person	, , 0	norethandrolone NN B-noun.person	, , 0	and CC 0	similar JJ B-adj.all	compounds NNS B-noun.relation	) ) 0	enhanced VBD B-verb.change	tendency NN B-noun.attribute	toward IN 0	edema NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d567.s14	However RB 0	, , 0	another DT 0	HMG NNP B-noun.group	- : 0	CoA_reductase_inhibitor NN B-noun.person	has VBZ 0	been VBN 0	found VBN B-verb.cognition	to TO 0	produce VB B-verb.creation	a DT 0	less JJR B-noun.quantity	than IN 0	two CD 0	- : 0	second JJ B-adj.all	increase NN B-noun.event	in IN 0	prothrombin NN B-adj.all	time NN B-noun.time	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	receiving VBG B-verb.communication	low JJ B-adj.all	doses NNS B-noun.event	of IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d277.s20	Ethanol NN B-noun.person	or CC 0	Triazolam NNP B-noun.person	, , 0	No DT 0	significant JJ B-adj.all	differences NNS B-noun.state	were VBD 0	observed VBN B-verb.perception	in IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	triazolam NN B-noun.cognition	( ( 0	0.125 CD 0	mg NN B-noun.quantity	) ) 0	and CC 0	tiagabine NN 0	( ( 0	10 CD B-adj.all	mg NN B-noun.quantity	) ) 0	when WRB 0	given VBN B-verb.possession	together RP 0	as IN 0	a DT 0	single JJ B-adj.all	dose NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d12.s7	For IN 0	these DT 0	reasons NNS B-noun.motive	, , 0	it PRP 0	is VBZ 0	felt VBN B-verb.cognition	that IN 0	, , 0	in IN 0	most JJS 0	subjects NNS B-noun.person	who WP 0	have VBP 0	had VBN 0	an DT 0	unsatisfactory JJ B-adj.all	lipid NN B-noun.body	response NN B-noun.communication	to TO 0	either DT 0	drug NN B-noun.state	alone RB 0	, , 0	the DT 0	possible JJ B-adj.all	benefits NNS B-noun.person	of IN 0	combined VBN B-verb.change	therapy NN 0	with IN 0	lovastatin NN B-noun.feeling	and CC 0	a DT 0	fibrate NN B-noun.person	do VBP 0	not RB 0	outweigh VB B-verb.communication	the DT 0	risks NNS B-noun.object	of IN 0	severe JJ B-adj.all	myopathy NN B-noun.person	, , 0	rhabdomyolysis NN B-noun.person	, , 0	and CC 0	acute VB B-verb.change	renal JJ B-adj.all	failure NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d531.s31	Alternatives NNS B-noun.person	to TO 0	clarithromycin VB B-verb.cognition	, , 0	such JJ 0	as IN 0	azithromycin NN B-noun.person	, , 0	should MD 0	be VB 0	considered VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d74.s0	FLUOTHANE NNP 0	augments VBZ B-verb.communication	the DT 0	action NN B-noun.process	of IN 0	non NN B-noun.person	- : 0	depolarising_muscle_relaxants NNS B-noun.person	and CC 0	the DT 0	muscle NN B-noun.body	relaxant JJ B-adj.pert	effects NNS B-noun.phenomenon	of IN 0	aminoglycosides NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d210.s33	In IN 0	post NN B-noun.act	- : 0	marketing NN B-verb.communication	experience NN B-noun.cognition	, , 0	bleeding VBG B-verb.body	events NNS B-noun.plant	have VBP 0	been VBN 0	reported VBN B-verb.communication	, , 0	predominantly RB B-adv.all	in IN 0	the DT 0	elderly JJ B-adj.all	, , 0	in IN 0	association NN 0	with IN 0	increases NNS B-noun.food	in IN 0	prothrombin NN B-adj.all	time NN B-noun.time	in IN 0	patients NNS B-noun.artifact	receiving VBG B-verb.change	VIOXX NNP B-noun.group	concurrently RB B-adv.all	with IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d267.s1	The DT 0	use NN 0	of IN 0	NUROMAX NNP B-noun.group	before IN 0	succinylcholine NN 0	to TO 0	attenuate VB B-verb.social	some DT 0	of IN 0	the DT 0	side NN B-noun.location	effects NNS B-noun.phenomenon	of IN 0	succinylcholine NN B-noun.person	has VBZ 0	not RB 0	been VBN 0	studied VBN B-verb.cognition	. . 0	. . 0
DDI-DrugBank.d509.s7	Agents NNS B-noun.person	that WDT 0	induce VBP B-verb.cognition	CYP3A4 NNP B-noun.person	( ( 0	eg UH 0	, , 0	carbamazepine NN 0	) ) 0	could MD 0	cause VB B-verb.communication	an DT 0	increase NN B-noun.act	in IN 0	aripiprazole JJ B-adj.all	clearance NN B-noun.person	and CC 0	lower JJR B-adj.all	blood NN B-noun.body	levels NNS I-noun.body	. . 0	. . 0
DDI-DrugBank.d500.s4	Barbiturates NNP B-noun.person	, , 0	carbamazepine NN 0	, , 0	and CC 0	phenytoin NN B-noun.person	decrease VB B-verb.communication	the DT 0	half NN B-noun.person	- : 0	life NN B-noun.time	of IN 0	doxycycline NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d301.s14	Other JJ 0	binding JJ B-verb.social	proteins NNS B-noun.person	may MD 0	be VB 0	elevated VBN B-verb.social	in IN 0	serum NN B-noun.body	, , 0	i.e. FW 0	, , 0	corticosteroid JJ B-adj.all	binding JJ B-adj.pert	globulin NN B-noun.substance	( ( 0	CBG NNP 0	) ) 0	, , 0	sex NN B-noun.person	hormone NN B-noun.person	- : 0	binding JJ B-verb.contact	globulin NN B-noun.substance	( ( 0	SHBG NNP 0	) ) 0	, , 0	leading VBG B-verb.motion	to TO 0	increased VBN B-verb.change	total JJ B-adj.all	circulating VBG B-verb.communication	corticosteroids NNS B-noun.person	and CC 0	sex_steroids NNS B-noun.body	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d567.s15	Also RB B-adv.all	, , 0	bleeding VBG B-verb.body	and/or CC 0	increased VBD B-verb.change	prothrombin NN B-noun.person	time NN B-noun.group	have VBP 0	been VBN 0	reported VBN B-verb.communication	in IN 0	a DT B-adj.all	few JJ I-adj.all	patients NNS B-noun.person	taking VBG B-verb.social	coumarin_anticoagulants NNS B-noun.person	concomitantly RB B-adv.all	with IN 0	lovastatin NN B-noun.feeling	. . 0	. . 0
DDI-DrugBank.d151.s0	Folic_acid JJ B-adj.all	in IN 0	large JJ B-adj.all	amounts NNS B-noun.quantity	may MD 0	counteract VB B-verb.change	the DT 0	antiepileptic JJ B-adj.all	effect NN B-noun.cognition	of IN 0	phenobarbital NN B-noun.artifact	, , 0	phenytoin NN B-noun.person	and CC 0	primidone NN B-noun.person	, , 0	and CC 0	increase VB B-verb.change	the DT 0	frequency NN B-noun.person	of IN 0	seizures NNS B-noun.body	in IN 0	susceptible JJ B-adj.all	pediatric JJ B-noun.person	patients NNS B-noun.person	. . 0	. . 0
DDI-MedLine.d126.s0	Cypermethrin NNP B-noun.person	- : 0	induced VBN B-verb.creation	oxidative JJ B-adj.all	stress NN B-noun.state	in IN 0	rat NN 0	brain NN B-noun.person	and CC 0	liver NN B-noun.person	is VBZ 0	prevented VBN B-verb.creation	by IN 0	vitamin_E CD 0	or CC 0	allopurinol NN B-noun.possession	. . 0	_ PRP 0	. . 0
DDI-DrugBank.d543.s1	MAO_inhibitors NNS B-noun.person	, , 0	narcotic_analgesics NNS B-noun.person	( ( 0	e.g. UH 0	, , 0	meperidine NN B-noun.location	) ) 0	, , 0	nitrates NNS B-noun.person	and CC 0	nitrites NNS B-noun.person	, , 0	sympathomimetic_agents NNS B-noun.person	, , 0	tricyclic_antidepressants NNS B-noun.person	, , 0	and CC 0	other JJ B-adj.all	drugs NNS B-noun.artifact	having VBG B-verb.change	anticholinergic JJ B-adj.pert	activity NN B-noun.state	. . 0	. . 0
DDI-DrugBank.d132.s20	Nonsteroidal_Anti SYM 0	- : 0	Inflammatory_Drugs NNS B-noun.time	, , 0	The DT 0	administration NN B-noun.time	of IN 0	diflunisal NN B-noun.person	to TO 0	normal JJ B-adj.all	volunteers NNS B-noun.person	receiving VBG B-verb.communication	indomethacin NN B-noun.person	decreased VBD B-verb.change	the DT 0	renal JJ B-adj.all	clearance NN B-noun.act	and CC 0	significantly RB B-adv.all	increased VBD B-verb.change	the DT 0	plasma NN B-noun.plant	levels NNS B-noun.state	of IN 0	indomethacin NN B-noun.act	. . 0	. . 0
DDI-MedLine.d137.s10	CONCLUSIONS NNS B-noun.artifact	/ IN 0	INTERPRETATION NNP B-noun.group	, , 0	Glucose NNP B-noun.person	and CC 0	insulin NN B-noun.person	can MD 0	exert VB B-verb.body	additive JJ B-noun.person	vasodilator NN I-noun.person	properties NNS B-noun.person	on IN 0	renal JJ B-adj.all	and CC 0	ocular JJ B-adj.all	circulation NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d501.s6	However RB 0	, , 0	appropriate JJ B-adj.all	monitoring NN B-noun.person	of IN 0	blood NN B-noun.act	glucose NN B-noun.attribute	should MD 0	be VB 0	performed VBN B-verb.social	when WRB 0	initiating VBG B-verb.communication	EXTRANEAL NNP B-noun.person	in IN 0	diabetic JJ B-adj.all	patients NNS B-noun.person	and CC 0	insulin NN B-noun.artifact	dosage NN B-noun.artifact	should MD 0	be VB 0	adjusted VBN B-verb.change	if IN 0	needed VBN B-verb.consumption	. . 0	. . 0
DDI-DrugBank.d286.s2	Coadministration NN B-noun.person	of IN 0	ethoxzolamide NN 0	with IN 0	other JJ 0	diuretics NNS B-noun.person	, , 0	amphotericin_B JJ 0	, , 0	and CC 0	corticosteroids NNS B-noun.object	may MD 0	cause VB B-verb.emotion	hypokalemia NN I-verb.emotion	. . 0	. . 0
DDI-DrugBank.d458.s10	Ketoconazole NNP B-noun.person	tablets NNS I-noun.person	may MD 0	alter VB B-verb.change	the DT 0	metabolism NN B-noun.attribute	of IN 0	cyclosporine NN B-noun.person	, , 0	tacrolimus NN B-noun.person	, , 0	and CC 0	methylprednisolone NN B-noun.attribute	, , 0	resulting VBG B-verb.stative	in IN 0	elevated JJ B-adj.all	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	the DT 0	latter JJ B-adj.all	drugs NNS B-noun.artifact	. . 0	. . 0
DDI-DrugBank.d210.s0	ACE_inhibitors NNS B-noun.person	, , 0	Reports NNS B-noun.person	suggest VBP B-verb.communication	that IN 0	NSAIDs NNP B-noun.person	may MD 0	diminish VB B-verb.change	the DT 0	antihypertensive JJ B-adj.all	effect NN B-noun.cognition	of IN 0	Angiotensin_Converting_Enzyme_(ACE)_inhibitors NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d297.s3	Concurrent JJ B-adj.all	administration NN B-noun.time	of IN 0	a DT 0	TNF_antagonist NN B-noun.person	with IN 0	ORENCIA NNP B-noun.group	has VBZ 0	been VBN 0	associated VBN B-verb.cognition	with IN 0	an DT 0	increased VBN B-verb.change	risk NN 0	of IN 0	serious JJ B-adj.all	infections NNS B-noun.motive	and CC 0	no DT 0	significant JJ B-adj.all	additional JJ B-adj.all	efficacy NN B-noun.phenomenon	over IN 0	use NN 0	of IN 0	the DT 0	TNF_antagonists NNS B-noun.person	alone RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d187.s14	Plasma NNP B-noun.person	valproate NN I-noun.person	concentration NN B-noun.person	should MD 0	be VB 0	monitored VBN B-verb.perception	when WRB 0	isoniazid NN B-noun.person	and CC 0	valproate NN B-noun.attribute	are VBP B-verb.stative	co RB 0	administered VBN B-verb.possession	, , 0	and CC 0	appropriate JJ B-adj.all	dosage NN B-noun.possession	adjustments NNS B-noun.act	of IN 0	valproate NN B-noun.attribute	should MD 0	be VB 0	made VBN B-verb.social	. . 0	. . 0
DDI-DrugBank.d568.s19	The DT 0	effect NN B-noun.cognition	of IN 0	theophylline NN 0	on IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	citalopram NN B-noun.location	was VBD B-verb.stative	not RB B-adv.all	evaluated VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d565.s10	If IN 0	combination NN 0	therapy NN 0	is VBZ 0	initiated VBN B-verb.possession	or CC 0	withdrawn VBN B-verb.contact	in IN 0	conjunction NN 0	with IN 0	propranolol NN B-noun.person	, , 0	an DT 0	adjustment NN B-noun.communication	in IN 0	the DT 0	propranolol NN B-noun.artifact	dose NN I-noun.artifact	may MD 0	be VB 0	warranted VBN B-verb.communication	. . 0	. . 0
DDI-DrugBank.d124.s22	HMG SYM 0	- : 0	CoA_Reductase_Inhibitors NNS B-noun.person	, , 0	lovastatin NN B-noun.person	, , 0	simvastatin JJ B-adj.all	WARNING NNP B-noun.location	potential NN I-noun.location	for IN 0	serious JJ B-adj.all	reactions NNS B-noun.state	such JJ 0	as IN 0	risk NN 0	of IN 0	myopathy JJ B-adj.all	including VBG B-verb.change	rhabdomyolysis NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d328.s28	Concomitant JJ B-adj.all	single JJ B-adj.all	dose NN B-noun.event	administration NN B-noun.time	of IN 0	valdecoxib NN B-noun.communication	20 CD B-adj.all	mg NN B-noun.quantity	with IN 0	multiple JJ B-adj.all	doses NNS B-noun.event	of IN 0	ketoconazole NN B-noun.shape	and CC 0	fluconazole NN B-noun.person	produced VBD B-verb.creation	a DT 0	significant JJ B-adj.all	increase NN B-noun.event	in IN 0	exposure NN B-noun.cognition	of IN 0	valdecoxib NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d289.s25	Simvastatin NNP B-noun.person	and CC 0	Other NNP B-noun.location	Statins NNP I-noun.location	, , 0	Co SYM 0	- : 0	administration NN B-noun.time	of IN 0	bosentan NN B-noun.substance	decreased VBD B-verb.change	the DT 0	plasma NN B-noun.plant	concentrations NNS B-noun.attribute	of IN 0	simvastatin NN B-noun.attribute	( ( 0	a DT 0	CYP3A4 JJ B-adj.all	substrate NN I-adj.all	) ) 0	, , 0	and CC 0	its PRP$ 0	active JJ B-adj.all	_ : 0	-hydroxy JJ B-adj.all	acid NN I-adj.all	metabolite NN B-noun.attribute	, , 0	by IN 0	approximately RB B-adv.all	50 CD B-adj.all	% NN 0	. . 0	. . 0
DDI-DrugBank.d542.s0	Interactions NNS B-noun.person	for IN 0	Vitamin_B3 NNP B-noun.person	( ( I-noun.person	Niacin NNP I-noun.person	) ) 0	, , 0	Antihypertensive NNP B-noun.person	Therapy NNP I-noun.person	, , 0	Nicotinic_acid JJ 0	may MD 0	potentiate VB B-verb.communication	the DT 0	effects NNS B-noun.phenomenon	of IN 0	ganglionic_blocking_agents NNS B-noun.group	and CC 0	vasoactive JJ B-adj.all	drugs NNS B-noun.artifact	resulting VBG B-verb.stative	in IN 0	postural JJ B-adj.all	hypotension NN B-noun.act	. . 0	. . 0
DDI-DrugBank.d509.s0	Drug NN B-noun.person	- : 0	Drug NN B-noun.person	Interactions NNS I-noun.person	Given VBN B-verb.possession	the DT 0	primary JJ B-adj.all	CNS NNP 0	effects NNS B-noun.phenomenon	of IN 0	aripiprazole NN B-noun.shape	, , 0	caution NN B-noun.communication	should MD 0	be VB 0	used VBN B-verb.consumption	when WRB 0	ABILIFY NNP B-noun.group	is VBZ 0	taken VBN B-verb.possession	in IN 0	combination NN 0	with IN 0	other JJ B-adj.all	centrally_acting_drugs NNS B-noun.location	and CC 0	alcohol NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d275.s1	Toxicologic NNP B-noun.person	and CC 0	toxicokinetic JJ B-adj.all	studies NNS B-noun.group	in IN 0	rats NNS B-noun.animal	did VBD 0	not RB B-adv.all	demonstrate VB B-verb.cognition	any DT 0	alterations NNS B-noun.possession	in IN 0	the DT 0	clearance NN B-noun.act	or CC 0	toxicologic JJ B-adj.all	profile NN B-noun.attribute	of IN 0	either DT 0	methotrexate NN B-noun.location	or CC 0	Kineret NNP B-noun.location	when WRB 0	the DT 0	two CD 0	agents NNS B-noun.person	were VBD 0	administered VBN B-verb.perception	together RB B-adv.all	. . 0	. . 0
DDI-MedLine.d111.s2	Acetaminophen NNP B-noun.person	, , 0	lidocaine NN B-noun.person	, , 0	phenobarbital JJ B-adj.all	, , 0	quinidine NN B-noun.location	, , 0	theophylline PRP 0	, , 0	and CC 0	valproic_acid NNP B-noun.person	were VBD 0	added VBN B-verb.change	to TO 0	pooled VBN B-verb.possession	human JJ B-adj.all	serum NN B-noun.person	at IN 0	therapeutic JJ B-adj.all	concentrations NNS B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d316.s14	Anticonvulsants NNS B-noun.person	, , 0	In IN 0	a DT 0	pharmacokinetic JJ B-adj.all	study NN B-noun.artifact	, , 0	maximum JJ B-adj.all	plasma NN B-noun.phenomenon	concentrations NNS B-noun.attribute	of IN 0	felodipine NN B-noun.person	were VBD B-verb.stative	considerably RB B-adv.all	lower JJR B-adj.all	in IN 0	epileptic JJ B-adj.all	patients NNS B-noun.person	on IN 0	long JJ B-adj.all	- : 0	term NN B-noun.time	anticonvulsant JJ B-adj.all	therapy NN B-noun.cognition	( ( 0	eg UH 0	, , 0	phenytoin NN B-noun.person	, , 0	carbamazepine NN 0	, , 0	or CC 0	phenobarbital JJ B-noun.body	) ) 0	than IN 0	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	. . 0
DDI-DrugBank.d317.s13	Other JJ 0	binding JJ B-verb.social	proteins NNS B-noun.person	may MD 0	be VB 0	elevated VBN B-verb.social	in IN 0	serum NN B-noun.body	, , 0	( ( 0	i.e. FW B-adv.all	, , 0	corticosteroid JJ B-adj.all	binding JJ B-adj.pert	globulin NN B-noun.substance	( ( 0	CBG NNP 0	) ) 0	, , 0	sex NN 0	hormone NN 0	binding JJ B-verb.contact	globulin NN B-noun.substance	( ( 0	SHBG NNP 0	) ) 0	) ) 0	leading VBG B-verb.stative	to TO 0	increased VBN B-verb.change	total JJ B-adj.all	circulating VBG B-verb.communication	corticosteroids NNS B-noun.person	and CC 0	sex_steroids NNS B-noun.body	, , 0	respectively RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d284.s8	The DT 0	concurrent JJ B-adj.all	use NN 0	of IN 0	intravenously RB B-adv.all	or CC 0	orally RB B-adv.all	administered VBN B-verb.possession	methylxanthines NNS B-noun.attribute	( ( 0	e.g. UH 0	, , 0	aminophylline NN B-noun.person	, , 0	theophylline NN 0	) ) 0	by IN 0	patients NNS B-noun.person	receiving VBG B-verb.change	BROVANA NNP B-noun.group	has VBZ 0	not RB 0	been VBN 0	completely RB B-adv.all	evaluated VBN B-verb.change	. . 0	. . 0
DDI-DrugBank.d97.s12	Sedative JJ 0	/ JJ 0	hypnotics NNS B-noun.person	, , 0	midazolam NN B-noun.person	, , 0	triazolam NN B-noun.person	. . 0
DDI-DrugBank.d443.s0	Uricosuric_Agents NNS B-noun.artifact	, , 0	Aspirin NNP B-noun.person	may MD 0	decrease VB B-verb.cognition	the DT 0	effects NNS B-noun.phenomenon	of IN 0	probenecid NN B-noun.person	, , 0	sulfinpyrazone NN 0	, , 0	and CC 0	phenylbutazone NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d97.s3	Drugs NNS B-noun.artifact	that WDT 0	induce VBP B-verb.cognition	CYP3A4 JJ B-noun.phenomenon	activity NN B-noun.process	would MD 0	be VB 0	expected VBN B-verb.cognition	to TO 0	increase VB B-verb.change	the DT 0	clearance NN B-noun.act	of IN 0	indinavir NN B-noun.person	, , 0	resulting VBG B-verb.stative	in IN 0	lowered VBN B-verb.change	plasma NN B-noun.substance	concentrations NNS B-noun.attribute	of IN 0	indinavir NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d263.s0	Zidovudine NNP B-noun.person	, , 0	There EX 0	is VBZ B-verb.stative	no DT 0	significant JJ B-adj.all	pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	between IN 0	ZDV NNP B-noun.person	and CC 0	zalcitabine NN B-noun.act	which WDT 0	has VBZ 0	been VBN 0	confirmed VBN B-verb.cognition	clinically RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d3.s10	Therefore RB 0	, , 0	concomitant JJ B-adj.all	use NN 0	of IN 0	TORADOL NNP B-noun.person	and CC 0	probenecid NN B-noun.person	is VBZ 0	contraindicated VBN B-verb.communication	. . 0	. . 0
DDI-MedLine.d86.s0	Pharmacokinetic JJ B-adj.all	interaction NN B-noun.act	between IN 0	single JJ B-adj.all	oral JJ B-noun.body	doses NNS I-noun.body	of IN 0	diltiazem NN B-noun.food	and CC 0	sirolimus NN B-noun.act	in IN 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	. . 0	_ PRP 0	. . 0
DDI-MedLine.d124.s6	1 CD B-adj.all	hour NN B-noun.communication	after IN 0	starting VBG B-verb.change	the DT 0	oxycodone NN B-noun.artifact	or CC 0	levofloxacin NN B-noun.communication	500 CD 0	mg RB 0	p.o RB 0	. . 0	. . 0
DDI-DrugBank.d198.s38	Alcohol NNP B-noun.person	, , 0	Alcohol NNP B-noun.person	( ( 0	0.5 CD 0	g FW 0	/ FW 0	kg FW 0	body NN 0	weight NN B-noun.artifact	, , 0	approximately RB B-adv.all	40 CD B-adj.all	mL CD B-noun.quantity	of IN 0	absolute JJ B-adj.all	alcohol NN B-noun.person	in IN 0	a DT 0	70 CD 0	kg DT 0	person NN B-noun.person	) ) 0	and CC 0	vardenafil VBP B-verb.change	plasma NN B-noun.plant	levels NNS B-noun.state	were VBD B-verb.stative	not RB B-adv.all	altered VBN B-verb.change	when WRB 0	dosed VBN B-verb.communication	simultaneously RB B-adv.all	. . 0	. . 0
DDI-DrugBank.d462.s7	Methotrexate NNP B-noun.person	, , 0	Piperacillin_sodium NN 0	may MD 0	reduce VB B-verb.change	the DT 0	excretion NN B-noun.act	of IN 0	methotrexate NN B-noun.food	. . 0	. . 0
DDI-DrugBank.d219.s18	Thus RB 0	, , 0	when WRB 0	NSAIDs NNP B-noun.person	and CC 0	lithium NN B-noun.person	are VBP 0	administered VBN B-verb.possession	concurrently RB B-adv.all	, , 0	subjects NNS B-noun.person	should MD 0	be VB 0	observed VBN B-verb.perception	carefully RB B-adv.all	for IN 0	signs NNS B-noun.communication	of IN 0	lithium NN B-noun.phenomenon	toxicity NN B-noun.attribute	. . 0	. . 0
DDI-DrugBank.d165.s4	Another DT 0	oral JJ B-adj.all	azole_antifungal JJ B-noun.other	, , 0	ketoconazole NN B-noun.person	, , 0	inhibits VBZ B-verb.stative	the DT 0	metabolism NN B-noun.attribute	of IN 0	astemizole NN B-noun.location	, , 0	resulting VBG B-verb.stative	in IN 0	elevated JJ B-adj.all	plasma NN B-noun.person	concentrations NNS I-noun.person	of IN 0	astemizole NN B-noun.shape	and CC 0	its PRP$ 0	active JJ B-adj.all	metabolite NN B-noun.attribute	desmethylastermizole NN B-noun.communication	which WDT 0	may MD 0	prolong VB B-verb.stative	QT NNP 0	intervals NNS 0	. . 0	. . 0
DDI-MedLine.d116.s5	This DT 0	effect NN B-noun.cognition	may MD 0	be VB 0	mediated VBN B-verb.cognition	by IN 0	the DT 0	ability NN B-noun.cognition	of IN 0	rifampin NN 0	to TO 0	induce VB B-verb.cognition	microsomal JJ B-adj.all	enzymes NNS B-noun.act	and CC 0	, , 0	thus RB 0	, , 0	the DT 0	catabolism NN B-noun.artifact	of IN 0	warfarin NN B-noun.act	. . 0	. . 0
DDI-MedLine.d93.s4	Thirty NNP 0	male NN 0	rats NNS 0	of IN 0	the DT 0	Fischer-344 JJ B-adj.all	strain NN B-noun.person	were VBD 0	divided VBN B-verb.social	into IN 0	three CD 0	equal JJ B-adj.all	groups NNS B-noun.group	and CC 0	were VBD 0	given VBN B-verb.possession	injections NNS B-noun.quantity	of IN 0	trimethyl_lead JJ B-noun.phenomenon	( ( 0	TML NNP 0	) ) 0	( ( 0	8.0 CD 0	or CC 0	17.0 CD 0	mg FW B-noun.quantity	/ FW 0	kg FW 0	/ FW 0	ml FW 0	SC NNP 0	) ) 0	or CC 0	the DT 0	saline NN B-noun.artifact	vehicle NN B-noun.communication	. . 0	. . 0
DDI-DrugBank.d530.s1	Concomitant JJ B-adj.all	use NN 0	of IN 0	L NNP 0	- : 0	phenylalanine NN B-noun.person	and CC 0	non NN B-noun.person	- : 0	selective_MAO_inhibitors NNS B-noun.person	may MD 0	cause VB B-verb.communication	hypertension NN B-noun.person	. . 0	. . 0
DDI-DrugBank.d410.s2	Sumatriptan NNP B-noun.person	and CC 0	D.H.E._45 NNP B-noun.person	_ . 0	( ( 0	dihydroergotamine_mesylate JJ 0	) ) 0	Injection NN B-noun.location	, , 0	USP NNP B-noun.group	should MD 0	not RB 0	be VB 0	taken VBN B-verb.social	within IN 0	24 CD B-adj.all	hours NNS B-noun.time	of IN 0	each DT 0	other JJ 0	.. . 0	. . 0
DDI-DrugBank.d460.s6	Digoxin NNP B-noun.person	, , 0	When WRB 0	Starlix NNP B-noun.communication	120 CD 0	mg NN B-noun.quantity	before IN 0	meals NNS B-noun.food	was VBD 0	administered VBN B-verb.possession	in IN 0	combination NN 0	with IN 0	a DT 0	single JJ B-adj.all	1-mg JJ B-adj.all	dose NN B-noun.quantity	of IN 0	digoxin NN B-noun.person	to TO 0	healthy JJ B-adj.all	volunteers NNS B-noun.person	, , 0	there EX 0	were VBD B-verb.stative	no DT 0	clinically RB B-adj.all	relevant JJ B-adj.pert	changes NNS B-noun.relation	in IN 0	the DT 0	pharmacokinetics NNS B-noun.person	of IN 0	either DT 0	agent NN B-noun.person	. . 0	. . 0
